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                                                               INTRODUCTION 
 Siddha system is one of the major system of medicine indigenous to our country. 
Siddha system can be termed as a scientific art which proves that health soul is the property 
of a healthy body.  
Siddha system of medicine not only deals with external body but also with the inner 
man or the soul. 
The word Siddha means “established truth” and comes from the word siddhi an 
object to be attained such as perfection in life or heavenly bliss. 
The concepts of Siddha system are based on fundamental principles of five basic 
elements of the universe, three humours , three  thathus and seven pillars (Physical 
constituents of the body), Envagai thervugal (An integral part of Siddha Medicine). 
The physical function of the body is mediated by three forces called vali, azhal, 
iyam. In normal state they are called three forces or three thathu that sustain and nourish the 
body. When the three humours are deranged, they become Kutrams which produce disease. 
Humoural basis of disease diagnosis is needed to select humour based treatment, 
which can result in better prognosis. 
Thiruvalluvar says this way of approach in the following lines; 
    “Meginum kuraiyinum noi seiyum noolor 
     Valimudhala enniya moondru” 
- Thirukkural 
  When this equilibrium is disturbed, it leads to ailment, which hinders longevity. 
The holistic approach adopted by the Siddha system of medicine is very aptly 
captured by the basic quote of Siddhars “FOOD ITSELF IS MEDICINE –MEDICINE 
ITSELF IS FOOD”. 
  Sivavaakiyar says in Sattamuni gnanam; 
„Andathil ullathae pindam‟ 
Which means, what is in the Macrocosm (world/Universe) is in Microcosm (Man). 
Siddha claims that the human body is the replicate of universe. 
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   In Siddha system, Yugimuni classified diseases into 4448. Yugimuni  mentioned 80 
types of vatha diseases in the text Yugi Vaidhiya Chinthamani. In which Valiazhal keelvayu 
is one among them and the signs and symptoms of this disease is correlated with 
Rheumatoid arthritis in Modern science. 
 Rheumatoid arthritis (RA) is the most common persistent inflammatory arthritis, 
occurring throughout the world and in all ethnic groups. The clinical course is prolonged, 
with intermittent exacerbations and remissions. The typical clinical signs are pain, joint 
swelling and stiffness affecting the small joints of the hands, feet and wrist. 
 
 
 
         Incidence of RA is of 3 cases per 10,000 populations per annum. Onset is uncommon 
under the age of 15 and from then on the incidence rises with age until the age of 80
(1)
 . 
 
            Prevalence of this disease affecting 0.75% population in India. Projected to the 
whole population, this would give a total of about 7 million patients. The prevalence of RA 
in India is quite similar to reported from the developed countries
 (2)
. 
Around 40% of RA patients are registered disabled within 3 years; around 80% are 
moderately to severely disabled within 20 years; and 25% will require a large joint 
replacement
(1)
 . 
             Many  formulations are available to treat Vali azhal keel vayu in Siddha system of 
medicine. I have chosen the drug “MERUGULLI THYLAM” (Reference: Theraiyar 
Thylavarga Surukkam, P. No. : 80-81Author:  T.C.Subbramaniya Pandither) as internal 
medicine. This preparation  reduced not only the joint pain but also the restricted 
movements and other symptoms of the disease Vali azhalkeel vayu.Because the  ingredients 
of the drug are well known for its Anti-inflammatory, Antioxidant, analgesic and 
Antibacterial activities 
(3)
.  
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AIM AND OBJECTIVES 
AIM 
To Evaluate the Therapeutic efficacy of the siddha formulation “MERUGULLI 
THYLAM” (Internal) in the treatment of “VALI AZHAL KEELVAYU (Rheumatoid 
Arthritis).” 
 
OBJECTIVES:  
 
PRIMARY OBJECTIVES: 
           To Evaluate the Therapeutic efficacy of the siddha formulation “MERUGULLI 
THYLAM” (Internal) in the treatment of “VALI AZHAL KEELVAYU (Rheumatoid 
Arthritis).” 
 
SECONDARY OBJECTIVES: 
 To conduct a clinical trial with a well defined Performa on identical patients with vali 
azhal keelvayu. 
 To study vali azhal keelvayu, on the siddha basic principles like  Mukkutram, 
Udalkattugal, Envagai thervu, pori, pulan, Neerkkuri  and Neikkuri  pattern etc  in   
vali azhal keelvayu patients.  
  To correlate the aetiology, clinical features, signs and symptoms of vali azhal 
keelvayu in Siddha system to Rheumatoid Arthritis in Modern science.                  
 To screen the elements present in the trial drug. 
 To screen the biochemical constituents of the drug. 
 To study the influence of other co factors such as Age, Sex, Socio-economic status, 
Dietary Habits, Family history etc., 
 To find out whether there are any side effects/ adverse effects produced by the trial 
drug MERUGULLI THYLAM (Internal) during treatment. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
        Siddha system was propounded by the siddhars and which is a vast and unique system 
which defines health as a perfect state of physical, psychosocial, social and spiritual well 
being of an individual. 
 
       The system not only deals with medicinal but with spirituality, righteous way of living, 
Rejuvenation and its main aim is attainment of perfection. 
 
VATHA NOI - DEFINITION 
Vatha noi  is a clinical condition characterised  by pain, swelling, pricking 
sensations and loss of function due to vitiated vatham which is the principle humour of the 
body. 
          “¦À¡üÈ¡ Á¨ÃÂ¡ý Ò¨É¦Áö ÂÃñ¸¡ìÌõ 
           ¦À¡üÈ¡ Á¨ÃÂ¡ý Ò¸øÅ¦¾ý ¦À¡üÈ¡õ 
            ÅÇÅ¢É¢§Ä Â¡ìÌÃõ¨À ÁýÉ¦ÉÉ ÁýÉ 
            ÅÇÅ¢É¢§Ä Â¡ìÌõ ÅÇ¢”. 
                             -§¾Ãý ÂÁ¸ ¦ÅñÀ¡ 
The above verse says that, vatham is being held as the king who rules the (fort) body 
and enables the wellbeing of the citizen (the uyir) in the fort. Hence, Theraiyar refers 
Vatham as prime force in normal state. 
 
        For wellbeing of a individual three vital humours should be maintained in a 
equilibrium state. If there is a imbalance in any one of them it will alter the other two 
resulting in a diseased condition. 
 
CHARACTERISTICS OF VATHA DISEASES 
“ghq;fhd thje;jhd; kPWkhfpw; 
gUtapW RthrKld; Fj;Jf;Nfhio 
ePq;fhj gpog;GisT thA njhe;jk; 
ePu;ntbj;Jg; gha;jy; ke;jk; tplkp;g;ghjy; 
J}q;Frd;dp thjRu kjdp;w; Njhlk; 
njhFj;j fpuh zp;f;fopr;r Yju Njhlk; 
thq;Fgy typFsp;u;r;rp Fd;kthj 
kyryq;fl; bly;thj te;jpg;ghNk.” 
-mq;fhjpghjk; 
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             According to Angaathipatham the deranged Vali produces constipation, scanty 
micturation , increased  lacrimation, with darkening of eyes, fissures in tongue, flatulence, 
abdominal distension , cough with expectoration, dysarthria, indigestion and diarrhoea. 
 
“NktpathjQ; nra;Aq; Fze;jiz tpak;gf; Nfsha; 
jhtpNa tapW je;jQ; re;Jfs; nghUj;J NehthQ; 
rPtpa jhJehrQ; nrWj;Jld; rpWePh; tPOq; 
fhtpaq; fz;zp dhNs kykJ fUfptPOk;.” 
                        -mfj;jpau; thj fhtpak;-1000 
 
“thjj;jpd; FzNknjd;dpy; tapwJ nghUkpf;nfhs;Se; 
 jhJfSyu;e;j iffhy; re;Jfs; fLg;Gj; Njhd;We; 
 jPJw;wr; rpWePu;jhDQ; rpWj;Jld; fLj;J tPOk; 
 NghJw;w thjnkd;W Gfd;wdu; Kdptu; jhNk.” 
                        - fz;Zrhkpak; 
 
According to Agathiyar vatha kaaviyum and kannusamiyam the deranged Vatham 
produces abdominal discomfort, pain in joints , oliguria,  dysuria, constipation and 
flatulence. 
 
VALI AZHALKEEL VAYU 
Definition (Iyal) 
        Vali azhal keelvayu is  a  type  of  Arthritis  characterised  by  pain,  swelling, 
stiffness of the joints  and restriction of movements due to deranged vatham and pitham. 
         VALI AZHAL KEEL VAYU mentioned in Sababathi kaiyedu which indicates 
Uthiravatha suronitham.  
 
DESCRIPTION OF NOMENCLATURE: 
According to T.V.Sambasivampillai Agarathy volume I 
Uthiravatha Suronitham - Uthiravatham + Suronitham 
Uthiravatham                   - Arthritis of rheumatic origin marked by severe  
pain and the formation of inflammatory nodules in the 
region of joints especially in the limbs of the body.  
Suronitham           - Blood and menstrual blood. 
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§¿¡ö ÅÕõ ÅÆ¢ -AETIOLOGY    
 
According to Yugi Vaithya Sinthamani,     
“vd;dNt thje;jh ndz;g jhFk; 
 kpFj;jpNy kdpjh;fSf; nfa;J khW 
gp;d;dNt nghe;jidNa NrhuQ; nra;J 
 ngupNahh;fs; gpuhkziuj; J}\; zp;j;Jk; 
td;dNt tr;nrhj;jpw; NrhuQ; nra;J 
 khjhgpjh FUit kwe;J Ngh;f;Fk; 
fd;dNt Ntjj;ij ep;e;ijnra;j Ngh;f;Fq; 
 fhaj;jpw; fye;jpLNk thje; jhNd. 
“jhndd;w frg;NghL Jth;;g;G iug;G 
 rhjfkha; kpQ;RfpDQ; rikj;j td;dk; 
Mndd;w thwpdJ nghrp;j;j yhYk; 
 Mfhj; NjwyJ Fbj;j yhYk; 
ghndd;w gfYwf;f kpuhtp opg;G 
 gl;bdpNa kpfTWjy; ghu nka;jy; 
Njndd;w nkhopahw; Nkw; rpe;ij ahfpy; 
 rPf;fpukha; thjkJ nrdp;f;Fe; jhNd.” 
“Mzhd tud;ndsNa kjpah khe;jh; 
 mfjpgu Njrpah;fl; fd;d kPahh; 
Nfhdhd Funkhopia kwe;j Ngh;fs; 
 nfhiyfsT ngha;fhkq; Fwpj;j Ngh;f;F 
Cdhd rle;jd;dpy; thjk; te;J 
 cw;gtpf;Fk; Ntjj;jp Yz;ik jhNd." 
                          -A+fp itj;jpa rpe;jhkzp 
                 
According to the text, those who are squandering money, insulting the elders, 
abandoning or forgetting the parents, blaspheming the Holy books, not respecting the divine 
gifts, having wickedness in their mind and those with day slumber and staying back at night 
will get Vatha diseases. Increased intake of bitter taste, astringent, pungent, increased intake 
of water, excessive starvation, increased sexual desire will produce diseases of vatham. 
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IN THE TEXT ANGAATHIPATHAM.., 
         “fhdilahyr; rj;jhw; fLk;grp ahw;Nfh gj;jhy; 
      Cdkp yputpy; thu;j;ij Auk;ngw tpiuf;f yhY}z; 
      Mdgpd; Kdpthy; khU jLj;jLj; Jiuf;FQ; nrhy;yhy; 
      <dkp ypfo;r;rp ahd tpfy;thj Nfhgq; fhZk;.” 
                                   
According to Angaathipatham, increased starvation and increased anger will 
produce diseases of vatham. 
 
OTHER IMPORTANT FACTORS THAT INFLUENCE THE VATHA TYPE OF 
DISEASE: 
fhy ,ay;G - ENVIRONMENTAL FACTORS; 
 
AS PER SIDDHA MARUTHUVAANGA CHURUKKAM 
              “gJkj;ijg; G+f;f itf;Fk; ghDkpff; fhAk; 
      KJNtdp ypw;G tpw;ePh; Kw;Wk; -fJnkd 
      tw;Wk; fgkp.Fk; thAkpFk; tho;khe;jf; 
      Fw;w eypf; Nfjpnjd; NwhJ” 
                           -rpj;j kUj;Jthq;f RUf;fk; 
 
      In Muthuvenil kaalam (Late summer), the increased solar radiation increases the 
evaporation of water content from the body in turn produces increase in the  Kapham and 
Vatham thus resulting in the production of vatha disease. 
 
   “Mbahjpaha; Ig;grp <wha; 
   mdpykjw; Nfhuurpay; fhyk;.” 
                                                     - Neha; ehly; Neha;  Kjy; ehly; jpul;L II 
 
Vatham elevates in the body from the month of Aadi to Iyppasi (August to 
November) i.e. from the middle of Muthuvenil kaalam, Karkaalam to half of Koothir kalam. 
 
HABITS THAT MAY CAUSE VATHA DISEASES 
1. In Theraiyar vagadam it is explained as.., 
           “nta;apypy; elf;ifahYk; kpfj;jz;zPh; Fbf;ifahYk; 
      nra;apio kfspdiur; Nrh;e;jDg tpf;ifahYk; 
      igaNd cz;ikahYk; ghfw;fha; jp;d;ifahYk; 
      ijaNy thj Nuhfk; rdpf;F nkd;wwp;e;J nfhs;Ns.” 
                     - Njiuah; thflk; 
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Excessive walking in hot sun, excessive intake of water, bitter guard and increased 
sexual indulgence, may play a role in disturbing the normal functions of Vatham  
 
TASTES THAT  MAY INCREASE THE VATHA KUTARM 
 “GspJth; tpQ;Rk; fwpahy; g+hpf;Fk; thjk” 
                     - Neha; ehly; Neha;  Kjy; ehly; jpul;L 
 
  “tspjUfha; fpoq;F tiutpyh jkpyy; Nfhio 
 Gsp japh; Nghd; kpUf;F Kiwapyh Tz;b Nfhly; 
 Fsph; jU tspapw; Nwfq; Fdp;g;Gw Tyty; ngz;bh; 
 Fsp jU Kaf;fk; ngw;Nwhh; fb nray; fUtpahkhy;” 
                               -rghgjp ifNaL 
 
    According to Sababathi Kaiyedu, increased intake of tubers, increased exposure to 
wind, living in higher altitudes, increased exposure to chill, increased sexual desire will 
aggravate Vali dieases. 
 
 “njhopy; ngW ifg;Gf; fhh;j;jy; Jth;j;jy; tpq;fpDQ; NrhWk; 
 gioajhk; tuF kw;iwg; ige;jpidaUe;jpdhYk; 
 vopy; ngwg; ,utpdpYwq;fhjjhYk; 
 kioepfh FoypdhNy thjq;Nfh gp;f;Fq;fhNz” 
- guuhr Nrfuk; 
 
Increased intake of bitter, astringent, acrid taste food , altered sleep pattern 
contribute to vatha diseases. 
 
CLINICAL FEATURES OF VALI AZHALKEEL VAYU 
 
ACCORDING TO SIDDHA MARUTHUVAM POTHU 
“thjgpj;jf; fPy; tha;tp;d; 
 tUq;Fwp rhw;wf; Nfsha; 
Vjkhh; ke;j Nkg;gk; 
 ,iur;rYk; tapw;wpw;fhZk; 
XjUq; Fj;jy; tPf;fk; 
 Xa;jypy; vhp;r;rYz;lhk; 
fhjWKwf;f kpd;ik 
 fha;;rrYk; fhZq;fz;lha;” 
 
It is characterized by belching, prickling pain, swelling, irritation, fever and lack of sleep. 
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 ACCORDING TO YUGI VAITHIYA SINTHAMANI 
“itfpjkha;f; fizf;fhY Koq;fhy; jhDk; 
 kw;flQ; re;J GwtbAk; tPq;fpr; 
nra;;fpj khw; rpWtpuy;fs; kpfTk; nehe;J 
 rpe;ij jLkhwpNa rypg;GzlhFk; 
igfpjkhk; gapj;jpaj; jpy;yhj kpQ;rpg; 
 ghukha; cw;gtpj;J moYz;lhFk; 
ca;fpjkhk; mrdkJ jhDk; Ntz;lh 
 cjpu thj RNuhzpjj;jp Dzh;;r;rpahNk.” 
- a+fp itj;jpa rpe;jhkzp 
 
    It is characterised by pain and swelling in both ankle joints, knee joints and all 
smaller joints of the hands, feeling of tiredness, fever, loss of appetite and mental 
depression.  
 
    Also the term „Markadam‟ (Áü¸¼õ) indicates the hand of monkey 
(T.V.Sampasivam Pillai dictionary Pg no: 753) anatomically, which can be correlated 
clinically with Swan neck deformity and wasting of tenar muscle in Rheumatoid Arthritis.   
„Pararasa sekaram‟ describes Suronitham as follows: 
 
“tPo;ngW RNuhzpje;jhd; kpfTld; nkypTkhfpj; 
jho;tpy; re;JfNs tPq;fpj; jif ngw eilnfhlhky; 
tho;TW ifAq;fhYk; trkpd;wp aod;W Nehthk; 
gho;ngW kzq;fpdhNs gaDwg; gfh;e;jp;l;NlhNk” 
  
It is characterized by debility in Ratha thathu (anaemia), swelling of peripheral  
joints, restricted movements and pain in limbs. 
 
ACCORDING TO „PARA RASA SEKARAM‟: 
“gf;fKk; khh;Gk; $lg;gw;wpNa ,Oj;Jk; nfhz;L 
nef;fpNa khh;gpisj;J Njhjha; euk;gpOj;J 
xf;fNt rapj;jpaq;fs; cah;e;Jld; NkYk; fhyk; 
kp;f;FNk cjputhjk; vd;wpJ tpsk;gyhNk.” 
- guuhr Nrfuk; 
It is characterised by pain and tenderness of the axilla, breathlessness, pain in the 
upper limbs and the lower limbs. 
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                                                  SIDDHA PATHOLOGY 
 
Siddha system of medicine is based on Thirithodam theory. They are Vatham, 
Pitham and Kabam the manifestation of all diseases are result of derangement of these Uyir 
thathus (Thirithodam). 
 
  These three humours are primary and essential factors of human body. These factors 
exist in 1:1/2:1/4 ratio respectively in the normal body any alteration in the above ratio can 
cause disease in the body. 
 
     In Vali azhal keelvayu 
1. Vatham – increased 
    “Å¡¾ÁÄ¡Ð §ÁÉ¢¦¸¼¡Ð”   - §¾¨ÃÂ÷  
 
2. The increased vatha kutram causes derangement of other two kuttrams (ie. Pitham and 
Kabam) as a result of this clinical features of disease is exhibited. 
 
DIAGNOSIS - §¿¡ö¸½¢ôÒ 
 
"§¿¡ö¿¡Ê §¿¡öÓ¾ É¡Ê ÂÐ¾½¢ìÌõ 
 Å¡ö¿¡Ê Å¡öôÀî ¦ºÂø" 
- ¾¢ÕìÌÈû 
This Thirukural quote explains the importance of diagnosis, as it is to be made in 
order of the aetiology, root of cause of the disease thereby treating the disease with 
appropriate medicine.  
 
Piniyari muraigal (Method of Diagnosis) 
It is based upon the three main principles: 
 Poriyal Arithal (Inspection) 
 Pulanal Arithal (Palpation) 
 Vinaathal (Interrogation)  
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DIAGNOSTIC METHODOLOGY IN SIDDHA SYSTEM OF MEDICINE 
ENVAGAI THERVUGAL (EIGHT DIAGNOSTIC TOOLS) 
 
These tools not only help in the diagnosis but also helps to observe the prognosis of 
the diseases and for reassuring the patient and to be informed about the nature of diseases, 
they are 
1. Naadi (Pulse)     
2. Sparisam (Sensation to Touch)   
3. Naa (Tongue)                 
4. Niram (Colour) 
5. Mozhi (Voice) 
6. Vizhi (Eyes) 
7. Malam (Faeces) 
8. Moothiram (Urine) 
 
I. Naadi (Pulse): 
     Naadi is the first and foremost diagnostic parameter of the Siddars. It is the seat 
anchor of energy. The pulse wave as felt on the radial artery, one inch from the wrist by 
means of palpation with the tip of index, middle and ring finger corresponds to VATHAM, 
PITHAM,KABAHAM. They normally exit in the ratio 1:1/2:1/4 respectively. 
 
In VALI AZHAL KEELVAYU the following types of Naadi can be commonly seen. 
They are  
 Vadhapitham 
 Pithavadham 
 Vadhakabam 
  “jpUj;jkhk; thje;NjhNl jPq; nfhL gpj;jQ; Nrhpy; 
 nghUj;Jfs; NjhWk; nehe;J” 
                          -Fzthflk; (Nehap;d; rhuk;) 
 
According to Gunavagadam, vathapiha naadi seen  in VALI AZHAL KEELVAYU.  
 
II. Sparisam (Touch): 
Inspection and Palpation of the skin , it reveals that the warmth or chillness, dry or 
weeping skin, rough or smooth, tenderness, swelling, wrinkle, soft or hard ,any ulcers or 
fissures etc.  
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In Valiazhal keelvayu mild warmth is felt over the affected joints with swelling, 
tenderness and sometimes subcutaneous nodules and the degree of warmth may vary from 
to other depending on the severity of disease. 
III.  Naa (Tongue Examination) 
The colour, character and condition of tongue are noted. 
In Vali azhalkeelvayu tongue commonly does not show any abnormality. In cases 
with anaemia it may appear pallor, glossy and coated. 
IV. Niram (Colour)  
Signs of different complexions in Vatham, Pitham, Kabham and Thontha thegis, 
cyanosis, pallor, yellowish discolouration may be noted.  
In Vali azhalkeelvayu no abnormalities are seen normally. Sometimes pallor of skin 
may be noted in case of anaemia. 
V. Mozhi: 
 It constitutes high ,low-pitched voice, nasal speech, horsiness of voice, slurring and 
incoherent speech etc. 
In Vali azhalkeelvayu no abnormalities are seen normally. 
VI. Vizhi:  
   Both motor and sensory disturbances of eyes noticed. Redness of eyes, paleness, 
swelling, excessive lacrimation, corneal ulcers may be noted .   
      In Vali azhalkeelvayu no abnormalities are seen normally. In anaemic patients pale 
conjunctiva may be noted. 
VII. Malam: 
Vatha type: Black coloured stool with constipation. 
Pitha type: Loose stools with yellowish red colour. 
Kabha type: White coloured stools with mucus. 
Thontha type: Stools possess of the features of two thonthams.  
In Vali azhalkeelvayu constipation was reported in most of the cases. 
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VIII. Moothiram: 
Neerkuri and Neikuri are special diagnostic methods regarding moothiram. 
 
NEERKURI: (PHYSICAL EXAMINATION OF URINE) 
The urine is collected and examined for the following. 
Niram     -  Colour 
Edai        -  Specific Gravity  
Manam   -  Smell 
Nurai      -   Frothy Nature 
Enjal     - Deposits/ quantity of urine voided 
 
In Vali azhalkeelvayu straw or hay coloured urine is noticed in Neerkuri. 
 
NEIKURI: (OIL ON URINE SIGN) 
When the oil drops lengthens like a snake it  indicates “Vatha neer”. 
When the oil drops spreads like a ring it indicates “Pithaneer” 
When the oil drops remains that of pearl it indicates “Kabaneer”. 
 
In Vali azhalkeelvayu  the pattern of Neikuri is mostly “Aravena neendathu -
Vatham”. In some cases the oil drop remain as that of a pearl or ring indicating Kaba neer. 
Pitha neer accordingly. 
 
MUKKUTRAM : 
VATHAM:[BIO ENERGY MOVEMENTS] 
When some of the factors like food, occupation, seasonal variations etc., disturb 
Vatham, it looses its control, which may be exaggerated or diminished. So the other two 
Uyir Thathus are also disturbed which leads to the genesis of “Vatha” diseases. Uyir thathu 
can be termed as “Vatha thodam”. 
The sites of vatham : 
Umbilicus, Abdomen, Rectum, Faecal matters , Anus, Bones, Hip joints,  Joints, 
Navel, Plexus, Hair follicle and Muscles. 
“ehnkd;w thjj;Jf; fpUg;gplNk Nfsha; 
ehgpf;Ff; fPnod;W etpy yhFk;” 
- a+fp ÓÉ¢ 
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“mwpe;jpLk; thj klq;F kyj;jpdpy;” 
- jpU%yu; 
 
            According to  Yugi muni and Sage Thirumoolar the location of Vatham are the anus 
and the sub naval region. 
 
Natural properties of Vatham:  
 Giving briskness 
 Functions of mind 
 Expiration and inspiration  
 Regulation of the “Fourteen Physical Reflexes” (Vegam). 
 Protection and strengthening of the five sensory organs (Iymporigal). 
 
Symptoms of Vatha thodam: 
 Body ache 
 Pricking pain 
 Nerve weakness 
 Tearing pain 
 Joints pain 
 Traumatic pain 
 Mental distress 
 Weakness of organs 
 Paralysis of limbs 
 Severe pain in calf and thigh muscles 
 Bony pricking pain 
 Unable to flexion and extension of the limbs 
 Excessive salivation 
 All tastes to be like astringent 
 Polydypsia 
 Anuria and constipation 
 
DESCRIPTION OF VATHAM: BIO ENERGY MOVEMENTS 
The Siddha classical texts divide the general principles of Vatham into ten 
subsidiary forms that differ from one another by their localization in the body (Anatomical) 
and by their particular functions (Physiological). They are 
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PRAANAN: Life force/Life air  
     It is otherwise called as “Uyirkkaal”.  It refers to be “Heart centre”. It maintains 
the action of the heart, the functioning of the mental faculties of perception and 
concentrations and also cares for the arteries, veins and nerves. It also regulates the 
respiration and digestion. 
 
ABAANAN: [Downward air] 
           It is otherwise termed as “Keezhnokkumkaal”, “Moolaadharam centre”. It 
corresponds to the pelvic area and controls the excretion. It occupies the sites in the bladder 
and genitals and focussed in the lower part of the gut . It has a tendency to travel 
downwards. It moves in the whole Genitourinary tract and regulates the defecation. 
menstruation, parturition and ejaculation.  
 
VIYAANAN: [Centrifugal air] 
          It also known as “Paravukaal” , “Forehead centre”. It corresponds to the naso cilary 
area i.e at the root of the nose and base of the skull and controls the will. It helps in the 
circulation of energy throughout the entire nervous system and the movements of the 
various parts of the body.  
 
UDHAANAN: [Upward air] 
           It is otherwise named as “Melnokkukaal”, “Throat centre”. This corresponds to the 
pharyngeal area  in the throat region and controls speech and breathing and also 
physiological reflex actions like vomiting, hiccup, cough etc. It has the tendency to travel 
upwards. 
 
SAMAANAN: [Homeostatic air] 
            It balances the other vayus. It is also called “Nadukkaal”, “Navel centre”. It 
corresponds to the navel region and controls digestion. It selects the useful substances from 
the swallowed food and supplies them to the whole body. 
 
NAAGAN: [Intellectual air] 
            It is responsible for the intelligence of an individual , wrinkling, singing and pilo 
erection. 
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KIRUGARAN: [Secretary air] 
            It is responsible for salivation and nasal secretion. It helps to indigestion and 
meditation. It produces cough and sneeze.  
 
DHEVATHATHAN: [Tiresome air] 
             It is responsible for laziness, lassitude, quarrelling, arguing, and also for much 
anger. It helps to movements of the eyeball in various directions and is present in genital 
and anal region. 
 
DHANANJEYAN: [Intracranial air]    
       It is present in nose and responsible for swelling of the body and tinnitus. It leaves 
the body by blowing up the cranium only on the third day  after death. 
                                                                          
 In Vali azhalkeelvayu,  
• Abanan  - affected (produces constipation). 
• Viyanan  - affected (produces restricted joint movements). 
• Samanan  - affected (due to derangement of other vayus). 
 
2. PITHAM: BIO ENERGY FIRE  
The sites of Azhal: 
        According to Vaithiya Sathagam, the pingalai, Urinary bladder, Stomach and heart 
are the places where Azhal is sustained. In addition to the above places, the umbilicus, 
epigastric region, stomach, sweat, saliva, blood, Essence of food, eyes  and skin where 
Azhal sustains. 
       According to  Yugi muni says that the Azhal resides in urine and the places below 
the neck region.  
 
The character of Azhal: 
             It is responsible for the digestion, hunger, thirst, maintenance of the body 
temperature, vision, taste etc. Its other functions include thought, knowledge, strength and 
softness.      
 
The types of Azhal 
• Anala pitham     –  The fire of digestion. 
• Ranjaga pitham  –  Haematinic fire. 
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• Saathaga pitham  –  The fire of achievement. 
• Prasaka pitham  –  The fire of brightness. 
• Alosaga pitham  –  The fire of vision. 
 
In case of Vali azhalkeelvayu,  
Saathagam – affected (Difficulty in walking, climbing upstairs, squatting etc). 
 
3.KABAM [Iyyam] –BIO ENERGY WATER 
Sites of Iyyam 
         Head, tongue, eyes, nose, throat, thorax, bone, bone marrow, Joints, blood, fat, sperm 
and colon . 
 
The natural quality of Iyyam: 
         Stability, greasiness, formation of joints, thirst, the ability to withstand hunger, sorrow 
and distress are the qualities. 
 
Five types of Iyyam: 
• Azhal Iyyam (Avalambagam) - Nodal/Pivotal Iyyam- It controls all other 4 Iyyams. 
• Neerpi Iyyam (Kilethagam) - Digestive/Aqueous Iyyam-It gives moisture and    
    softness  to  ingested food. 
• Suvaikaan Iyyam(Pothagam)       - Taste/gustatory Iyyam-It is responsible for the sense  
of  taste. 
• Niraivu Iyyam (Tharpagam)        -  Coolant Iyyam-It gives coolness to the eyes. 
• Ondri Iyyam (Santhigam)         -    Articular Iyyam-Its gives lubrication to the bones     
                                                        particularly in the joints.  
 
In Vali azhalkeelvayu Santhigam is affected. 
 
UDAL KATTUGAL: SEVEN PHYSICAL CONSTITUENTS OF THE BODY: 
In Vali azhalkeelvayu, the udal kattugal affected are 
 
Saaram  [Essence/chyme]       -    Weakness 
Senner [Blood]                   -     Tiredness, Anemia 
Kozhuppu [Fat]  -      Pain in the affected joint 
Enbu [Bone]          -     Weakness of bones 
Moolai [Marrow]     -     Osteoporotic changes, Swelling in joints  
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IV. GNANENTHIRIYAM [ORGANS OF PERCEPTION] 
Gnanenthiriyam are Mei, Vaai, Kan, Mooku and Sevi. 
In Vali azhalkeelvayu „Mei‟ is affected. This is due to pain, swelling, morning 
stiffness and deformities. 
 
IV.KANMENTHIRIYAM [MOTOR ORGANS] 
Kanmenthirium  are Kai, Kaal, vaai, Eruvai, Karuvai. 
In Vali azhalkeelvayu Kai and Kaal are affected. This is due to pain, swelling, 
morning stiffness and deformities. 
 
YUGI VAIDHYA CHINTHAMANI CLASSIFIED VATHA SURONITHAM INTO 7 
TYPES. 
• Vadha Suronitham 
• Sithuvatha Suronitham 
• Vaithiya Vatha Suronitham 
• Paithiya Vatha Suronitham 
• Slethumavatha Suronitham 
• Utharavatha Suronitham 
• Uthiravatha Suronitham 
 
DIFFERENTIAL DIAGNOSIS 
Vali azhalkeelvayu is differentiated from other types of Vatha Suronitham as 
follows: 
thjRNuhzpjk; 
“mwpe;jp;l;l mq;fnky;yh nkypt jhfp 
 mirthd jt;tplq;fs; tPf;f khfp 
ewp;e;jpl;l eilnfhlh jhdp Uj;jy; 
 typahfp nkhopnkhopa tPf;f khfr; 
nrhwpe;jpl;l Njfnkq;F kirT fhzy; 
 Nrhw;wp;d;Nk dpidapd;wpj; J}f;f khjy; 
Twp;e;jpl;l thajdp dPu;jh E}wy; 
      thjRNuh zpje;jhDk; tFj;j thNw.” 
 -a+fp itj;jpa rpe;jhkzp 
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VATHA SURONITHAM 
 Emaciation 
 Swelling of joints 
 Restricted movements 
 Joint pain 
 Discomfort 
 Excessive salivation 
 Loss of appetite 
 
rpj;JthjRNuhzpjk; 
“thwhd ruPunky;yh Eioe;J Cjy; 
khrw;w Njhy;jhDe; jpiue;J NghFk; 
ehwhd ehWNghy; euk;G Rf;Fk; 
 ehf;Fj;jhd; totoj;Jf; Nfhio ahFk; 
J}whd neUg;Gj;jhd; gl;lhu; Nghy 
 nehe;JNk rlnky;yhq; nfhg;g spf;Fk; 
tPwhd tup;e;Jgp;d;id ntJk; gPq;Fk; 
 kpf;frpj;J thjRNuh zpjkh khNk.” 
                                        -a+fp itj;jpa rpe;jhkzp 
 
SITHUVATHA SURONITHAM 
 Anasarca 
 Wrinkles 
 Neural pain 
 Glossy tongue 
 Sialorrhoea 
 Bullous eruption as in burn 
 Exfoliation, swelling  and Warm 
 
                   gapj;jpathjRNuhzpjk; 
“czu;r;rpaha;r; RNuhzpje;jhd; kpfnt Jk;gp 
 Cf;fkha;j; Njfnkq;F kpfNt nehe;J 
Kzu;;r;rpaha; Koq;fhy;fs; Koq;if nahf;f 
 Kidahd rpWtpuy;fs; fd;dk; new;wp 
jzu;r;rpaha;r; re;JrU thq;f nkq;Fk; 
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 jhl;bf kha;f;File;J RuK Kz;lhk; 
gzu;r;rpaha;g; ghz;lJNghd; Nkdp ahFk; 
 gapj;jpath jRNuhzpjj;jpd; gz;G jhNd.” 
                       -a+fp itj;jpa rpe;jhkzp 
 
PAITHIYA VATHA SURONITHAM 
 Hyperaemia 
 Tenderness in knee, elbow and smaller joints 
 Poly arthralgia 
 Pyrexia 
 Anaemia 
 
                 Nrj;JkthjRNuhzpjk; 
“gz;ghf Tly;Fspu;e;J VW tPq;fpg; 
 gijg;ghd tple;njhl;lhw; ghu Nehthk; 
jpz;ghd rpuRnew;wp Nehf;fh Lz;lhk; 
 rpNyl;Lkkha;f; NfhionahL Rthr khFk; 
kz;ghf kaf;fnkhL fdT Kz;lhk; 
 tha;tuz;L Urpapy;yh tUj;j khFk; 
ez;ghf ehbANk glg l;fFk; 
 ew;Nrl;g RNuhzpjkhk; ehL;q; fhNy”  
                       -a+fp itj;jpa rpe;jhkzp 
                                               
SLETHUMAVATHA SURONITHAM 
  Chillness with abdominal distension 
 Severe pain and Head ache 
 Syncope and Hallucination 
 Dryness of mouth and Anorexia 
 Tachycardia 
 
cjuthjRNuhzpjk; 
“ehLNk Ruk;te;J eLf;f Yz;lhk; 
 ehtuz;L jiynehe;J clk; gOj;jp 
thLNk Njfnky;yh kdpr;rk; g+g;Nghy; 
   kfhtUj;j Kz;lhfp kaf;f khFk; 
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rhLNk abf;fbjhd; Ngjp jhDk; 
 jtpf;FNk jz;zPu;jh dhl;l khfpj; 
NjLNk Nrhw;wpd;Nky; epidT jhDk; 
 nra;Tju thjRNuh zpje;jh ndd;Nd.” 
                                    -a+fp itj;jpa rpe;jhkzp 
 
UTHARAVATHA SURONITHAM 
  Fever with rigor 
 Dryness of mouth 
 Pain in all over the joints 
 Headache 
 Diarrhoea 
 Excessive thirst 
 Hunger 
                                            itfpjthjk;  
“Mnkd;w tPq;fpdNjhu; tplj;jpy; uj;jk; 
 mOj;jkha;j; jpuz;LNk vq;Fk; gha;e;J 
Xnkd;W Xl;bNa jpuz;b Uf;Fk; 
 cWjpaha;j; njhl;LlNd nkj;njd; whFk; 
Njnkd;w Njfnkq; fZK Rf;Fk; 
 rPwpaNjh upUknyhL fhr;rYz; lhFk; 
ghnkd;w gle;jdpNy jpkpUz; lhFk; 
 ghukha; itfpjkhk; thje; jhNd.” 
                               -a+fp itj;jpa rpe;jhkzp 
VAIKITHA VATHA SURONITHAM 
 Swelling with hyperaemia 
 Soft on touch 
 Cough with pyrexia 
 Irritability 
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MANAGEMENT IN SIDDHA 
 
According to siddha system, the main aim of the treatment is to cure physical illness 
and mental illness Treatment is not only for complete healing but also for the rejuvenation. 
           
"Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö¦ºöÔõ á§Ä¡÷                          
       ÅÇ¢ Ó¾Ä¡ ¦Åñ½¢Â ãýÚ"   
                                      -¾¢ÕìÌÈû  
  Siddha system line of treatment consists of the following 
 
                    1. Neekam (Treatment) 
                    2. Niraivu  (Restoration of wellbeing)                     
                    3. Kappu   (Prevention) 
 
NEEKAM 
    a) To bring the Three Thodams to equilibrium state. 
    b) To treat the patient by Internal medicine. 
    c) To stabilize 7 Udal thadhukal and 3 Uyir thadhukal. 
 
            "Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ" 
                                  -rpj;j kUj;Jthq;f RUf;fk; 
The trial drug MERUGULLI THYLAM (internally) was given on the first day of 
the treatment. 
 
NIRAIVU 
   By promoting the awareness about the dietary, seasonal, emotional influence on the 
disease assurance from disease recovery was given .Life-style modification was also 
advised to them. 
“nrq;fOePh; Nfhilj; NjdkpsF ey;nyz;nza; 
jq;F ngUq;fhaj; jOjhio – vq;nfq;Fk; 
fl;L rpW Kj;J nea; Nfhjpy; cSe;jpitfs; 
thl;L kdpyj;ij kjp” 
- gjhh;j;j Fz rpe;jhkzp 
Honey collected during summer, pepper , gingely oil , asafoetida, castor oil, oil and 
black gram are very useful in Vatha disease. 
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KAAPU: 
Knowing the cause there by removing it and thus preventing the disease is the main 
aim of Siddha system of medicine. 
Siddha system emphasizes the purification of thought and activities  as mentioned in 
the siddha text “Theraiyar Pinianuga Vithi” which emphasizes virtuousness to be followed 
even in the daily life activities. 
 
DIETARY ADVICE 
               In Siddha system of medicine the importance of dietary habits have been 
emphasised for the management of diseases and its prevention in a effective manner. 
 
fLF ew;wpyj; njz;nza; $o;ghz;lq;fs; fliy 
tUtjhfpa njq;Fkh tUf;if ew;fhak; 
kbtpyhj nts;Ss;spnfhs; Gifapiy kJngz; 
,lW ghfNyh lfj;jp ePf;fplyp;r;rh gj;jpak;” 
                        -rpj;j kUj;Jthq;f RUf;fk; 
 
“GspJth; tpQ;Rk; fwpahy; g+hpf;Fk; thjk” 
- Neha; ehly; Neha; Kjy; ehly; jpul;L 
 
During the course of treatment, the patients were advised to follow certain diet 
regimen (pathiyam) which is mentioned for vatha diseases. 
 
1. Kadugu         -   Brassica nigra.Linn. (Mustard seed) 
2. Ell Nei          -     Gingelly oil 
3. Poosanikkai  -       Bennicasa hispida.Thunb. 
4. Kadalai         -      Arachis hypogeal.Linn. 
5. Thengai        -      Coccus nucifera.Linn. 
6. Mangai         -     Mangifera indica.Linn. 
7. Pala              -       Artocarpus heterophyllus.Lam. 
8. Kollu            -       Macrotyloma uniflorum.Lam.(Horse gram) 
9. Pugaiyilai      -        Nicotiana tobaccum.Linn. 
10. Pagal          -         Momordica charantia.Linn. 
11. Agathi         -          Sesbania grandiflora.Linn. 
12.  Sour taste 
13.  Astringent taste 
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                                    REVIEW OF LITERATURE  
MODERN ASPECT 
INTRODUCTION 
                   The bones of the skeleton are joined by a variety of structural arrangements 
collectively known as “Joints”. Joints allow differential growth to the remission of forces 
and movements. 
 
Normal structure of joints: 
                    The joints are two types, 
1. Diarthrodial or synovial joints with a joint cavity. 
2. Synarthrodial  or non synovial joints without a joint cavity. 
 
 Most of the diseases of joints affect diarthrodial or synovial joints. In Diarthrodial 
joints, the ends of the two bones are held together by joint capsule with ligaments and 
tendons inserted at the outer surface of the capsule. The articular surfaces of bones are 
covered by hyaline cartilage which is thicker  in weight-bearing areas than in non weight-
bearing areas. The joint space is lined by synovial membrane or synovium which forms 
synovial fluid that lubricates the joint during  movements. The synovium may be smooth or 
thrown into numerous folds and villi. The synovial membrane is composed of inner layer of 
1-4 cell thick synoviocytes and outer layer of loose vascular connective tissue. 
 
 The structure of the joints consists of: 
[1] Soft tissues: 
Joint space  - Joint space contains articular cartilage with thin flim of     
    synovial fluid. 
Joint capsule and ligaments   - The size of the capsule varies as per the joint involved,  
                           small  joints have close filling joint capsules, but larger  
                           joints like knee and hip have larger joints capsule. 
Periarticular tissue   -The soft tissue covering the periosteum is called  
               periarticular soft tissue. 
[2] Bone ends 
 In adults it consists of sub articular cortex, joint margin and Medulla  and In younger 
age group it consists of Epiphysis and  diaphysis 
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[3] Structure of synovial joints: 
             The majority of joints in our body are synovial joints. In this type, the bone ends are 
not directly connected by any tissue. They have smooth articular surface covered by a layer 
of hyaline cartilage. Two bones are held together by a capsule made up of fibrous tissue. 
The capsule encloses the articular surfaces within a joint cavity. The capsule is lined by a 
synovial membrane which secretes a synovial fluid that acts as a lubricating agent and 
provides nourishment to the articular cartilage. 
 
CLASSIFICATION OF JOINTS 
Cartilaginous  
( synchondroses and symphyeses)  –  Partially movable jonts. 
Fibrous (synarthrodial)   –  Immovable joints found in cranial vault  and teeth. 
Synovial joints ( diarthrosis)   –  Freely movable joints are the most common joints  
                found in the skeleton. 
 
Cartilaginous ( synchondroses and symphyeses) 
a. Synchondroses : Eg. Costal cartilage -  sternum 
b. Symphyses: Eg. Pubic symphysis. 
 
Fibrous (synarthrodial) 
     a. Suture   –E.g.Skull 
     b. Gomphoses  –E.g  Alveoli/Teeth 
     c. Syndesmoses  – E.g Tibiofibular ligament  
 
Synovial joints ( diarthrosis) 
a. Uniaxial joints 
 Pivot joint ( neck, atlas and axis bones, Radio-ulna joint) 
 Hinge joint ( elbow and knee) 
 
b. Biaxial joints  
 Condoler joint ( wrist) 
 Saddle joint ( thumb) 
c. Multi axial joints 
  Gliding joint ( intercarpal, Between vertebrae in spine) 
 Ball and socket joint ( shoulder and hip) 
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ARTHRITIS 
 
 Definition: 
                    Arthritis means inflammation of joints  
 
Characteristic features of  arthritis:  
 Inflammation of the Joint 
 Pain 
 Redness 
  Increased warmth  
 Stiffness  
 Swelling( major and minor joints) 
 Fluid accumulation (synovial effusion) 
 degenerative changes 
 Resulting from infection,  
 Metabolic disturbances or other causes. 
 
Types of arthritis: 
 Osteoarthritis 
 Rheumatoid arthritis 
 Gout and Pseudo-gout 
 Septic arthritis 
 Juvenile idiopathic arthritis 
 Ankylosing spondylitis 
 Still‟s disease 
 
RHEUMATOID ARTHRITIS (RA) 
Rheumatoid Arthritis is an autoimmune disease that results in a chronic, systemic 
inflammatory disorder of unknown causes. It may affect many tissues and organs, but 
principally attacks flexible (synovial) joints usually with a symmetrical distribution,  It can 
be a disabling and painful condition, which can lead to substantial loss of functioning and 
mobility if not adequately treated. Its systemic manifestations include hematologic, 
pulmonary, neurological and cardiovascular abnormalities. 
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The name Rheumatoid arthritis originates from the Greek word 
                        Rheuma  = "that which flows as a river or stream,"  
                               Oid = like or resembling 
Arthritis = Inflammation of joints. 
 
 The name is based on the term "rheumatic fever", an illness which includes joint 
pain and is derived from the Greek word rheuma (nom.), -rheumatos (gen.) ("flow, 
current"). The suffix -oid ("resembling") gives the translation as joint inflammation 
that resembles rheumatic fever.  
 The first recognized description of RA  was in 1800 by the French physician  
Dr.  Augustin Jocob Landre-Beauvais (1772 -1840) who was based in the famed 
Salpetriere Hospital in Paris.  
 The name “Rheumatoid Arthritis” itself was coined in 1859 by British 
Rheumatologist Dr Alfred Baring Garrod. 
 
PREVALENCE 
 The prevalence of rheumatoid arthritis in most Caucasian populations approaches 
1% of adults and  increases with age, approaching 2% in men and  5% in women, 
respectively. 
 The incidence also increases with age, peaking between the 4th and 6th decades. 
 The annual incidence for all adults has been estimated at 67 per 100,000. 
 About 1% of the world's population is affected by rheumatoid arthritis, women three 
times more often than men. The incidence of RA is of 3 cases per 10,000 
populations per annum. Onset is uncommon under the age of 15 and from then on 
the incidence rises with age until the age of 80 
(1)
.  
  In India a local survey in Delhi shows the prevalence of this disease affecting 
0.75% of population
 (2)
. 
 Around 40% of RA patients are registered disabled within 3 years; around 80% are 
moderately to severely disabled within 20 years; and 25% will require a large joint 
replacement 
(1)
. 
 It is 4 times more common in smokers than non-smokers.  
 Family history is an important risk factor because  It is strongly associated with the 
inherited tissue type Major histo compatibility complex (MHC) antigen HLA-DR4 
(most specifically DR0401 usually in Indian patients and 0404)  
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 80% affected are women. Male: Female ratio is 1:3. 
 
 ONSET:  
Mostly its onset is insidious and slow onset varying from weeks to months .In some 
people it is acute or sub acute onset. 
 
PATTERNS OF ONSET ON RHEUMATOID ARTHRITIS. 
                  Insidious  - 75%                      Acute      -15%                   Sub acute  -10% 
                  Monoarticular - 20%            Palindromic -5%                
                  Oligo articular  - 45%           Poly articular -35%       
 
CLINICAL COURSE 
 Rheumatoid arthritis is usually life long with intermittent exacerbations and 
remissions. 
 
CAUSES 
The exact causes of RA are unknown. But research has shown that several factors 
may contribute to the development of  RA . 
 
Antigenic agents: 
In which probably act as predisposing factors are Epstein bar, rubella, viruses etc, 
Genetic, psychological stress, endocrine factors, metabolic factors and  allergic factors  may 
also play a role. 
 
Genetic  
Certain genes play a role in the immune system - for some people, genetic factors 
may be involved in determining whether they will develop RA. It is associated with Class II 
major histocompatability complex allele HLA-DR4 and HLA-DRB1 
 HLA-DR4 gene   - 50 to 75 % (Severe deformities) 
 HLA-DRB1 gene  - Common in Indian patients. 
 
ENVIRONMENTAL RISK FACTORS:  
 Life style factors: 
 Obesity is a risk factor for Rheumatoid arthritis 
 Smoking is a major environmental risk factor for developing Rheumatoid 
    arthritis 
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 Alcohol cuts the risk most in smokers with genetic risk factors for RA 
 There are complex interactions between the female sex hormones and 
    Rheumatoid arthritis 
 Coffee drinkers seems to be at increased risk of developing Rheumatoid 
    arthritis 
 The oral contraceptive pill or some other factor associated with its use 
    appears to protect against the development of severe Rheumatoid arthritis 
  Stress aggravates this disease 
  
TRIGGERING FACTORS: 
 Viral infections –Hepatitis B, Hepatitis C ,Epstein –Barr Virus and others. 
 Bacterial infections – Shigella, salmonella , group A Streptococcal ,Mycobacterium 
tuberculosis. 
 Drugs , Toxins, UV light, vaccination, physical trauma. 
 
CLINICAL FEATURES   
 Morning stiffness for at least one hour and present for at least six weeks. 
 Swelling of three or more joints for at least six weeks. 
 Swelling of  major and minor joints like wrist joints, Metacarpophalangeal joints  or 
proximal interphalangeal joints for at least six weeks. 
 Symmetrical joint swelling. 
  Low - grade fever. 
 Fatigue 
 Anorexia 
 Depression 
 Changes in appearance of the joints (Spindle shaped appearance of fingers , 
      Rheumatoid nodules , Swan neck deformity, Button hole deformity ) 
 
INVOLVEMENT OF INDIVIDUAL JOINTS 
Meta Carpo Phalangeal /Meta Tarso phalangeal  
/Proximal Inter Phalangeal joints               -           90% 
Knee, ankle and Wrist          - 80% 
Shoulder joint     - 60% 
Hip, elbow, acromion    - 50% 
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Cervical spine     - 40% 
Temporomandibular & Sternomastoid joints - 30% 
Cricoartenoid joint                              - 10% 
 
Commonly involved joints: Finger joint (Meta Carpo Phalangeal /Meta 
Tarso phalangeal /Proximal Inter Phalangeal joints ), Shoulder joint, and  Foot joint.                        
  
 
  
 HAND DEFORMITIES IN RHEUMATOID ARTHRITIS 
 Swan neck deformity 
 Button hole deformity or Boutonniere‟s deformity. 
 Z deformity or hitch 
 Morant baker‟s cyst 
 Ulnar deviation of hand 
 Trigger finger 
 Equinus deformity 
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SWAN NECK DEFORMITY 
Hyperextention of Proximal Inter Phalangeal joints with flextion of Distal Inter 
Phalangeal  joints. 
 
BUTTON HOLE DEFORMITY OR BOUTONNIERE‟S DEFORMITY   
Hyperextension of Distal Inter Phalangeal (DIP)  and Meta Carpo Phalangeal (MCP)  
joints with flexion of Proximal Inter Phalangeal (PIP) joints 
 
.Z DEFORMITY  OF THUMP OR HITCH 
   Severe hyperextension of the inter phalangeal joint of  thumb with flexion of Meta 
Carpo Phalangeal (MCP) joint 
.  
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ULNAR DEVIATION OF HAND:  
Ulnar deviation or ulnar drift, it is a deformity of the hands in which the meta carpo 
phalangeal (MCP)joints bends or deviate towards the little finger.  
 
 
 
 
 
 
 
 
 
 
TRIGGER FINGER 
   Also known as Stenosing tenosynovitis, it is an inflammation of synovial sheath 
that encloses the flexor tendons of the thumb and fingers. it may result from enlargement of 
tendon itself or narrowing of 1 st annular pulley. 
 
 
 
SHOULDER JOINT: 
The shoulder  can not be moved, forward, backward in rotation. Difficulty in 
dressing, combing hair, eating, may be produced. It may lead to the formation of frozen 
shoulder. 
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OTHER DEFORMITIES (OR) FETURES  
ANKLE AND KNEE JOINTS 
 Hallus valgus 
  Claw toes  
 Hammer toes  
 Over- riding of 2 and 3 toes 
 Flattening of longitudinal arch , 
 Prominent metatarsal head 
 Excessive plantar tilt of meta tarsals 
 Rheumatoid nodules 
 Achilles tendinitis 
 Calcaneal erosions. 
 
HALLUS VALGUS 
           Also known as bunion, is when there is a medial deviation of the 1 st metatarsal and 
lateral deviation of the great toe (hallux). 
 
 
CLAW TOES 
           It is characterized by hyper extension of Meta Tarso Phalangeal joint and flexion of 
Inter Phalangeal joint, except big toe. 
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HAMMER TOES     
           Hammer toe or contracted toe is a deformity of Proximal Inter Phalangeal joint of the 
second, third, or fourth 
Toe causing it to be permanently bent, resembling hammer. 
 
 
EQUINUS DEFORMITY 
   Decreased ankle dorsiflexion  duo to gastrocnemius contracture. 
 
PATHOLOLGY OF RHEUMATOID ARTHRITIS 
Synovial tissues are the primary target of auto immune inflammatory process in 
Rheumatoid arthritis. 
The following changes occurs in synovial tissues 
 Proliferation of Tcells ,B cells, macrophages, synovial cells in synovium. 
 Production of excess amount of pannus and infiltration of pannus which 
results in synovitis. 
 Destruction of cartilage and bones associated with tendons and ligaments 
occurs 
 As a result signs and symptoms of rheumatoid occurs. 
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STAGES IN PATHOLOLGY OF RHEUMATOID ARTHRITIS  
I. Pathology of Joints and Tendons. 
II. Pathology of Extra-articular tissues. 
 
 
 
I. PATHOLOGY OF JOINTS AND TENDONS  
It can be explained in three stages. 
1. Synovitis. 
2. Destruction. 
3. Deformity. 
 
1. SYNOVITIS 
Initial lesion occurs in the synovium, leading on to vascular stasis, and infiltration of 
the sub synovial layers with inflammatory cells and formation of fibrinous exudates. 
Synovial hypertrophy occurs with the thickening of capsular structures. 
Though this stage is painful, tender and swollen, their structures are still intact and 
mobile.  So, these disorders are reversibly potential. 
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2.DESTRUCTION: 
 
Pannus formation:  
Hypertrophied synovium along with granulation tissue leads to formation of pannus 
which encroaches the articular from its periphery. 
 
Articular cartilage: 
The articular cartilage gets destroyed gradually. Further the bony surface is 
involved, leading to obliteration of joint face. Joint get destroyed and deformed. 
 
3. DEFORMITY: 
The extending granular pannus gets into fibrous tissue, bone, which leads to fibrous 
ankylosis and later bony ankylosis. 
Muscles, tendons, and soft tissues around the joint also undergo inflammatory 
changes and get contracted or ruptured. 
Juxta-articular osteoporosis occurs, Not all patients progress through all three stages. 
 
 
 
EXTRA – ARTICULAR MANIFESTATIONS – COMPLICATIONS 
 SYSTEMIC: 
Weight loss 
 Fatigue 
 Susceptibility of infection 
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 VASCULITIS:  
Digital arteritis 
Pyoderma gangrenosum  
Ulcers 
 
 HAEMATOLOGICAL: 
Anaemia  
Thrombocytosis 
Eosinophilia 
Mononeuritis multiplex Visceral arteritis 
 
 MUSCULOSKELETEL: 
       Muscle Wasting   
           Tenosynovitis 
               Bursitis 
               Osteoporosis 
 
 LYMPHATIC: 
Spleenomegaly 
Lymphadenopathy  
Felty‟s syndrome  
 
 OCCULAR: 
Episcleritis  
Scleritis  
Scleromalacia  
Kerato conjunctivitis sicca 
 
 CARDIAC: 
Pericarditis 
Myocarditis 
Endocarditis  
Conduction defects  
Coronary vasculitis  
Granulomatous arthritis 
38 
 
 PULMONARY: 
Nodules  
Pleural effusion 
Fibrosing alveolitis  
Bronchiolitis 
 
 NEUROLOGICAL: 
Cervical Cord compression  
Compression neuropathies  
Peripheral neuropathy 
Mononeuritis multiplex  
Amyloidosis 
 
 NODULES: 
Sinuses  
Fistula 
 
DIAGNOSIS 
I.CRITERIA FOR DIAGNOSING RHEUMATOID ARTHRITIS 
- (American Rheumatism Association 1988) 
 
 Morning stiffness more than 1 hour for more than 6 weeks. 
 Arthritis of three or more joints for more than 6 weeks. 
 Arthritis of hand joints (wrist, MCP or PIP joints.) for more than 6 weeks. 
 Symmetrical arthritis, at least one area lasting for 6 weeks. 
 Rheumatoid factor. 
 Rheumatoid nodules. 
 Radiological changes. 
 Duration of 6 weeks or more. 
       Diagnosis of Rheumatoid Arthritis is made with 4 or more criteria 
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LABORATORY INVESTIGATIONS 
 1.BLOOD 
 
  Complete Blood Count   
Haemoglobin      - Anaemia  
  Thrombocytes     - Thrombocytosis  
  ESR                 - Increased  
 
   Serum proteins: 
Albumin   - Decreased 
Gamma globulin       - Increased 
IgG, IgM, IgA  - Increased 
 
  2. SEROLOGICAL TESTS 
 
    a) RHEUMATOID FACTOR 
 Rheumatoid factor measures how many of one type of antibodies (IgM, sometimes 
IgA) binds to a second type of your antibodies (IgG). Initially, only one third of people with 
RA test positive for the set of antibody called the Rheumatoid Factor (RF). 
 
Most people with Rheumatoid Arthritis will eventually develop this marker and a 
positive RF is considered a sign and symptom of rheumatoid arthritis. However, some 
people test positive for rheumatoid factor, yet never develop the disease.  
 
b) ANTI-CCP 
 These anti-CCP antibodies bind to some self proteins that are found predominately 
in the synovial tissue. The citrullinated proteins include filaggrin and its circular form 
(cyclic citrullinated peptide: CCP). The presence of these antibodies often correlates with 
some joint destruction. Although this test is relatively recent, a high level of anti-CCP is 
considered a sign and symptom of Rheumatoid Arthritis. 
 
c) ERYTHROCYTE SEDIMENTATION RATE 
It measures the quantity and how quickly the cells are pelleted by spinning in a 
centrifuge. Indirectly, it measures how many cells are bigger and thus activated. 
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d) C-REACTIVE PROTEIN 
A higher than normal level of C-reactive protein (CRP) in the blood also indicates 
that your body has chronic inflammation, and is a common sign and symptom of 
Rheumatoid Arthritis.  
 
3 .RADIOLOGY:  X-rays 
Early changes 
           Soft tissue swelling 
Peri articular osteoporosis 
Erosions-Peri articular and sub articular cysts 
 
Late changes 
           Articular surface irregularity 
Osteoporosis 
Subluxation 
Ankylosis 
Secondary Osteoarthritis 
 
4. ULTRASOUND: Soft tissue abnormalities, e.g. synovial cysts. 
 
5. CT SCAN, MRI: Much greater information of bone, joint and soft tissue. 
 
6. ARTHROSCOPY 
 Direct view of joint and synovial fluid. 
 Potential for biopsy and therapeutic procedures. 
 
7. SYNOVIAL FLUID 
 White cell count raised in infection. 
 Crystal identification: Presence of Urate, Calcium pyrophosphate, crystals present. 
 Synovial fluid analysis confirms the presence of inflammatory arthritis.  
 
8.BIOPSY 
         Synovial biopsy : Villu formation with thickening of synovial layer and infiltration 
with abnormal cells. 
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DIFFERENTIAL DIAGNOSIS  
Several other medical conditions can resemble RA, and usually need to be 
distinguished from it at the time of diagnosis.  
 
Systemic Lupus Erythematosus (SLE) 
Distinguished by specific clinical symptoms and blood tests. 
 Anti Nuclear Antibody (ANA) titre 
 Anti-DNA 
 Complement fixation decreased 
 ESR increased 
 Complete Blood Count, Urine Analysis 
 Kidney biopsy 
 
Crystal Induced arthritis (Gout, and Pseudo gout) 
 It usually involves particular joints (knee, Meta tarsal phalanges, heels)  
 It can be distinguished with aspiration of joint fluid if in doubt. Redness (RA doesn't 
have redness at the joints),  
 Asymmetric distribution of affected joints, 
 Pain occurs at night and the starting pain is less than an hour with gout. 
 
Osteoarthritis : 
      Due to “wear and tear”, develops slowly in Middle-aged and elderly 
 Late joint changes,  
 bony sclerosis,  
 minimal inflammation, 
 Synovial fluid increased,  
 spur formation 
 Gait analysis 
 
Psoriatic arthritis:  
Resembles RA, skin symptoms and nail changes distinguish between them. 
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Reactive Arthritis (previously Reiter's disease) 
Asymmetrically involves heel, sacroiliac joints, and large joints of the leg. It is 
usually associated with urethritis, conjunctivitis, iritis, painless buccal ulcers, 
and keratoderma blennorrhagica. 
 
Ankylosing spondylitis:  
This involves the spine, although a RA-like symmetrical small-joint polyarthritis 
may occur in the context of this condition. 
 
Hepatitis C : 
Hepatitis C may also induce Rheumatoid Factor auto-antibodies. 
 
Sarcoidosis, Amyloidosis and Whipple's disease can also resemble RA. 
 
Hemochromatosis 
May cause hand joint arthritis. 
 
Acute Rheumatic fever 
It  can be differentiated from RA by a migratory pattern of joint involvement and 
evidence of antecedent streptococcal infection. Bacterial arthritis (such as streptococcus )is 
usually asymmetric. While RA usually involves symmetrical joints. 
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                             MATERIALS AND METHODS 
   
The Study on  VALIAZHAL KEELVAYU was  carried out in the OPD and IPD  of 
the  Maruthuvam department, National Institute of Siddha, Chennai. 
 
The trial drug  “MERUGULLI THYLAM”(Internal)  was indicated in the 
authorised Siddha text Theraiyar Thylavarga Surukkam, P.NO 80-81  for VALIAZHAL  
KEELVAYU. 
 
STUDY DESIGN 
 An open Clinical trial 
 
STUDY PLACE 
 OPD and IPD of Ayothidoss Pandithar Hospital,  
 National Institute of Siddha, Tambaram Sanatorium, Chennai-47. 
 
STUDY PERIOD 
             November 2015-2018 October 
 
SAMPLE SIZE 
       40 patients, 39 cases were treated in OPD and one case was admitted in IPD and the 
trial drug was given. 
 
TRIAL DRUG 
INTERNAL MEDICINE 
Drug  : Merugulli thylam       
Dosage : kaal balam-9 grams (9 ml)-3 days morning only(2 days drug   
       holiday) 
Duration :  45 days 
Reference :  Theraiyar Thylavarga Surukkam  
Publication    : B. Rathna Nayakar & Sons. 
Author :   T.C.Subbramaniya Pandither 
Page No.  :  80-81 
        Edition          : 11
th
 edition, 2012. 
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Source of raw drugs 
          The required raw drugs for preparation of “Merugulli thylam” (Internal) were 
purchased from a well reputed country shop and the purchased drugs were authenticated by   
Assistant professor of the Medicinal botany at National Institute of Siddha,Chennai. 
 
Drug Storage 
            Merugulli thylam  was  stored in a  clean and narrow mouthed glass bottles. 
 
Dispensing: 
     The Internal medicine (9 ml) was distributed in Disposable pet bottles. 
 
SUBJECT SELECTION 
Patients reporting to NIS were subjected to screening by screening Proforma. After 
screening they were enrolled for the study fulfilling the inclusion criteria as said below. 
 
Inclusion Criteria  
 Age: 20- 60 years. 
 Both male and female. 
 Symmetrical joint involvement at least one joint for more than 6 weeks 
 Arthritis of three or more joints for more than 6 weeks 
 Swelling present in major and minor joints especially in the inter-phalangeal 
joint. 
 Rheumatoid factor positive or negative. 
 Morning stiffness for more than one hour for more than 6 weeks 
 Deformities like Button hole deformity and Swan neck deformity, spindle 
shaped deformity etc. 
 Anti CCP positive. 
 American criteria for rheumatoid arthritis were followed. 
 Patients willing for admission and stay in IPD or willing to attend OPD. 
 Patient willing to undergo Radiological investigation and for laboratory 
investigation. 
 Patient willing to sign the informed consent stating that he/she was consciously 
stick to the treatment during 45days but could opt out of the trial of his/her own 
conscious discretion.  
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Exclusion Criteria 
 Pregnancy and lactation 
 Tubercular arthritis 
 Any other serious systemic illness like cancer, Cardiac Disease 
 Osteoarthritis 
 Psoriatic arthritis 
 Gouty arthritis 
 Diabetic Mellitus 
 Hypertension 
 Thyroidism (Hypo/hyper) 
 
Withdrawal Criteria 
 Intolerance to the drug and development of adverse reactions during the trial. 
 Poor patient compliance and defaulters. 
 Patient turned unwilling to continue in the course of clinical trial. 
 
Tests and Assessments 
           A. Clinical assessment  
           B. Siddha investigation 
           C. Laboratory investigations 
           D. Radiological investigation 
 
A. Clinical Assessment 
 Arthritis involving three or more joints 
 Symmetrical joint involvement  
 Morning stiffness 
 Anorexia 
 Spindle shaped appearance of fingers 
 Rheumatoid nodules 
 Depression 
 Swelling of small joints of hands and foot. 
 Swan neck deformity 
 Button hole deformity 
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B. Siddha System Examination 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
a. Neer kuri   
 Niram - colour 
 Edai - Specific gravity 
 Manam- Smell 
 Enjal - Deposits/quantity urine voided. 
            b.Neikuri: 
 When the oil drops lenthens like a snake it indicates ‟Vatha Neer‟ 
 When the oil drops Spreads like a ring it indicates ‟Pitha Neer‟ 
 When the oil drops Remains that of pearl it indicates ‟Kaba Neer‟ 
 
C. ROUTINE INVESTIGATIONS 
BLOOD 
Hb 
Total WBC Count 
DC- Polymorphs 
1. Lymphocytes  
2. Eosinophils  
3. Monocytes  
4. Basophils  
Total RBC count  
ESR 
  ½ Hr:              1 Hr: 
Blood sugar 
Fasting:           PP: 
Serum cholesterol 
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URINE 
            Albumin 
            Sugar (F)          (PP) 
      Deposits 
 
Renal function tests 
           Blood Urea 
          Uria acid 
           Serum Creatinine 
 
 Liver function tests 
Serum Total bilirubin 
Direct bilirubin 
            Indirect bilirubin 
            Serum Alkaline phosphatases 
            SGOT 
            SGPT 
 
D. SPECIFIC INVESTIGATIONS 
CRP  
RA factor 
ASO Titre 
 
E. RADIOLOGICAL INVESTIGATIONS 
X-Ray of affected joints (AP and Lat view)  
 
G. DATA COLLECTION FORMS: 
Required information was collected from each patient by using following forms. 
 
FORMS 
FORM I         :    Screening and Selection Proforma   
FORM II       :    History Taking And Clinical Assesment    
             Proforma  
FORM III       :    Laboratory Investigation form  
FORM IV   :   Drug Compliance form  
48 
 
FORM V              :    Patient Information Sheet  
FORM VI            :    Informed Consent Form 
FORM VII          : Withdrawal Form  
      FORM  VII-B      : Adverse Drug Reaction (or) Pharmacovigilance form  
      FORM VIII  : Dietary form 
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT FORM 
 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
PHARMACOVIGILANCE                  
NIS 
FURTHER MANAGEMENT 
OF ADVERSE DRUG 
REACTION 
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METHODOLOGY 
STUDY ENROLLMENT  
           After registered in CTRI (Clinical Trials Registry-India) the patients were enrolled 
for the study. 
 
CTRI NO: CTRI/2018/03/012365 
Patients reporting at the OPD of NIS with the clinical symptoms of Vali Azhal 
Keelvayu were examined clinically. Based on the inclusion and exclusion criteria, they were 
enrolled for the study. 
 
The patients who were enrolled were informed about the study, trial drug, possible 
objectives and outcomes of the study in their vernacular language. After ascertaining the 
patient‟s willingness, informed consent were obtained in concent form. 
 
Complete clinical history, complaints and duration, examination findings and 
laboratory findings were recorded in the prescribed Proformas. Patients were advised to 
take the trial drug and appropriate dietary advice. 
 
CONDUCT OF THE STUDY 
             The trial drug Merugulli thylam (Internal) was given for 45 days. OPD patients 
were asked to visit the hospital once in 5 days. At each clinical visit clinical assessment was 
done and prognosis was noted. For IPD patient the clinical assessment was done daily. The 
results were compared at the end of the study. Laboratory investigations and radiological 
investigation was done before and after trail. At the end of the treatment, the patients were 
advised to visit the OPD without trail drug for follow-up for further 2 months for observing 
any recurrence. Defaulters were not been allowed to continue and be withdrawn from the 
study. 
 
DATA MANAGEMENT 
After enrolling the patient in the study, separate files were maintained for each and 
every patient and all forms and other information were kept in the file. The screening forms 
were filed separately. The data entries were monitored by the Head of the department, 
Maruthuvam. All collected data were statistically analyzed by Senior Research Officer 
(Statistics) for logical errors and incompleteness of data to avoid any bias. No modification 
in the results was permitted for unbiased reports. Then final report was generated. 
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STATISTICAL ANALYSIS 
         All the data were entered into computer using MS access software for logical errors 
and manually cross checked for data entry error. Then the data was explored to 
STATAL/SPSS software for univariate /multivariate analysis. Student „t‟  test and paired „t‟ 
test and Mantel-Haenszel chi-square test was performed for determining the significance of 
a particular effect variable. 
 
OUTCOME 
PRIMARY OUTCOME 
Assessment of pain was by Universal pain assessment scale. Other clinical signs and 
symptoms were assessed by Gradation method. 
       
SECONDARY OUTCOME 
Laboratory investigations such as RA factor, CRP, ASO titre, were also be done at 
the end of the study. 
 
UNIVERSAL PAIN ASSESMENT SCALE 
 
 
  
               Grade 0    :  No Pain 
               Grade 1-3  :  Mild pain 
               Grade 4-6  :  Moderate pain 
               Grade 7-10 :  Severe pain 
                                           - Ref: Clinical Manual for Nursing Practise (National Institute  
                                              of Health Warren Grant Magnuson Clinical Centre )  
 
Restricted movements is assessed by the following Gradation,  
Grade 1  – Able to perform normal duties 
Grade II  – Moderate Restriction – Self care is possible 
Grade III  – Marked restriction – Limited self care/some assistance required. 
Grade IV  – Confined to bed or wheel chair 
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ADVERSE EFFECTS/ SERIOUS EFFECTS MANAGEMENT 
If the trial patient developed any adverse reaction, he/she would be immediately 
informed to the Pharmaco-vigilance committee of NIS for further management.  
 
ETHICAL ISSUES 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments 
were used. 
2. The patients were informed about the treatment and other procedures in his/her 
vernacular language. After received written consent only (language understandable 
to the patient) they were enrolled in the study.  
3. The data collected from the patient were kept confidential.  
4. No other external or internal medicines were used, other than the trial drug during 
the trial period. There was no infringement on the rights of the patient.    
5. Treatment were provided free of cost.  
6. For those tests which are performed in outside lab the money should be borne by the 
patients. 
7. If any serious adverse reactions occur during trial, the patients were given 
alternative treatment at regular OPD of National Institute of Siddha.  
8. If the patient was not willing to continue the treatment, he/she was allowed to 
withdrawed from the trial at any time.  
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PURIFICATION OF RAW DRUGS 
 
1.Merugan kizhangu (Alocasia indica.Schott) 
                  Removed the skin of merugan kizhangu and cut into small pieces & dried. 
                                                Ref:Theraiyar thylavarka surukkam. P.no:80 
 
2.Bulb of Garlic (Allium sativum.Linn) 
                    Peeled  and cleaned the outer layer of garlic 
                                                Ref: Theraiyar thylavarka surukkam.P.no:80 
 
3.Castor oil (Ricinus communis) 
                    Castor oil was taken in a bottle and 1/4 th of the glass bottle was kept under the 
sand. Then it was under sun shade for 2 days and the filtrate was taken 
 Ref:Sigicha rathna theebam ennum vaithiya nool.P.no:27  
 
Internal medicine – Merugulli thylam: 
Ingredients:  
      1.Merugan kizhangu (Alocasia indica.Schott) Equal quantity 
              2. Garlic (Allium sativum.Linn) 
               
              3. Caster  oil(Ricinus communis.Linn)= Equal quantity of 1 and 2 
 
METHOD OF PREPARATION 
            Peeled  and cleaned skin of the merugan tuberous stem and garlic and cut into small 
pieces, then it grinded  into a paste. Heat the paste with castor oil boiled  until it reached a 
wax consistency. Then filtered and took the oil. Used after 3 days. 
 
Drug Storage: 
            Merugulli thylam was stored in a clean and narrow mouthed glass bottles. 
 
Dispensing: 
      The Internal medicine (9 ml) was given in Disposable pet bottles. 
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PROPERTIES OF THE INGREDIENTS OF TRIAL DRUGS 
                                           1. Merugan kizhangu (Alocasia indica.Schott) 
 
English name  :  Great leaved caladium , Giant taro,ape. 
Botanical name :  Alocasia indica.Schott 
Family   : Araceae 
Parts used  :         Tuber  
Constituents            :          Alomacrorrhiza A and allocasin, ascorbic acid. 
Organoleptic Characters 
Taste  :    Kaarppu 
Potency  :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions     :       Anti-inflammatory 
                                           Antinociceptive 
                                            Antioxidant  
Analgesic activity 
                                                 
Therapeutic effects 
nkUfq; fpoq;F 
mur dikr;r djpfhhp Nridf; 
fur dpth;;f;fpfNy ahfpg;-nghUTk; 
kpUfnkD ehiaKay; Nky;tpL jy;Nghy; 
nkUfbia NaTtpid Nky;.             
                       (Njud;-ntz;gh) 
 
                The analgesic and anti-inflammatory activities of the crude ethanolic extract of 
dried rhizome of Alocasia indica (Roxb.) Schott 
(9) . 
                 
The detoxified tuber is used to treat influenza, high fever and malaria; diarrhea and 
typhoid fever, rheumatic; pulmonary tuberculosis and tuberculous lymphadenopathy; 
headache; abscesses and ring worms 
(10) . 
 
Alocasia indica Schott had ascorbic acid anti-inflammatory, antinociceptive 
activities and antioxidant  property 
(11)
 . 
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                                       2.Bulb of Garlic (Allium sativum.Linn) 
 
English name  :  Garlic 
Botanical name :  Allium sativum.Linn  
Family   : Amaryllidaceae 
Parts used  :          Bulb 
Constituents            :         Alliin,tryptophan,sativioside, allyl methyl trisulphide, 
Scordinine A,,A1, A2 & B,Five saponins , n-3 fatty acids, indolic and phenolic compounds, 
5-hydroxy-l-tryptophan, in RAW 264.7 cells, organosulfur compounds, phenolic acids, 
allyl thiosulfinates, flavonoids, and vitamins etc 
 
Organoleptic Characters 
Taste  :         Kaarppu. 
Potency  :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions    :      Anti-inflammatory 
                                            Antinociceptive 
                                            Antioxidant  
                                          Analgesic activity 
                                           Antiarthritic activity  
                                            Hypolipidemic 
                                              Anticoagulant    
                                              Anticancer 
                                               Antigenotoxic,  
                                           Anticlastogenic effects 
 
 
Therapeutic effects 
rd;dpnahL thje; jiyNehT jhs;typ 
kd;dptU ePh;f;Nfhit td;rPjk;- md;dNk! 
cs;Ss;sp fz;gha; cis%y NuhfKk; Nghk; 
nts;Ss;sp jd;dhy; ntUz;L.              
(mfj;jpau; Fzthflk;) 
 
           Alliin  the precursor of the antibiotic principle of Allium sativam was found useful in 
the treatment of  rheumatoid arthritis. A beneficial change in mucoprotein level and ESR   
was observed when clinically evaluated. It gives a significant effect  such as pain relief, 
morning stiffness, swelling in patients with different rheumatic disorder
(12)
 .             
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Allicin exhibits hypolipidemic, antiplatelet, and procirculatory effects. Moreover, it 
demonstrates antibacterial, anticancer, and chemopreventive activities. Allicin ((R, S)-
diallyldisulfid-S-oxide), one of the sulfur compounds from garlic, is formed by the action 
of the enzyme alliinase on alliin. It possesses antioxidant activity 
(13) . 
Antioxidant and Antiarthritic Activity of Allicin were done in Animal Models 
(14). 
                                                
                             CASTER  OIL(Ricinus communis.Linn ) 
 
English name  :  Castor,Castor oil plant. 
Botanical name :  Ricinus communis.Linn 
Family   : Euphorbiaceae 
Parts used  :         Root,leaf, Flower, seed, seed oil. 
Constituents            :         Alkaloids, ricinine, albumin, ricin and 1-methyle-3-cyano-4-
methoxy-2-2pyridone, β- stosterol,ricinine,Gallic acid,Flavonoid- lucenin , Hydro cyanic 
acid and uric acids (oil) etc . 
 
Organoleptic Characters 
Taste  :    Kaarppu. 
Potency  :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions    :         Anti-inflammatory; 
                                             Spasmogenic,  
                                              Hepato protective, 
                                            Anti  fertility 
                                             Purgative 
                                            Imminizing 
                                            CNS depressant, 
                                               Spasmolytic. 
IN SIDDHA ASPECT 
Mkzf; nfz;nza; jd;id azpepy kwpaf; Nfz;kpd; 
G+kzr; re;jNjhWk; nghUe;jpa thjk; Nghf;Fk; 
jPke;je; jhDk; Nghf;Fe; jpfo;Tld; tpiuT Kz;lhk; 
jPkdf; Flypy; thjQ; Nrh;Fl Nyw;wk; NghNk 
(Fzghlk; - %ypif) 
Seed oil-anti pyretic, recommended for abdominal disorders, dysentery, chronic articular 
rheumatism, oedema
(15). 
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BIO -CHEMICAL ANALYSIS OF MERUGULLI THYLAM AT  
                                       NATIONAL INSTITUTE OF SIDDHA 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of sample Dark brown in 
colour 
 
2. Solubility: 
a. A little  of the sample is         shaken 
well with distilled water. 
b. A little  of the sample is shaken well 
with con. HCl / Con. H2So4 
 
 Sparingly soluble 
 
 
Presence of 
Silicate 
3. Action of Heat: 
        A small amount of the sample is 
taken in a dry test tube and heated gently 
at first and then strong. 
 No brown  fumes   
 
Absence of 
Nitrate 
 
4. Flame Test: 
        A small amount of the sample is 
made into a paste with con. HCl in a watch 
glass and introduced into non-luminous 
part of the Bunsen flame. 
 No Bluish green 
flame appeared. 
Absence of 
Copper 
5. Ash Tests:  
        A filter paper is soaked into a mixture 
of sample and cobalt nitrate solution and 
introduced into the Bunsen flame and 
ignited 
 No Yellow colour 
flame 
Absence  of 
sodium 
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Preparation of Extract:   
       5gm of Merugulli thylam is weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 minutes. 
Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml with 
distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I. Test For Acid Radicals   
1. Test For Sulphate: 
       2ml of the above prepared 
extract is taken in a test tube to 
this added 2ml of 4%  
ammonium oxalate solution. 
 No Cloudy 
appearance present 
Absence of  Sulphate 
2. Test For Chloride: 
      2ml of the above prepared 
extract is added with dil.Hno3 till 
the effervescence ceases. Then 2 
ml of Silver nitrate solution is 
added . 
No Cloudy 
appearance present 
Absence of Chloride 
3. Test For Phosphate: 
       2ml of the extract is treated 
with 2ml of dil.ammonium 
molybdate solution and 2ml of 
con.HNo3 
Cloudy yellow 
appearance present 
Presence of 
Phosphate 
4.  Test For Carbonate: 
       2ml of the extract is treated 
with 2mldil. magnesium sulphate 
solution 
 No  Cloudy 
appearance present 
Presence of 
Carbonate 
C Test For Nitrate: 
      1gm of the substance is 
heated with copper turning and 
con.H2So4 and viewed the test 
tube vertically down. 
 
No Brown gas is 
evolved 
Absence of Nitrate 
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6. 
Test For Sulphide: 
     1gm of the substance is 
treated with 2ml of con. HCL 
 No Rotten Egg 
Smelling gas evolved 
Absence of Sulphide 
7. Test For Fluoride & Oxalate: 
     2ml of extract is added with 
2ml of dil. Acetic acid & 2ml 
dil. calcium chloride solution & 
heated. 
No Cloudy         
appearance 
Absence of fluoride 
and oxalate 
8. Test For Nitrite: 
     3drops of the extract is placed 
on a filter paper, on that-2 drops 
of dil.acetic acid and 2 drops of 
dil. Benzidine solution is placed. 
No Characteristic 
changes 
Absence of Nitrite 
 Test For Borate: 
      2 Pinches (50mg) of the 
substance is made into paste by 
using dil. sulphuric acid and 
alcohol (95%) and introduced 
into the blue flame. 
 
 
Bluish green colour 
flame not appeared 
 
 
Absence of borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
       2ml of the extract is added 
with 2ml of dil. potassium iodine 
solution. 
No Yellow 
Precipitate is 
obtained. 
Absence of Lead 
 Test For Copper: 
a. One pinch(50mg) of substance 
is made into paste with con. 
HClin a watch glass and 
introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
Absence of copper 
3. Test For Aluminium: 
        To the 2ml of extract 
dil.sodium hydroxide is added in 
No characteristic 
changes 
Absence of aluminium 
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5 drops to excess. 
4. Test For Iron: 
a. To the 2ml of extract add 2ml 
of dil. ammonium solution 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of 
con HNo3 is added 
 
   Blood Red colour          
appeared 
 
Presence of Iron 
5. Test For Zinc:  
      To 2ml of the extract 
dil.sodium hydroxide solution is 
added in 5 drops to excess and 
dil.ammonium chloride is added.  
 
White precipitate is   
not formed 
 Absence of Zinc 
6. Test For Calcium:  
      2ml of the extract is added 
with 2ml of 4% dil. ammonium 
oxalate solution  
 Cloudy appearance 
and white precipitate 
is obtained 
 Presence of calcium 
7. Test For Magnesium:  
      To 2ml of extract dil. sodium 
hydroxide solution is added in 
drops to excess. 
No White precipitate 
is  obtained 
 Absence  of 
Magnesium 
8. Test For Ammonium: 
       To 2ml of extract 1 ml of 
Nessler's reagent and excess of 
dil. sodium hydroxide solution 
are added. 
 Brown colour 
appeared 
Presence of 
ammonium 
9. Test For Potassium:  
       A pinch (25mg) of 
substance is treated of with 2ml 
of dil. sodium nitrite solution 
and then treated with 2ml of dil. 
cobalt nitrate in 30% dil. glacial 
acetic acid. 
 
 
No Yellowish 
precipitate is 
obtained. 
 
Absence of Potassium 
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10. Test For Sodium: 
        2 pinches (50mg) of the 
substance is made into paste by 
using HCl and introduced into 
the blue flame of Bunsen burner. 
  
No Yellow colour 
flame appeared 
  
Absence  of Sodium 
11. Test For Mercury:  
     2ml of the extract is treated 
with 2ml of dil. sodium 
hydroxide solution.  
 
  No yellow       
precipitate is 
obtained 
   
 
Absence of Mercury 
12. Test For Arsenic:  
      2ml of the extract is treated 
with 2ml of dil. sodium 
hydroxide solution. 
No brownish red 
precipitate is 
obtained 
Absence of Arsenic 
 III. Miscellaneous   
1.  Test For Starch:  
2ml of extract is treated with 
weak dil. Iodine solution  
 Blue colour 
developed 
Presence  of starch 
2.  Test For Reducing Sugar:  
    5ml of Benedict's qualitative 
solution is taken in a test tube 
and allowed to boil for 2 minutes 
and added 8 to 10 drops of the 
extract and again boil it for 2 
minutes. The colour changes are 
noted. 
  
 
 No Brick red colour  
is developed 
 
 
Absence of reducing 
sugar 
3.  Test For The Alkaloids: 
a)2ml of the extract is treated 
with    2ml of dil. potassium 
lodide solution. 
b)  2ml of the extract is treated 
with 2ml of dil. picric acid. 
c)  2ml of the extract is treated 
with 2ml of dil. phosphotungstic 
acid. 
 
No  Red colour 
developed 
 Yellow colour 
developed 
No White precipitate 
developed 
 
 
 
Presence of Alkaloid 
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4.  Test For Tannic Acid:  
      2ml of extract is treated with 
2ml of dil. ferric chloride 
solution  
  
No black precipitate 
is obtained 
 
Absence of Tannic acid 
  Test For Unsaturated 
Compound: 
      To the 2ml of extract 2ml of 
dil. Potassium  permanganate 
solution is added.  
 
Potassium 
permanganate is not 
decolourised 
 
Absence of unsaturated 
compound  
6.  Test For Amino Acid: 
    2 drops of the extract is placed 
on a filter paper and dried well. 
20ml of  Biurette reagent is 
added. 
 
No Violet colour 
developed 
 
Absence of amino 
acids 
 
7. Test For Type Of Compound: 
    2ml of the extract is treated 
with 2 ml of dil.ferric chloride 
solution.  
No green colour 
Developed 
 
No red colour 
developed 
 
No violet colour 
developed 
No blue colour 
developed 
Absence of oxy 
quinole pinephrine and 
pyro catechol. 
Anti pyrine, Aliphatic 
amino acids and 
meconic acid are 
absent  
Apomorphine 
salicylate and 
Resorcinol are absent 
Morphine, Phenol 
cresol and 
hydrouinoneare absent 
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                                           BIO -CHEMICAL ANALYSIS 
 
S.NO CONSITUENTS INFERENCE 
1.  Silicate  Present 
2.  Iron Present 
3.  Alkaloids Present  
4.  Phosphate Present 
5.  Calcium Present 
6.  Ammonium Present 
     7. Starch Present 
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Standardization Report 
           
 
 
 
 
 
 
 
 
  Test for Aflatoxin 
 
                   The trial drug Merugulli thylam was free from Aflatoxins. 
    
 
                                     TEST FOR AFLATOXIN 
The procedures recommended for the detection of Aflatoxin as per WHO (2007).   
 
Instrument Details:  
Name of the Instrument : CAMAG (CAMAG - Automatic TLC sampler, 
   Scanner and Visualiser) 
Spray Gas : N2 
Lamp used : Mercury Lamp 
 
The samples were processed as per procedures recommended in WHO 2007 and 
applied for the Thin Layer Chromatography and High Performance Thin Layer 
Chromatography study with suitable solvent systems. After development the plate was 
allowed to dry in air and examined under 366nm.   
 
 
S.NO      PARAMETERS  RESULTS 
1 Refractive index 1.4752 
2 Acid value 9.41 
3 Saponification Value 181.45 
4 Peroxide Value 5.36 
5 Iodine value 83.11 
6 Weight 0.964 
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RESULTS 
 
TEST FOR AFLATOXIN ANALYSIS: 
 The sample TS: Merugulli thailam, 15µl and Standard  Std - G2, G1, B2 and B1 (20 
µl) were applied on TLC aluminium sheet silica gel 60 F 254 (E.MERCK) and plate was 
developed using the solvent system Chloroform : acetone : water (14 : 2 : 0.2). After 
development the plate was allowed to dry in air and examined under  UV 366 nm 
  
 
UV-366nm 
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HPTLC Densitometric chromatogram (366nm)  
Test sample (TS) : Merugulli Thailam ; Standard (S) – G2, G1, B2 & B1  
 
 
 
 
HPTLC finger print of Sample (TS) : Merugulli thailam at 366nm  
 
 
Rf value of  Sample (TS) : Merugulli thailam at 366nm  
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HPTLC finger print of Standard (S) at 366nm  
 
Rf value of Standard (S) at 366nm  
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OBSERVATION AND RESULTS 
 
1. AGE DISTRIBUTION 
AGE (YEARS) NUMBER OF PATIENTS PERCENTAGE % 
20  - 30 yrs 
 
                     4 10% 
31 – 40 yrs                     14                       35% 
41 – 50 yrs                     15 37.5% 
51 – 60 yrs                       7 17.5% 
Total 40 100% 
 
                  
Fig.1. Age Distribution 
Observation:  
 10% (4) of the affected patients came under the age group between 20-30 years. 35 
%(14) of the patients came under the age group between 31-40 years, 37.5 % (15)of them 
were between 41-50 years and 17.5 %(7) of them were between 51-60 years. 
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2. GENDER DISTRIBUTION 
GENDER NUMBER OF PATIENTS PERCENTAGE % 
Male 7 17.5% 
Female 33  82.5% 
Total 40 100% 
 
 
Fig.2. Gender Distribution 
 
Observation: 
           Among the 40 patients selected, the disease (R.A) was found to be higher in 33 
females (82.5%) and lower in 7 males (17.5%). 
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3. MENOPAUSAL STATUS: 
MENSTURAL HISTORY  NUMBER OF PATIENTS PERCENTAGE 
NOT YET MENOPAUSE                      23                 69.69% 
ATTAINED 
MENOPAUSE 
                      8                  24.24% 
HYSTERECTOMY                       2                 6.06% 
TOTAL                     33                 100% 
 
 
Fig.3. Menopausal status 
Observation: 
 In this study, out of 33 females 8(24%) females attained menopause, 2(6%) females 
were in hysterectomy status. 
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 4. GUNAM 
GUNAM NUMBER OF PATIENTS PERCENTAGE( %) 
Sathuvam 0 0% 
Rasatham 38 95% 
Thamasam 2 5% 
Total 40 100% 
 
 
Fig. 4. Gunam 
Observation: 
          In Gunam, 38 cases (95%) had Rasatha gunam, 2 cases(5%)  had Thamasa gunam. 
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5. BODY CONSTITUTION 
CONSTITUTION 
OF THE BODY 
NUMBER OF PATIENTS 
PERCENTAGE 
% 
Vatha thegi - - 
Pitha thegi - - 
Kabam thegi 5 12.5% 
Thontha thegi 35 87.5% 
 
 
Fig. 5. Body constitution 
 
Observation: 
              Out of 40 cases,5 (12.5%)cases came under kabha thegi, 35 cases (87.5%) were 
came under Thontha Thegi. 
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6. EDUCATIONAL STATUS 
EDUCATIONAL 
STATUS 
NUMBER OF 
PATIENTS 
PERCENTAGE 
Literate 24 60% 
Ill literate 16 40% 
TOTAL 40 100% 
 
 
Fig.6. Educational Status 
Observation: 
 Among 40 cases 24 cases (60%) were literate and 16 cases (40%) were ill literate. 
 
 
 
 
 
 
 
 
 
 
 
82 
 
7. MARITAL STATUS 
MARITAL STATUS NUMBER OF 
PATIENTS 
PERCENTAGE 
Married 39 97.50% 
Unmarried 1 2.50% 
TOTAL 40 100% 
 
 
 
Fig.7. Marital Status 
 
Observation: 
  Among 40 cases 39 (97.5%) got married and 1 case (2.5%) not married. 
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8. PARUVA KAALAM (SEASON)  
 
                  
Fig.8. Paruva kaalam (Season) 
Observation: 
            Out of 40 cases 26(65%) cases were included  in Koothirkaalam , 12(30%) cases 
were included in Munpani kaalam and 2(5%) in Pinpani kalam. 
SEASONS 
Month and the year 
Number of the 
patients 
Percentage 
% 
Kaarkaalam 17
th
 Aug-17
th
 Oct - - 
Koothirkaalam 18
th  
Oct-15
th
 Dec 26 65% 
Munpanikaalam 16
th
  Dec-12
th
 Feb 12 30% 
Pinpanikaalam 13
th
  Feb-13
th
Apr 2 5% 
Ilavenil kaalam 14
th
  Apr-16
th
 June - - 
Mudhuvenil kaalam 17
th
 June-16
th
 Aug - - 
Total  40 100% 
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9.  THINAI 
THINAI Number of patients 
Percentage 
% 
Kurinji 2 5% 
Mullai 
 
- - 
Marutham 
 
1 2.5% 
Neithal 
 
37 92.5% 
Palai 
 
- - 
Total 
 
40 100% 
 
                   
Fig.9.  Thinai 
Observation: 
 Among the 40 cases, 37(92.5%) cases were from Neithal thinai and 2(5%) cases 
were from Kurinji thinai and 1( 2.5% ) case were from Marutham thinai. 
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10. DIET 
 
Diet No of cases Percentage % 
Vegetarian 10 25% 
Non vegetarian 30 75% 
Total 40 100% 
 
 
 
Fig.10. Diet 
 
Observation:  
Out of 40 patients , 30 cases were Non vegetarian (75%) dieter  and 10 cases were 
(25%)  vegetarian dieter. 
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11. OBESITY 
OBESITY NUMBER OF PATIENTS PERCENTAGE 
OBESE 5 12.5% 
NORMAL WEIGHT 35 87.5% 
TOTAL 40 100% 
 
 
Fig.11. Obesity 
 
Observation: 
In this study 5 cases (12.5 %) were Obese and 35 cases (87.5 %) were belongs to 
normal weight. 
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12. OCCUPATIONAL DISTRIBUTION  
OCCUPATION NO. OF CASES 
 
PERCENTAGE 
% 
Home maker 
 
30 75% 
Farmer 1 2.5% 
Driver 2 5% 
Coolie 4 10% 
Student 1 2.5% 
Beautician 1 2.5% 
Tailor 1 2.5% 
Total 40 100% 
 
 
                                 
Fig.12. Occupational distribution 
Observation:  
Among 40 cases, 30cases (75%) were home maker, 1case (2.5% ) was Student,1 
Case ( 2.5%)  was Beautician, 4 Cases (10%) were cooli, 1 Case (2.5%) was Farmer, 2 
cases (5%)were Driver, 1 case (2.5%) was tailer.  
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13. SOCIO-ECONOMIC STATUS 
 
Socio- economic status No. of cases Percentage % 
Low Income Group 10 25% 
Middle Income Group 29 72.5% 
High Income Group 1 2.5% 
Total 40 100% 
 
 
Fig.13. Socio-economic status 
 
Observation:  
 In my study the disease was found  higher in the middle  income group 29 cases 
(72.5% ), Moderate in the low income group 25%(10 cases), Lower in the High income 
group 2.5% (1 case). 
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14. FAMILIAL HISTORY 
 
In this study family history of RA is  present in one case (2.5%)  in all 40 cases.  
 
 
                
 
 
Fig.14. Family history 
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 15.  DURATION OF ILLNESS: 
DURATION OF ILLNESS NUMBER OF  CASES PERCENTAGE % 
Upto 1 yr 9 22.5% 
1  year -2 years 11 27.5% 
2 years-5 years 13 32.5% 
5 years -7years 5 12.5% 
7years-10 years 1 2.5% 
10 years-15 years 1 2.5% 
Total 40 100% 
 
                           
Fig.15. Duration of Illness 
Observation: 
                In this study, about 9(22.5% )cases had symptoms upto 1  yr of duration,11( 
27.5%) cases had the sign and symptoms of  RA 1 to 2 yrs of duration,13( 32.5% )cases had 
2-5 yrs of duration,  5(12.5%) cases had  5 to 7yrs of duration ,one ( 2.5%) case had 7-10 
yrs and  another  one case (2.5%)  had 10-15 yrs  of duration. 
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16. TREATMENTAL HISTORY OTHER THAN SIDDHA TREATMENT: 
CRITERIA FOR OPTING 
SIDDHA TREATMENT 
NO.OF CASES PERCENTAGE 
Adverse effects of drugs(like 
NSAIDS, Steroids) 
9 22.5% 
Fear for adverse effects 25 62.5% 
Referred from rheumatologist 2 5% 
Not undergone any treatment 
before 
4 10% 
Total 40 100% 
 
 
Fig.16. Treatmental History Other Than Siddha Treatment 
Observation:  
 Among 40 patients the reason for the patients to undergo Siddha treatment was 
more in 25 (62.5%) cases due to fear for adverse effects in other system of medicine. 9 
cases (22.5%) due to Adverse effects of drugs, 2 cases (5%) were referred from 
Rheumatologist, and 4 cases (10%) were not undergo any treatment. 
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17. MODE OF ONSET  
 
 
 
Fig. 17. Mode of Onset 
 
Observation : 
                    In this study 30 cases(75%) had Gradual onset of illness, 10 cases(25%) had 
Sudden onset of the disease. 
 
 
 
Mode  
of onset 
No of Cases 
 
Percentage % 
Gradual onset 30                        75% 
Sudden onset 10 25% 
Total 40 100% 
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18. INVOLVEMENT OF JOINTS: 
Name of the joint BeforeTrt After  Trt 
 
Before trt % After trt % 
Cervical joint 
vertebrae 
15 5 
 
37.5% 12.5% 
Elbow joint 35 10 87.5% 25% 
Wrist joint 39 12 97.5% 30% 
MCP joint 37 19 92.5% 47.5% 
Knee joint 36 20 90% 50% 
Ankle joint 35 24 87.5% 60% 
PIP joint 40 25 100% 62.5% 
Hip joint 10 5 25% 12.5% 
Lumbosacral jt 14 8 35% 20% 
 
 
Fig.18. involvement of joints 
Observation: 
Cervical vertebrae were involved in 15cases (37.5%), elbow joint and ankle  joint 
were involved in 35 cases(87.5%),39 cases (97.5%) in wrist joint, after treatment it was 
12.5%,25%,60%,30%   respectively. MCP joint was involved in 37 cases (92.5%), Knee 
joint in 36 cases 90% after treatment it was reduced 47.5% (19 cases)  and 20 cases (50%). 
PIP joint were affected 40 cases (100%) before treatment, After treatment it was 62.5% (25 
cases).  Before treatment Lumbosacral joint was  affected  in 14 cases  (35%) after 
treatment it was 20% (8 cases). 
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19. NAADI 
NAADI 
NUMBER OF 
PATIENTS 
PERCENTAGE  
% 
Vatha pitham 32 80% 
Pitha vatham 3 7.5% 
Pitha kabam 1                 2.5% 
Vatha kabam 2 5% 
Kaba vatham 2 5% 
Total 40 100% 
 
                     
Fig. 19. Naadi 
 
Observation : 
                  Among 40 cases,Vatha pitha naadi was found in 32 cases (80%), Pitha vatha 
naadi was found in 3  cases (7.5%), Pitha kaba naadi was found in 1 case (2.5%), Vaatha 
kaba naadi was found in  2cases (5%)  and kaba vatha naadi was found in 2 cases (5%). 
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THREE HUMORS 
20. DISTURBANCES IN VALI 
VALI 
NUMBER OF  
PATIENTS 
PERCENTAGE 
% 
Praanan 5 12.5% 
Abaanan 37 92.5% 
Udhaanan - - 
Viyaanan 40 100% 
Samaanan 40 100% 
Naagan 1 2.5% 
Koormam - - 
Kirukaran - - 
Devathatan 28 70% 
Dhananjeyan - - 
 
Fig.20. Disturbances in Vali 
Observation: 
 In Vatham, Viyaanan and Samanan were affected in all 40 cases 
(100%), pranan was affected in  5 cases(12.5%)  ,Abanan was affected in 37 cases (92.5%) 
and Devathathan was affected in 28 cases (70%)  and naagan was affected in 1 case(2.5%). 
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21.  DISTURBANCES IN AZHAL 
AZHAL 
NUMBER OF  
PATIENTS 
PERCENTAGE  
% 
Analakam 31 77.5% 
Ranjagam 27 67.5% 
Saathagam 19 47.5% 
Alosagam - - 
Prasagam - - 
 
                    
Fig. 21.  Disturbances in Azhal 
 
 
Observation: 
       Among 40 cases, Analagam was affected in 31 cases (77.5%) , Saathagam was affected 
in all 19 cases (47.5%) , Ranjagam was  affected in 27 cases(67.5%).  
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 22. DISTURBANCES IN IYAM 
IYYAM NUMBER OF PATIENTS PERCENTAGE 
AVALAMBAGAM 40 100% 
KILETHAGAM 31 77.5% 
POTHAGAM 0 0% 
THARPAGAM 1 2.5% 
SANTHIGAM 40 100% 
 
 
Fig. 22. Disturbances in Iyam 
Observation:  
Santhigam was affected in all the 40 cases(100%), Avalambagam affected in 40 
cases (100%),  kilethagam affected in 31 cases (78%)and tharpagam affected in 1 
case(2.5%). 
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23. UDAL THAATHUKKAL  
 
Fig.23. Udal Thaathukkal 
Observation: 
                      In this  study Saram, Oon, Kozhuppu, Enbu and moolai  were affected in all 
40 cases(100%) and  Senneer was affected in  27(67.5%) cases only. 
 
 
 
UDAL THAATHUKKAL NUMBER OF  
PATIENTS 
PERCENTAGE 
% 
Saaram 40 100 % 
Senneer 27 67.5% 
Oon 40 100% 
Kozhuppu 40 100% 
Enbu 40 100% 
Moolai 40 100% 
Sukkilam / Suronitham - - 
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24.  ENVAGAI THERVUGAL 
ENVAGAI THERVUGAL NUMBER OF CASES PERCENTAGE % 
Naadi (Thontha naadi) 40 100% 
Sparisam 40 100% 
Niram - - 
Mozhi - - 
Vizhi 27 67.5% 
Naa 27 67.5% 
Malam 37 92.50% 
Moothiram - - 
 
 
Fig.24.  Envagai Thervugal 
Observation:    
 In Envagai thervu , Thontha naadi in all 40 cases, Sparisam was affected in 
40(100%) patients where as Vizhi was affected in 27 cases (67.5%), Naa was affected in 27 
cases( 67.5%) and Malam was affected in 37(92.5%) of patients. 
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25.  KOSANGAL: 
KOSANGAL NUMBER OF PATIENTS PERCENTAGE 
Annamaya kosam 31 77.5% 
Pranamaya kosam 5 12.5% 
Manomaya kosam 26 65% 
Vinyanamaya kosam 40 100% 
Ananthamaya kosam 3 7.5% 
 
                             
Fig.25.  Kosangal 
Observation 
                  In this study Annamaya kosam was affected in 31 cases(77.5%), Pranamaya 
kosam  was affected in 5 cases(12.5%), Manomaya kosam  was affected in 26 cases (65%), 
Vinyanamaya kosam was affected in 40 cases (100%) and Ananthamaya kosam affected in 
3 cases (7.5%). 
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26. KANMENTHIRIYAM 
Kanmenthiriyam No of cases Percentage % 
Kai 40 100% 
Kaal 40 100% 
Vai -  - 
Eruvai 37 92.5% 
Karuvai - - 
 
 
Fig 26. Kanmenthiriyam 
 
Observation: 
                 In Kanmendrium Kai and Kaal were affected in 40(100%) cases, Eruvai was 
affected in  37 ( 92.5%)  cases. 
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27. NEIKKURI 
SPREADING PATTERN 
NUMBER OF  
PATIENTS 
PERCENTAGE 
% 
Aravena neendathu – Vatha neer 5 12.5% 
Aazhi pol paraviyadhu – Pitha neer - 0% 
Muthothu nindrathu – Kaba neer 35 87.5% 
Total 40 100% 
 
 
Fig.27. Neikkuri 
 
Observation: 
               Among  40 cases,  Vatha neer was found in 5 cases (12.5%) , and Kaba neer was  
found in 35 cases (87.5%). 
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28. DEFORMITIES: 
DEFORMITY NO OF CASES PERCENTAGE % 
Button hole 7 17.5% 
Swan neck 1 2.5% 
Spindle shape deformity 11 27.5% 
No deformity 21 52.5% 
 
 
Fig.28. Deformities 
 
Observation 
 In this study,   11 cases (27.5%)  had spindle shape deformity,7cases (17.5%) had 
buttonhole deformity and 1case (2.5%) had swan neck deformity. Remaining 21 cases 
(52.50%) had not any  deformities. 
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29. CLINICAL SYMPTOMS 
 
                   
Fig.29. Clinical Symptoms 
Observation:   
In this study, all 40 cases (100%) had pain before treatment,after treatment it was 
reduced to 24 cases(60%). All 40 cases (100%) had swelling before treatment, after 
treatment no one had swelling.All 40 cases (100%) had morning stiffiness before treatment, 
after treatment it was reduced to  2 cases (5%). All 40 cases (100%) had tenderness before 
treatment, after treatment it was reduced to 0% . All 40 cases (100%) had warmth before 
Clinical features Before trt After trt Berfore trt% After trt % 
Pain 40 24 100% 60% 
Swelling 40 0 100% 0% 
Morning stiffness 40 2 100% 5% 
Tenderness 40 0 100% 0% 
Warmth 40 1 100% 2.5% 
Fever 2 - 5% 0% 
Poly arthralgia 40 25 100% 62.5% 
Deformity 19 19 47.5% 47.5% 
Restricted movements 40 10 100% 25% 
Anorexia 31 - 77.5% 0% 
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treatment, after treatment it was reduced to 1 case (2.5%). Before treatment 40 cases 
(100%) had polyarthralgia, after treatment it was reduced to 25 cases (62.5%). Deformitis 
remained the same before and after treatment in 19 cases (47.5%). Before treatment 
anorexia was in 31 cases (77.5%)  after treatment no cases were reported with anorexia. 
Before treatment Fever was found in 2 cases (5%)  which was  releived after treatment. 
Before treatment 40 cases (77.5%) had restrictrd movements, after treatment it was reduced 
to 10 cases (25%). 
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PRIMARY OUTCOME 
PAIN ASSESSMENT SCALE 
 
30.  REDUCTION OF PAIN 
Pain 
Before Treatment After Treatment 
No of patient 
Percentage 
% 
No of patient Percentage % 
Severe Pain 25 62.5% 0 0% 
Moderate Pain 15 37.5% 1 2.5% 
Mild Pain 0 0% 23 57.5% 
No Pain - - 16 40% 
Total 40 100% 40 100% 
 
                   
Fig.30. Reduction Of Pain 
Observation:  
 In this study, Before treatment 25 cases (62.5%) had Severe pain, 15 cases 
(37.50%) had Moderate pain. After treatment no one had Severe pain, one case( 2.5%)  had 
Moderate pain,  23 cases  (57.5%) had Mild pain and 16 cases(40%) had No pain. 
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31. FUNCTIONAL ABILITY GRADATION 
Grade 
No. of patients 
Before Treatment % After Treatment % 
Grade IV 4 10% 0 0% 
Grade III 19 47.5% 0 0% 
Grade II 17 42.5% 10 25% 
Grade I - 0% 30 75% 
Total 40 100% 40 100% 
Grade I - Fit for all activities 
Grade II - Mild restriction 
Grade III - Moderate restriction 
Grade IV  - Confined to chair or bed ridden 
 
Fig.31. Functional Ability Gradation 
Observation:     
            Among 40 cases,  Before treatment  4 (10%)cases came under  grade IV  and 19 
(47.5%) cases came under  Grade III, 17(42.5%) cases in Grade II. after treatment   no  one 
came under Grade IV and III ,10(25%) cases came under Grade II  and 30 cases (75%) 
came under   Grade I.  
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 32. IMPROVEMENT IN FUNCTIONAL ABILITY ASSESSMENT PER PATIENT: 
As per Cross tabulation 31 
Before treatment functional ability –After treatment functional ability 
 AFTER TREATMENT   FUNCTIONAL ABILITY  
TOTAL I II III IV 
BT 
 
II 17 0 0 0 17 
III 12 7 0 0 19 
IV 1 3 0 0 4 
TOTAL 30 10 0 0 40 
 
 
          
Fig.32. Improvement in functional ability Assessment Per Patient 
Observation:     
Before treatment 4 cases (10%) came under grade IV after treatment 1 case (2.5%) 
under grade I and 3 cases (7.5%) under Grade II. Before treatment  19 cases  (47.5%) came 
under  Grade III after treatment 12 cases (30%) came under grade I and 7  cases (17.5%) 
came under grade II, Before treatment 17(42.5%) cases in Grade II  after treatment  all 17 
(42.5%) cases came under Grade I. 
In this study, 100% cases showed improvement in functional ability. 
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SECONDARY OUTCOME 
 
LAB PARAMETERS 
33.  RA FACTOR 
Before 
treatment 
Number of 
patients 
Percentage After 
treatment 
Number 
of cases 
Percentage 
POSITIVE 27 67.5% POSITIVE 18     45% 
 
                      
Fig.33. RA Factor 
 
Observation:   
Among 27 cases (67.5%)   who are positive at  commencement of the treatment  9 
(33.3%) were screened negative and  18 cases  (45%) remained positive for RA factor after 
the treatment. 
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34. C-REACTIVE PROTEIN 
Before 
treatment 
Number of 
patients 
Percentage After 
treatment 
Number 
of cases 
Percentage 
POSITIVE 25 62.5% POSITIVE 19 47.5% 
 
 
Fig.34. C - reactive protein 
Observation: 
Among 25 cases (62.5%)   who are positive at commencement of the treatment 
6(24%) were screened negative and  19 cases (47.5%) remained positive for C reactive 
protein after the treatment. 
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35. ASO TITRE 
Before 
treatment 
Number of 
patients 
Percentage After 
treatment 
Number 
of cases 
Percentage 
POSITIVE 10 25% POSITIVE 8 20% 
 
               
Fig.35. ASO Titre 
Observation:  
Among 10 cases   who are positive at commencement of the treatment 2(20%) cases 
were screened negative and 8 (20%) cases remained positive for Aso titre after the 
treatment. 
 
 
 
 
 
 
 
                                 
112 
 
                                  STATISTICAL ANALYSIS 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical 
significance. Paired „t‟ test was performed for determining the significance between before 
and after treatment. In my study statistical analysis was done for pain score and all Blood 
investigations to find the significance of the treatment statistically. 
Paired Samples Statistics 
A) PAIN SCORE 
           PAIN SCORE         MEAN ± SD     t VALUE p VALUE 
Before treatment         7 ± 1.22        28.50 P <  0.001 
After treatment         1.3±1.24 
 
The mean± standard deviation of pain score before and after treatment were 7 ± 1.22 
and  1.3±1.24  respectively which is statistically significant (p<0.001) The analysis revels 
that  significant reduction of pain with the trial drug  i.e. there is 81.4% reduction in pain 
compared to start of the treatment. 
           B.) ERTHROCYTE SEDIMENTATION RATE (ESR) 
  ESR (1/2 AN HOUR)         MEAN ± SD     t VALUE p VALUE 
Before treatment         32.02± 19.75        6.09 P <  0.001 
After treatment         16.1 ±10.91 
 
       ESR (1   HOUR)         MEAN ± SD     t VALUE p VALUE 
Before treatment        57.97± 32.54        6.84 P <  0.001 
After treatment        27.57 ±19.52 
 
The mean  ± standard deviation before treatment is 32.02± 19.75 and after treatment is 
16.1 ±10.91 for  ½ hr.  The analysis revels that there is 49.7% reduction in ESR ½ hr 
compared to start of the treatment. 
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The mean  ± standard deviation before treatment is 57.97± 32.54 and after treatment is 
27.57 ±19.52 for 1 hr. The analysis revels that there is 52.44% reduction in ESR 1 hr 
compared to start of the treatment. 
The statistical analysis reveals that there has been a significant reduction in ESR 
value after treatment indicating the control over the inflammatory process of the disease.                                               
 
HAEMOGLOBIN 
 
 
 
 
       The mean  ± standard deviation before treatment is 11.44± 2.57 and after treatment is 
11.78±1.83 . The analysis revels that among 40 cases , there was no significant increase after 
the treatment statistically. 
 
      HAEMOGLOBIN         MEAN ± SD     t VALUE p VALUE 
Before treatment         11.44 ± 2.57            -1.2252               P > 0.2279           
After treatment        11.78±1.83 
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SL 
NO 
 
OP 
NO/IP 
NO 
 
AGE 
 
SEX 
 
 
 
                         SEROLOGY 
 
 
RA before RA   after ASO titre 
before 
ASO titre 
after 
1 
I09544 25 F   + ve   - ve   - ve   - ve 
2 
I59413 41 F   + ve   + ve   - ve   - ve 
3 
J35977 54 F   + ve   + ve   - ve   - ve 
4 
H94125 48 F   + ve   + ve   - ve   - ve 
5 
J22144 40 F   + ve   - ve   + ve   + ve 
6 
J70445 48 F   + ve   - ve   + ve   + ve 
7 0075-18 
(IP) 46 F   + ve   - ve   - ve   - ve 
8 
J73469 40 F   - ve   - ve   - ve   - ve 
9 
H77668 40 M   + ve   - ve   + ve   + ve 
10 
G15638 22 M   - ve   - ve   - ve   - ve 
11 
I10061 47 M   + ve   + ve   - ve   - ve 
12 
J73797 36 M   - ve   - ve   - ve   - ve 
13 
J65069 32 M   - ve   - ve   - ve   - ve 
14 
J74063 55 F   + ve   + ve   - ve   - ve 
15 
I32409 50 F   - ve   - ve   - ve   - ve 
16 
J65774 30 F   + ve   + ve   + ve   + ve 
17 
J44905 44 F   - ve   - ve   - ve   - ve 
18 
J64112 47 F   + ve   + ve   + ve   + ve 
19 
I14459 32 F   - ve   - ve   + ve   - ve 
20 
I97794 47 M   + ve   + ve   - ve   - ve 
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SL NO OP NO AGE SEX  
 
                         SEROLOGY 
 
RA before RA   after ASO titre 
before 
ASO titre 
after 
21 
F91016 40 F   - ve   - ve   - ve   - ve 
22 
J67779 50 M   - ve   - ve   - ve   - ve 
23 
J69753 42 
F 
  + ve   + ve   + ve   + ve 
24 
H91904 36 
F 
  - ve   - ve   - ve   - ve 
25 
I73928 33 
F 
  + ve   - ve   + ve   + ve 
26 
H15822 50 
F 
  + ve   - ve   - ve   - ve 
27 
G17963 48 
F 
  + ve   + ve   - ve   - ve 
28 
J77255 38 
F 
  + ve   + ve   + ve   - ve 
29 
J57078 52 
F 
  - ve   - ve   - ve   - ve 
30 
J75796 58 
F 
  + ve   + ve   - ve   - ve 
31 
J73061 39 
F 
  + ve   + ve   - ve   - ve 
32 
J64099 49 
F 
  - ve   - ve   - ve   - ve 
33 
J83067 56 
F 
  + ve   + ve   - ve   - ve 
34 
I48032 36 
F 
  + ve   + ve   - ve   - ve 
35 
H62467 38 
F 
  + ve   - ve   - ve   - ve 
36 
J10306 55 
F 
  + ve   + ve   - ve   - ve 
37 
I85405 58 
F 
  - ve   - ve   - ve   - ve 
38 
H88015 39 
F 
  + ve   - ve   - ve   - ve 
39 
K04937 27 
F 
  + ve   + ve   + ve   + ve 
40 
D0092 44 
F 
  + ve   + ve   - ve   - ve 
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  S.NO  OP NO/IP 
NO 
AGE  SEX              SEROLOGY 
C-Reactive 
protein 
before 
C-Reactive 
protein after 
1 
I09544 25 F   + ve   + ve 
2 
I59413 41 F   - ve   - ve 
3 
J35977 54 F   + ve   + ve 
4 
H94125 48 F   + ve   + ve 
5 
J22144 40 F   + ve   + ve 
6 
J70445 48 F   - ve   - ve 
7 
0075-18 (IP) 46 F   + ve   + ve 
8 
J73469 40 F   + ve   + ve 
9 
H77668 40 M   + ve   + ve 
10 
G15638 22 M   - ve   - ve 
11 
I10061 47 M   + ve   + ve 
12 
J73797 36 M   - ve   - ve 
13 
J65069 32 M   + ve   - ve 
14 
J74063 55 F   + ve   + ve 
15 
I32409 50 F   - ve   - ve 
16 
J65774 30 F   + ve   - ve 
17 
J44905 44 F   - ve   - ve 
18 
J64112 47 F   + ve   + ve 
19 
I14459 32 F   + ve   + ve 
20 
I97794 47 M   + ve   + ve 
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S. NO 
 
OP NO 
 
 
AGE 
 
SEX 
SEROLOGY 
 
CRP before 
 
CRP after 
21 
F91016 40 F - ve - ve 
22 
J67779 50 M + ve - ve 
23 
J69753 42 
F 
+ ve + ve 
24 
H91904 36 
F 
+ ve + ve 
25 
I73928 33 
F 
+ ve + ve 
26 
H15822 50 
F 
+ ve + ve 
27 
G17963 48 
F 
- ve - ve 
28 
J77255 38 
F 
- ve - ve 
29 
J57078 52 
F 
+ ve - ve 
30 
J75796 58 
F 
- ve - ve 
31 
J73061 39 
F 
- ve - ve 
32 
J64099 49 
F 
+ ve + ve 
33 
J83067 56 
F 
+ ve - ve 
34 
I48032 36 
F 
- ve - ve 
35 
H62467 38 
F 
- ve - ve 
36 
J10306 55 
F 
+ ve + ve 
37 
I85405 58 
F 
- ve - ve 
38 
H88015 39 
F 
+ ve + ve 
39 
K04937 27 
F 
+ ve - ve 
40 
D0092 44 
F 
- ve - ve 
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SL NO OP NO/IP 
NO 
Haemoglobin      
(gm/dl) 
Total WBC count 
(cells/µL) 
Total RBC count 
(million/ µL) 
Before After Before After Before After 
1 I09544 10.4 10.3 6800 7600 4.2 4.2 
2 I59413 6.8 8 3300 3900 3.5 3.9 
3 J35977 8.7 8.8 7500 8900 3.7 3.8 
4 H94125 11.6 11.5 9300 8500 4.1 4 
5 J22144 12.1 12.1 6600 6200 3.9 3.9 
6 J70445 12.2 12.3 6200 5400 4.3 4.2 
7 0075-18(IP) 7 6.6 6900 6400 3.7 3.6 
8 J73469 10.9 11.1 7800 7800 4.5 4.6 
9 H77668 14.4 13.5 8000 9500 5.7 5.4 
10 G15638 15.2 14.6 7200 8000 5.1 4.8 
11 I10061 13.6 13.4 8800 9200 4.6 4.6 
12 J73797 15 15.2 7100 7200 5 5.1 
13 J65069 15 15.1 7300 7200 5.2 5.2 
14 J74063 10.7 10.9 14300 11200 4.4 4.4 
15 I32409 11.2 11.1 6000 6900 4.7 4.6 
16 J65774 10.4 11.2 6700 6900 4.6 4.6 
17 J44905 13.2 13.2 6800 6500 4.6 4.7 
18 J64112 12.3 12.1 8900 10900 4.7 5.1 
19 I14459 11.2 11.6 4900 5100 4 4.1 
20 I97794 14.7 14.9 8500 7700 5.1 5.2 
21 F91016 10.4 11.4 8700 9000 3.9 4 
22 J67779 12.9 13 6900 6000 4.6 4.8 
23 J69753 11.6 11.8 6200 7100 4.8 4.8 
24 H91904 11.5 11.6 11800 11400 4.2 4.8 
25 I73928 8.3 8.5 4500 4480 3.5 3.5 
26 H15822 12.7 12.6 5700 5710 4.3 4.2 
27 G17963 11.5 11.5 10800 10600 4.2 4.2 
28 J77255 9.7 9.8 9000 9400 4.5 4.5 
29 J57078 11.9 11.8 3400 4200 4.3 4.3 
30 J75796 13.3 13 6800 7500 4.3 4.3 
31 J73061 12.1 12.1 6700 5800 4.7 4.7 
32 J64099 12.2 11.9 6800 9000 4.4 4.3 
33 J83067 9.3 10.1 7400 7500 4 4.1 
34 I48032 14 14.1 7100 7200 4.7 4.7 
35 H62467 10.9 11 9400 9500 4 4 
36 J10306 12 12.1 6900 7000 4.2 4.2 
37 I85405 11.4 11.1 6800 5400 4.2 4.1 
38 H88015 12 12.1 10400 9600 4.5 4.5 
39 K04937 12.1 12.1 7530 7600 4.2 4.2 
40 D0092 1.3 12.2 6300 7400 4.2 4.2 
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SL 
NO 
OP NO/IP 
NO 
                                                     Differential count 
Polymorphs 
before (%) 
Polymorphs 
after (%) 
Lymphocyt
es before 
(%) 
Lymphocytes 
after (%) 
Monocytes 
before (%) 
Monocyte
s after 
(%) 
1 I09544 56 64 39 31 3 2 
2 I59413 58 60 40 36 0 0 
3 J35977 58 69 37 28 2 0 
4 H94125 71 71 26 27 0 0 
5 J22144 60 45 39 48 0 3 
6 J70445 53 50 42 45 2 2 
7 0075-18(IP) 73 67 24 28 0 2 
8 J73469 66 64 31 34 1 0 
9 H77668 68 78 29 20 1 0 
10 G15638 69 74 28 23 0 0 
11 I10061 60 62 31 25 0 4 
12 J73797 70 69 27 28 0 1 
13 J65069 60 61 37 38 1 0 
14 J74063 72 68 26 29 0 1 
15 I32409 46 64 49 30 1 2 
16 J65774 55 58 42 41 1 0 
17 J44905 53 48 44 50 1 0 
18 J64112 66.3 74 23.8 24 4.3 0 
19 I14459 50 54 43 43 2 1 
20 I97794 58 63 38 35 0 0 
21 F91016 68 71 24 26 3 1 
22 J67779 75 72 23 27 0 0 
23 J69753 60 61 36 36 0 1 
24 H91904 65 63 33 35 0 0 
25 I73928 59 60 38 38 1 1 
26 H15822 60 50 33 30 0 4 
27 G17963 64 63 34 34 0 1 
28 J77255 61 65 31 32 2 1 
29 J57078 62 63 33 34 2 2 
30 J75796 65 64 32 33 0 0 
31 J73061 65 60 30 37 1 0 
32 J64099 52 43 45 54 1 0 
33 J83067 62 63 36 35 0 1 
34 I48032 67 66 30 29 0 2 
35 H62467 76 77 19 20 2 1 
36 J10306 64 65 34 34 0 1 
37 I85405 70 65 27 30 1 2 
38 H88015 77 76 21 20 0 2 
39 K04937 63 66 32 33 2 1 
40 D0092 67 68 30 30 1 1 
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SL 
NO 
OP NO/IP 
NO Differential count Platelet count lkhs/µL 
Eosinophils
before (%) 
Eosinophils
after (%) 
Basophils 
before(%) 
Basophils 
after(%) Before 
After 
 
1 I09544 2 3 0 0 4.7 4.1 
2 I59413 2 4 0 0 5 5 
3 J35977 3 3 0 0 6.1 5.8 
4 H94125 3 2 0 0 3 3.1 
5 J22144 1 4 0 0 2.9 2.9 
6 J70445 3 3 0 0 2.5 2.5 
7 007518(IP) 3 3 0 0 5.2 5.4 
8 J73469 2 2 0 0 4 4 
9 H77668 2 2 0 0 2.7 2.7 
10 G15638 3 3 0 0 2 2.1 
11 I10061 9 9 0 0 3 3 
12 J73797 3 2 0 0 2 2.1 
13 J65069 2 1 0 0 1.9 1.9 
14 J74063 2 2 0 0 5.5 5.5 
15 I32409 4 4 0 0 3.4 3.4 
16 J65774 2 1 0 0 2.5 2.6 
17 J44905 2 2 0 0 2.5 2.3 
18 J64112 5.4 2 0.2 0 2.4 2.5 
19 I14459 4 2 1 0 3.1 3.1 
20 I97794 4 2 0 0 3.6 3.5 
21 F91016 5 2 0 0 1.5 1.5 
22 J67779 2 1 0 0 2 2 
23 J69753 4 2 0 0 2.5 2.5 
24 H91904 2 2 0 0 3.3 3.3 
25 I73928 2 1 0 0 2.3 2.3 
26 H15822 7 6 0 0 2.4 2.3 
27 G17963 2 2 0 0 3.3 3.3 
28 J77255 6 2 0 0 4 4 
29 J57078 3 1 0 0 2.3 2.4 
30 J75796 3 3 0 0 2.2 2.3 
31 J73061 4 3 0 0 3.4 3.2 
32 J64099 2 3 0 0 4 3.6 
33 J83067 2 1 0 0 1.8 1.8 
34 I48032 3 3 0 0 2.9 2.9 
35 H62467 3 2 0 0 3.4 3.4 
36 J10306 2 1 0 0 2.9 2.9 
37 I85405 2 3 0 0 2.8 2.1 
38 H88015 2 2 0 0 3.5 3.5 
39 K04937 3 0 0 0 2.1 2.1 
40 D0092 2 1 0 0 2.4 2.4 
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SL 
NO 
OP NO/IP 
NO 
Erythrocytesedimentatio
n rate ½ hr (mm) 
Erythrocytesedimentation 
rate 1 hr (mm) PCV (%) 
before after before after before After 
1 I09544 42 12 24 20 31.8 32 
2 I59413 40 30 80 62 23.6 26.8 
3 J35977 40 34 80 70 29.5 29.3 
4 H94125 12 26 24 52 33.8 38 
5 J22144 44 14 90 38 34.7 34.6 
6 J70445 40 18 80 20 35.7 35.8 
7 0075-18(IP) 44 4 90 10 25.8 24.2 
8 J73469 10 10 20 20 35.4 35.5 
9 H77668 14 6 30 14 42.5 43.2 
10 G15638 14 4 30 8 44.3 42.7 
11 I10061 20 10 42 18 38.9 38.8 
12 J73797 40 14 82 30 44 44.3 
13 J65069 10 4 20 10 42.7 41 
14 J74063 54 24 110 38 34.7 33.8 
15 I32409 10 20 20 40 35.4 34.6 
16 J65774 15 10 32 12 40.1 40 
17 J44905 14 10 30 22 40.2 39.4 
18 J64112 38 17 54 12 36.9 37 
19 I14459 80 24 100 41 32.9 33.4 
20 I97794 24 12 50 26 44.4 44.6 
21 F91016 40 19 68 24 37.5 37 
22 J67779 20 2 40 4 37.9 38.4 
23 J69753 64 20 130 40 36 37.2 
24 H91904 16 12 32 20 35 34.6 
25 I73928 40 18 80 24 26.3 28 
26 H15822 20 19 42 18 36.9 36.7 
27 G17963 15 12 32 20 35 36.1 
28 J77255 10 7 20 10 32.5 31.5 
29 J57078 64 20 130 40 35.3 35.2 
30 J75796 18 8 28 18 39.6 38.1 
31 J73061 12 10 24 12 36.9 37 
32 J64099 46 60 92 100 37.6 36 
33 J83067 30 10 62 14 36.1 36 
34 I48032 8 10 16 18 39.7 38.5 
35 H62467 42 12 54 20 36.8 36.4 
36 J10306 40 21 82 40 35 36.1 
37 I85405 90 40 100 60 35 33.4 
38 H88015 30 11 62 18 36.6 35.5 
39 K04937 37 20 89 24 40 39 
40 D0092 34 10 48 16 35.2 35 
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SL NO OP NO/IP 
NO 
MCV (% ft) MCH (pg) MCHC (gm/dL) 
before after before after before after 
1 I09544 75.4 75.8 24.6 24.4 32.7 32.2 
2 I59413 66.5 67.7 19.2 20.2 28.8 29.9 
3 J35977 78 76.7 23 23 29.5 30 
4 H94125 81.6 80.9 28 28.2 34.3 34.8 
5 J22144 88.1 88.3 30.9 30.9 34.9 38.9 
6 J70445 82.3 81.4 28.1 28 34.2 34.2 
7 007518(IP) 68.6 66.1 18.6 18 27.1 27.3 
8 J73469 77.5 77 23.9 24.1 30.8 31.3 
9 H77668 74.2 73.9 25.1 24.8 33.9 33.6 
10 G15638 86.4 88.2 29.6 30.2 34.3 34.2 
11 I10061 84.4 84.3 29.5 29 25 34.5 
12 J73797 84.4 86 29 29.6 34 34.3 
13 J65069 80.9 81.2 28.4 30 35.1 34 
14 J74063 77.5 79.1 23.9 26.4 30.8 31.4 
15 I32409 74.4 74.1 23.5 23.8 31.6 32.1 
16 J65774 84.9 85.4 29.2 28.4 32.8 33.2 
17 J44905 85.9 83.1 28.2 27.8 32.8 33.5 
18 J64112 78.3 79 26.1 27 33.3 34 
19 I14459 82 82.5 27.9 27.5 34 34.2 
20 I97794 85.5 85 28.3 28.4 33.1 33.4 
21 F91016 85 84.5 32.4 32 32.5 32.5 
22 J67779 80.8 79.2 27.5 26.8 34 33.9 
23 J69753 74.7 75 24.1 24.4 32.2 31.8 
24 H91904 82.5 82.4 27 27.6 32.9 33.5 
25 I73928 73.3 75.3 23.1 23 31.6 31 
26 H15822 85.6 85.6 29.5 29.4 34.4 34.4 
27 G17963 82.5 82 27 27.2 33 33.1 
28 J77255 71.7 70.4 21.4 20.5 29.8 29.9 
29 J57078 81.5 80.4 27.5 28 33.7 34.2 
30 J75796 90.4 87.8 30.4 30 33.6 34.1 
31 J73061 77.7 77.9 25.7 25.5 32.8 32.7 
32 J64099 85.1 83.5 27.6 27.6 32.4 33.1 
33 J83067 80.1 80.4 26.4 24.4 32.4 32.5 
34 I48032 84.5 84 29.8 29.5 35.3 35 
35 H62467 84.2 84 27.2 27.1 83.4 82.8 
36 J10306 81.6 82.6 28 28.1 34.3 34.5 
37 I85405 81.6 80.1 26.6 26.6 32.6 33.2 
38 H88015 80.3 79.2 26.3 26.2 32.8 32.4 
39 K04937 82.2 82.4 30.4 31.2 36.2 36 
40 D0092 79.5 84.5 30.5 29 34.8 32.4 
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SL 
NO 
OP NO/IP 
NO 
Blood sugar Blood 
Urea 
before(mg/dl) 
Blood 
Urea 
after(mg/dl) 
Fasting (mg/dl) Post prandial(mg/dl) 
before after before After 
1 I09544 83 82 119 92 11 14 
2 I59413 86 83 109 112 11 9 
3 J35977 91 103 108 130 22 11 
4 H94125 85 90 102 104 35 37 
5 J22144 86 95 137 115 24 17 
6 J70445 96 90 87 100 28 27 
7 007518(IP) 91 89 119 82 11 14 
8 J73469 90 92 110 114 16 16 
9 H77668 80 88 95 99 19 16 
10 G15638 86 90 89 89 10 7 
11 I10061 85 87 93 113 14 15 
12 J73797 90 86 110 89 10 14 
13 J65069 77 90 100 110 24 28 
14 J74063 119 120 140 138 18 20 
15 I32409 94 96 99 84 23 13 
16 J65774 80 95 110 115 15 18 
17 J44905 88 90 95 139 15 17 
18 J64112 80 91 100 119 18 15 
19 I14459 92 89 110 120 14 16 
20 I97794 85 87 101 106 15 13 
21 F91016 70 85 100 110 17 18 
22 J67779 126 123 145 210 18 20 
23 J69753 81 90 130 120 12 16 
24 H91904 88 90 105 120 17 15 
25 I73928 76 90 110 120 18 20 
26 H15822 90 92 71 100 15 15 
27 G17963 88 100 105 120 18 20 
28 J77255 91 106 106 120 18 20 
29 J57078 88 90 127 130 13 16 
30 J75796 108 109 96 116 16 14 
31 J73061 90 96 110 120 18 19 
32 J64099 86 85 119 102 20 22 
33 J83067 82 90 102 110 15 20 
34 I48032 83 90 112 130 13 18 
35 H62467 90 94 130 135 12 14 
36 J10306 102 110 128 130 17 18 
37 I85405 102 101 91 118 14 11 
38 H88015 84 90 147 138 9 10 
39 K04937 90 102 110 130 41 35 
40 D0092 98 180 118 120 19 20 
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SL 
NO 
OP NO/IP 
NO 
Liver function test (mg/dl) 
T.bilirubin 
before 
T.bilirubin 
after 
D.bilirubin 
before 
D.bilirubin 
after 
I.bilirubin 
before 
I.bilirubin 
after 
1 I09544 0.3 0.2 0.1 0.1 0.2 0.3 
2 I59413 0.2 0.3 0.1 0.1 0.1 0.2 
3 J35977 0.3 0.3 0.2 0.1 0.1 0.3 
4 H94125 0.2 0.3 0.1 0.1 0.1 0.2 
5 J22144 0.6 0.2 0.3 0.1 0.3 0.6 
6 J70445 0.6 0.4 0.3 0.3 0.3 0.6 
7 007518(IP) 0.3 0.2 0.1 0.1 0.2 0.3 
8 J73469 0.3 0.3 0.1 0.1 0.2 0.3 
9 H77668 0.6 0.5 0.2 0.2 0.4 0.6 
10 G15638 0.5 0.5 0.3 0.3 0.3 0.5 
11 I10061 0.5 0.3 0.2 0.2 0.3 0.5 
12 J73797 0.5 0.4 0.3 0.1 0.3 0.5 
13 J65069 0.9 0.8 0.3 0.2 0.5 0.9 
14 J74063 0.3 0.3 0.1 0.2 0.2 0.3 
15 I32409 0.3 0.3 0.1 0.1 0.2 0.3 
16 J65774 0.5 0.4 0.2 0.2 0.2 0.5 
17 J44905 0.5 0.5 0.2 0.2 0.3 0.5 
18 J64112 0.4 0.6 0.1 0.2 0.2 0.4 
19 I14459 0.3 0.2 0.1 0.1 0.2 0.3 
20 I97794 0.4 0.4 0.1 0.1 0.3 0.4 
21 F91016 0.3 0.2 0.2 0.2 0.1 0.3 
22 J67779 0.5 0.6 0.2 0.2 0.2 0.5 
23 J69753 0.3 0.3 0.1 0.2 0.2 0.3 
24 H91904 0.3 0.3 0.2 0.1 0.1 0.3 
25 I73928 0.2 0.9 0.1 0.1 0.1 0.2 
26 H15822 0.4 0.3 0.2 0.2 0.2 0.4 
27 G17963 0.2 0.3 0.2 0.2 0.1 0.2 
28 J77255 0.2 0.3 0.1 0.2 0.1 0.2 
29 J57078 0.3 0.2 0.2 0.1 0.1 0.3 
30 J75796 0.5 0.5 0.2 0.2 0.3 0.5 
31 J73061 0.3 0.2 0.1 0.1 0.2 0.3 
32 J64099 0.2 0.3 0.1 0.1 0.1 0.2 
33 J83067 0.5 0.3 0.2 0.1 0.3 0.5 
34 I48032 0.5 0.3 0.2 0.2 0.3 0.5 
35 H62467 0.3 0.2 0.2 0.1 0.1 0.3 
36 J10306 0.4 0.2 0.1 0.1 0.3 0.4 
37 I85405 0.5 0.6 0.2 0.2 0.3 0.5 
38 H88015 0.3 0.2 0.1 0.1 0.2 0.3 
39 K04937 0.1 0.3 0.3 0.2 0.2 0.1 
40 D0092 0.2 0.3 0.2 0.2 0.1 0.2 
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SL NO OP NO/IP 
NO 
CREATININE (mg/ dl) Liver Function Test (IU/L) 
BEFORE  AFTER 
SGOT 
BEFORE 
SGOT 
AFTER 
SGPT 
BEFORE 
SGPT 
AFTER 
1 I09544 0.7 0.6 10 15 10 12 
2 I59413 0.8 0.7 19 19 13 17 
3 J35977 1 0.8 14 9 5 9 
4 H94125 0.9 0.8 13 9 12 6 
5 J22144 0.8 0.7 22 19 41 25 
6 J70445 1.2 1 18 19 16 17 
7 007518(IP) 0.7 0.6 10 15 10 12 
8 J73469 0.9 0.8 12 15 12 32 
9 H77668 1.4 0.8 14 12 12 10 
10 G15638 0.9 0.8 14 16 6 12 
11 I10061 1.1 0.8 13 20 6 10 
12 J73797 0.9 1.2 14 16 6 20 
13 J65069 1.1 1.2 21 24 20 30 
14 J74063 0.8 0.9 14 18 9 12 
15 I32409 0.9 0.7 16 13 13 13 
16 J65774 0.9 1.2 15 16 20 23 
17 J44905 0.9 0.7 16 17 23 16 
18 J64112 0.7 0.8 10 15 8 11 
19 I14459 0.8 0.7 12 18 8 12 
20 I97794 1.1 0.9 11 15 12 13 
21 F91016 0.4 0.9 30 29 28 25 
22 J67779 0.8 0.9 20.6 13 14.6 3 
23 J69753 0.9 0.9 38 36 33 38 
24 H91904 1 1 9 13 10 12 
25 I73928 0.8 0.9 19 18 8 10 
26 H15822 0.9 1 17 17 20 21 
27 G17963 1 1.2 12 9 15 10 
28 J77255 1 1.2 14 18 9 12 
29 J57078 0.6 0.8 35 32 37 34 
30 J75796 1.1 0.9 13 21 21 28 
31 J73061 1 1 17 20 16 15 
32 J64099 1 1 21 15 13 20 
33 J83067 0.6 1.2 24 25 9 12 
34 I48032 1 1.2 16 20 9 10 
35 H62467 1.8 1.2 18 19 17 20 
36 J10306 0.8 0.3 18 20 15 18 
37 I85405 0.8 0.9 15 12 17 8 
38 H88015 0.7 0.8 13 20 13 19 
39 K04937 0.9 0.8 23 25 18 20 
40 D0092 0.9 0.8 18 24 17 22 
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SL 
NO 
OP NO/IP 
NO 
ALKALINE 
PHOSPHATASE 
(IU/L) 
SERUM CALCIUM 
(mgm /dl)  
SERUM PHOSPHORUS  
(mgm /dl) 
BEFORE AFTER BEFORE AFTER  BEFORE  AFTER 
1 I09544 72 61 9 8.8 3.8 3.6 
2 I59413 95 84 8.2 8.5 3.8 3.9 
3 J35977 159 132 9.9 8.9 3.9 4 
4 H94125 91 92 9.7 9 3.8 3.9 
5 J22144 84 87 9.6 10.2 4 3.9 
6 J70445 68 70 10.1 10.2 3.8 3.7 
7 007518(IP) 72 61 9 8.8 4 4.1 
8 J73469 82 93 7.3 9.7 3.7 3.9 
9 H77668 100 91 9 9.1 4 4 
10 G15638 110 98 9.3 9.4 3.8 3.9 
11 I10061 96 110 8.4 8.2 3.8 3.5 
12 J73797 120 104 9 9.4 3.1 3.1 
13 J65069 57 90 9.7 9 3.8 4 
14 J74063 117 140 9.5 9.5 3.8 3.6 
15 I32409 59 62 9.4 8.5 3.4 3.4 
16 J65774 99 110 9.4 9.6 4 4.2 
17 J44905 99 106 9.6 10.5 3.8 3.9 
18 J64112 70 68 9.4 10 3 3.4 
19 I14459 60 120 8.4 9 3.8 3.5 
20 I97794 125 117 9.4 9.3 4 3.9 
21 F91016 110 120 9.8 9.8 3.4 3.5 
22 J67779 61 56 9.6 10.4 3.8 3.5 
23 J69753 105 110 9.3 9.4 3.8 3.6 
24 H91904 88 95 9.7 8.9 3.8 3.8 
25 I73928 95 110 8 8.2 3.8 3.4 
26 H15822 105 102 9.1 9.1 3.2 3 
27 G17963 120 140 9.7 9.5 3.8 3.5 
28 J77255 78 120 9 9.2 3.4 3.2 
29 J57078 94 102 9.1 9 3.8 3.6 
30 J75796 59 54 10 9.3 4 4.2 
31 J73061 87 110 9.5 9.4 4 3.9 
32 J64099 117 102 9.3 8.9 3.4 3.8 
33 J83067 108 110 10 10.1 4 4.1 
34 I48032 84 110 10 10.1 3.8 4 
35 H62467 110 120 9.8 9.4 3.4 3.2 
36 J10306 146 152 10 9.8 3.8 3.4 
37 I85405 90 91 10.2 9.2 4 4.1 
38 H88015 61 90 10.1 9.8 4 4.1 
39 K04937 140 184 9 9.1 3.4 3.2 
40 D0092 112 120 8.5 8.9 3.4 3.5 
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SL 
NO 
OP NO/IP 
NO 
SERUM URIC ACID 
(mg/dl)  
SERUM PROTIEN 
(gms / dl)  
SERUM ALBUMINE  
(gms / dl)  
BEFORE AFTER BEFORE AFTER BEFORE AFTER 
1 I09544 2.7 3.8 7.7 7.7 3.3 3.8 
2 I59413 4.2 4.5 6.7 6.6 3.1 3.1 
3 J35977 4.2 4.9 7.2 6.8 3.7 3.2 
4 H94125 4.2 4.1 7.8 7.7 4.2 3.9 
5 J22144 4.2 4 6.8 7 4.2 3.8 
6 J70445 5.4 5 7.9 7.8 4.1 4.1 
7 007518(IP) 2.7 3.8 7.7 7.7 3.3 3.8 
8 J73469 4 5.4 6.6 6.6 3.8 3.7 
9 H77668 6.5 6.2 7.5 7.1 4 3.6 
10 G15638 4.6 4.8 7.6 7.9 4.1 4 
11 I10061 7.4 7 7.7 7.5 3.5 3.2 
12 J73797 4.5 4 7 7.9 4.2 4 
13 J65069 5.5 5 8.2 8 4.5 4.2 
14 J74063 6.1 6 7.6 7.2 3.6 3.4 
15 I32409 3.6 4 7 6.6 3.7 3.6 
16 J65774 5.2 4.2 7 7.2 4 4.2 
17 J44905 4.2 3.8 7.2 7.7 4.2 4 
18 J64112 4.9 5.6 7.4 8.3 3 3.7 
19 I14459 3.3 3.1 7.5 7 3.9 3.5 
20 I97794 7.4 7.2 7.3 7.1 3.7 3.5 
21 F91016 3.9 4 7.4 7.3 4.5 4.4 
22 J67779 6 5.7 7.4 7.4 4 4.1 
23 J69753 3.4 3 7.6 7.5 3.8 3.4 
24 H91904 4.7 5.1 6.5 7.3 3.6 3.5 
25 I73928 4.9 4 8.3 8 3.4 3.5 
26 H15822 4 4.1 7.8 7.5 4.2 4.2 
27 G17963 4.7 4.5 6.7 6.5 3.6 3.5 
28 J77255 3.7 3.5 7.3 8 3.8 3.5 
29 J57078 3.9 4 0.5 7.5 4 4.2 
30 J75796 3.9 4.6 7.2 7.5 4.2 4 
31 J73061 4.7 4.5 7.4 7.2 3.7 3.5 
32 J64099 5.6 5.9 7.8 7.5 4.3 3.7 
33 J83067 4.8 4.7 7.4 7.2 3.5 3.2 
34 I48032 4.9 4.8 7.5 7.4 4 4.2 
35 H62467 3.8 3.4 7.4 7.8 4 4.1 
36 J10306 3.4 3.3 8 7.8 3.7 3.5 
37 I85405 3.9 4.6 7.3 6.3 4.1 3.7 
38 H88015 3 3.8 8.1 8 4.1 4.2 
39 K04937 3.2 3.8 7.4 7.8 3.8 3.9 
40 D0092 3 2.9 7 7.3 3.8 3.7 
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SL 
NO 
OP NO/IP 
NO 
SERUM GLOBULIN 
(gms/dl)  URINE ANALYSIS  
BEFORE AFTER 
URINE 
ALBUMIN  
URINE 
ALBUMIN  
FASTING 
BEFORE 
FASTING 
AFTER 
1 I09544 4.7 3.9 nil nil Nil Nil 
2 I59413 3.5 3.5 nil nil Nil Nil 
3 J35977 3.4 3.6 nil nil Nil Nil 
4 H94125 3.6 3.8 nil nil Nil Nil 
5 J22144 3.3 3.2 nil nil Nil Nil 
6 J70445 3.8 3.5 nil nil Nil Nil 
7 007518(IP) 4.7 3.9 nil nil Nil Nil 
8 J73469 2.9 2.9 nil nil nil Nil 
9 H77668 3.5 3.5 nil nil nil Nil 
10 G15638 3.5 3.9 nil nil nil Nil 
11 I10061 4.2 4 nil nil nil Nil 
12 J73797 3.9 3 nil nil nil Nil 
13 J65069 3.7 3 nil nil nil Nil 
14 J74063 4 3.8 nil nil nil Nil 
15 I32409 3.4 3 nil nil nil Nil 
16 J65774 3 3.4 nil nil nil Nil 
17 J44905 3 3.7 nil nil nil Nil 
18 J64112 3.9 4.6 nil nil nil Nil 
19 I14459 3.6 3.7 nil nil nil Nil 
20 I97794 3.6 3 nil nil nil Nil 
21 F91016 2.8 3 nil nil nil Nil 
22 J67779 3.1 3.3 nil nil nil Nil 
23 J69753 3.8 3.6 nil nil nil Nil 
24 H91904 3.1 3.8 nil nil nil Nil 
25 I73928 4.9 4.5 nil nil nil Nil 
26 H15822 2.9 2.2 nil nil nil Nil 
27 G17963 3.1 3 nil nil nil Nil 
28 J77255 3.6 2.9 nil nil nil Nil 
29 J57078 3.2 3.1 nil nil nil Nil 
30 J75796 3.5 3.5 nil nil nil Nil 
31 J73061 3.7 3.4 nil nil nil Nil 
32 J64099 3.6 3.8 nil nil nil Nil 
33 J83067 3.9 3.7 nil nil nil Nil 
34 I48032 2.6 2.8 nil nil nil Nil 
35 H62467 3.9 3.8 nil nil nil Nil 
36 J10306 4.3 4.2 nil nil nil Nil 
37 I85405 3.2 2.6 nil nil nil Nil 
38 H88015 4 4 nil nil nil Nil 
39 K04937 3 3.2 nil nil nil Nil 
40 D0092 3.6 3.6 nil nil nil Nil 
 
 
 
`129 
 
 
SL 
N
O 
OP NO/IP 
NO 
URINE ANALYSIS  
POST 
PRANDIA
L 
BEFORE 
POST 
PRANDIA
L AFTER 
PUS 
CELLS 
BEFOR
E 
PUS 
CELLS
AFTE
R 
EPITHELIL 
CELLS 
BEFORE 
EPITHELIL 
CELLS 
AFTER 
1 I09544 nil Nil 4 to 6 2 to4 1 to 2 2 to 4 
2 I59413 nil Nil 1 to 2 4 to 6 1 to 2 4 to 6 
3 J35977 nil Nil 3 to4 1 to 2 1 to 2 1 to 2 
4 H94125 nil Nil 2 to 4 3 to 5 1 to 2 3 to 5 
5 J22144 nil Nil 2 to3 2 to 3 2 to 3 1 to 2 
6 J70445 nil Nil 1 to2 1 to 2 1 to 2 1 to 2 
7 007518(IP) nil Nil 3 to 5 1 to 2 1 to 2 1 to 2 
8 J73469 nil Nil 1 to 2 6 to 8 1 to 2 10 to 12 
9 H77668 nil Nil 2 to 4 3 to 5 1 to 2 1 to 2 
10 G15638 nil Nil 2 to 4 3 to 5 1 to 2 1 to 2 
11 I10061 nil Nil 1 to 2 1 to 3 1 to 2 1 to 3 
12 J73797 nil Nil 2 to 4 1 to2 1 to 2 1 to 2 
13 J65069 nil Nil 2 to 4 1 to 2 1 to 2 1 to 2 
14 J74063 nil Nil 1 to 2 1 to 2 1 to 2 1 to 3 
15 I32409 nil Nil 3 to 5 1 to 2 2 to 4 1 to 2 
16 J65774 nil Nil 3 to 4 1 to 2 3 to4 1 to 2 
17 J44905 nil nil 3 to 4 1 to 3 3 to 4 1 to 3 
18 J64112 nil nil 3 to 4 1 to 2 1 to 2 1 to 2 
19 I14459 nil nil 8 to 10 2 to 4 3 to 4 1 to 2 
20 I97794 nil nil 10 to 12 6 to 8 1 to 2 1 to 2 
21 F91016 nil nil 3 to 5 1 to 2 1 to 3 1 to 2 
22 J67779 nil nil 1 to 2 3 to 5 1 to 2 3 to 5 
23 J69753 nil nil 1to 2 1 to 2 1 to 2 1 to 2 
24 H91904 nil nil 2 to 4 1 to 2 1 to 2 1 to 2 
25 I73928 nil nil 3 to 4 1 to 2 1 to 2 1 to 2 
26 H15822 nil nil 1 to 2 1 to 2 1 to 2 1 to 3 
27 G17963 nil nil 3 to 5 1 to 2 1 to 2 1 to 2 
28 J77255 nil nil 2 to 4 1 to 2 2 to 4 1 to 2 
29 J57078 nil nil 2 to 4 1 to 2 1 to 2 1 to 3 
30 J75796 nil nil 2 to 3 1 to 2 2 to 4 1 to2 
31 J73061 nil nil 1 to 2 1 to 2 1 to 2 1 to 2 
32 J64099 nil nil 1 to 2 2 to 4 1 to 2 2 to 4 
33 J83067 nil nil 2 to 4 1 to2 2 to 4 1 to 2 
34 I48032 nil nil 2 to4 1 to 2 2 to 4 1 to 2 
35 H62467 nil nil 3 to 5 1 to 2 3 to4 1 to 2 
36 J10306 nil nil 4 to 6 1to 4 1 to 2 1 to 2 
37 I85405 nil nil 3 to 5 2 to 4 2 to 4 2 to 4 
38 H88015 nil nil 1 to 2 1 to 2 3 to 5 1 to 2 
39 K04937 nil nil 3 to 4 1 to 2 1 to 2 1 to 2 
40 D0092 nil nil 3 to 4 1to2 1 to 3 1 to 2 
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                                          DISCUSSION 
The main aim of this study was to evaluate the Therapeutic effect of the trial drug 
MERUGULLI THYLAM ( Internal medicine) to reduce pain, swelling and restricted joint 
movements in the disease VALI AZHAL KEELVAYU (Rheumatoid arthritis) in which, 
there occur a derangement of Vatha thathu and Pitha thathu.  
Vatham, Pitham, Kabam the three vital humours (uyir thathukkal) are responsible 
for the physiological functions of udal thathukkal (7 body constituents).Life style 
modifications (Food and deeds, stress, mental and physical environmental) causes 
derangement of vital humours resulting in vitiation of uyir thathukkal called mukkutram 
(disease). 
Derangement of the vatham leads to impairment in Udal thathukkal and in turn 
produces symptoms like pricking pain, body ache, mental stress, difficulty in flexion and 
extension of joints. 
Pitham maintains the body temperature and has the basic function of production and 
maintenance of the internal environment (Homeostasis). Hence Pitham when deranged 
produces symptoms like fever and changes in the internal environment. The vitiates vatham 
and pitham causes vatha noigal ,one among is vali azhalkeelvayu. The signs and symptom 
of valiazhal keelvayu may be correlated with RA in that of modern scientific system of 
medicine.  
Siddha literature THERAN MARUTHUVA BHARATHAM predicts the fact that 
we should choose medicines for diseases and not diseases for medicine. 
Dryness , Roughness, coldness and subtleness are one among the basic qualities of 
Vatham. Hence a drug possesses the opposite qualities like Heaviness, hotness and 
solidness would rectify the derangement of  vatham. According to siddha philosophy 
PUNGENT taste  balances Vatham and sweet taste balances pitham. 
The ingredients of the trial drug  Merugulli thylam posses Veppa Veeriyam (Hot 
potency) naturally and predominantly contains Kaarpu suvai( Pungent taste) . Hence the 
trial drug expected to balance and rectify the deranged vatham.  
 Hence the trial drug which possess anti-vatha property as mentioned in Siddha 
literature were selected and the trial drug was prepared in the Gunapadam laboratory of  
National Institute of Siddha,Chennai. After getting proper authentication of raw drugs from 
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the Assistant professor of Medicinal Botany  at NIS, Chennai 47,The trial drug was 
prepared by the standard operating procedure as mentioned in the protocol. 
Standardization of the trial drug through biochemical analysis was carried out. 
The Biochemical qualitative and quantitative analysis were done at the biochemistry 
lab of NIS. It revealed the presence of effective minerals like calcium, iron etc. 
The Drug standardization and TLC, HPTLC were carried out by Captain Srinivasa 
Murthy Regional Ayurveda Drug Development Institute, Arumbakkam, Chennai and Test 
for Aflatoxin were done by Regional Research Institute of Unani Medicine, Royapuram 
respectively.  
The clinical study was conducted with a well defined protocol and a proper 
proforma after the approval of the Institutional Ethical Committee, the clinical study was 
registered in CTRI (Clinical Trial Registry -India). After that the enrolment of patients was 
started. 
 IEC NO: NIS/IEC/2016/11-07/14.10.2016 
CTRI NO: CTRI/2018/03/012365 
After screening   patients  reporting at the OPD of department of  Maruthuvam, 40 
cases of both genders were selected for induction to the trial. Before enrolment into the trial 
the informed consent was obtained from the patients. 
 Among the 40 patients 39 were OPD patients and the remaining one was  an IPD 
patient. For In-Patient, who was not in a situation to stay in the hospital for a long time, was 
advised to attend the Out-Patient Department of   Maruthuvam . 
    From the First day on wards , the patients were treated with trial drug Merugulli 
thylam ( Internal medicine)  9 ml/dose -3 days morning only in empty stomach  (2 days 
drug holiday)  this fashion of drug administration was followed for 45 days . Patients were 
instructed to take the medicines regularly and advised to follow pathiyam  (avoid tamarind, 
tubers, etc) and advised to avoid cold exposure . Out-Patients were asked to visit the 
hospital once in 5 days to collect the drug and as well as for clinical assessment and the 
clinical assessment was done on 0
 th
 day, 5
th
 day, 10
th
 day, 15
th
 day , 20
th
 day,25
th  
day, 30
th  
day, 35
th  
day, 40
th   
day, 45
th  
day. 
  After the treatment, the patients were advised to visit the Out-Patient department of  
Maruthuvam for another 2 months for follow-up without trial drug. 
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The results observed during the study period were discussed on the basis of below.   
OBSERVATION AND RESULTS 
AGE GROUP     
 In Age group    
  4 (10%) cases affected patients came under the age group between 20-30 years.14 
(35 %) cases fall under the age group between 31-40 years.15 (37.5 %) cases were between 
41-50   years and 7 (17.5 %) cases were between 51-60 yrs. 
Inference: 
        Most of the cases were affected in the age group of 41-50 yrs. 
GENDER 
           According to the Gender Among the 40 patients selected, the disease (R.A) was 
found to be higher in females 33 cases (82.5%) and lower in males 7 cases (17.5%).  
Inference:  
The prevalence was more in females than in Males. The male female ratio is 1:8 . 
The most prominent theory about the development of RA being more common in 
women is associated with changes in the levels of sex hormones, including oestrogen and 
progesterone which   have critical roles in the inflammatory response, and in the overall 
regulation of the immune system.  
 
 SOCIO-ECONOMIC STATUS   
    In  socio-economic status  the incidence of the disease was as follows,  
        In  Middle income group  - 29 cases(72.5%) 
        The low income group - 10 cases(25%)  
        Higher income group  - 1 case (2.5%) 
Inference: 
      In this study , most of the cases -  29 cases (72.5%) under middle income group 
          
MENSTURAL HISTORY 
              Among 40 cases observed, out of 33 females, 8(24.24%) females attained 
menopause, 2 (6.06%) females in hysterectomy status.     
 
The risk of developing RA is hightest in peri and postmenopausal women 
(4)
. 
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MARITAL STATUS 
Among 40 cases 39 (97.5%) got married and 1 case (2.5%) not married. 
 
EDUCATIONAL STATUS 
Among 40 cases 24 cases (60%) were literate and 16 cases (40%) were ill literate. 
 
 INCIDENCE DUE TO FAMILIAL INVOLVEMENT HISTORY: 
Among 40 cases,  39 (97.5%)cases did not have any familial history.1 (2.5%) case 
had the incidence of the disease in their relationship.  
 In this study most of the cases 39 (97.5%) cases did not have familial history. 
 
OCCUPATIONAL  DISTRIBUTION 
  In Occupational  distribution  Among 40 cases,  30cases (75%) were home maker, 
1case (2.5% ) was Student,1 Case ( 2.5%)  was Beautician, 4 Cases (10%) were cooli, 1 
Case (2.5%) was Farmer,2 Cases (5%) were Driver  and 1 Case (2.5%) was Tailor. 
In this study 30 cases(75%) were Home maker. 
 
DIET   
 In diet out of 40 patients, 30 cases were Non vegetarian (75%). They were higher 
than the vegetarian 10 cases (25%). 
 
Inference: 
  In this study most of the cases were observed to be non vegetarians. 
 Higher plasma levels of fat derived hormones leptin, adiponectin  and visfatin 
are found to be a modulation of the inflammatory environment in patients 
with RA. More over prevalence of RA is 50% greater in non vegetarians 
(5)
.  
OBESITY 
        In my study Out of 40 cases 5 cases 12.5 % were Obese, 35 cases 87.5 % were 
belongs to normal weight. 
 
Inference: 
         In Obesity there seems to be an increase in the inflammatory markers in the blood, 
most of them produced by the WAT (White Adipose Tissue) in RA 
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TREATMENTAL HISTORY OTHER THAN SIDDHA TREATMENT: 
      9 cases (22.5%)   due to adverse effects of drugs (like NSAIDS, Steroids), 2 cases 
(5%) were referred from rheumatologist, 4 cases (10%)  were not undergone any treatment 
before 
      Among 40 patients, 25 (62.5%) cases came to  Siddha treatment  due to fear for 
adverse effects in other system of medicine. 
     
THINAI 
In Thinai Amoug the 40 cases, 37 (92.5%) cases were from Neithal thinai, 2  (5%) 
cases were from Kurinji and 1 (2.5%) case was Marutham. 
In  Siddha literatures; it is mentioned that vaatha diseases are common in Neithal 
nilam.  
 
“nea;jdpy NkYth;g;ig ePq;fh JwpDkJ 
   nta;jdpy Nkjq;F tPlhFk;- neha;jPd; 
kUq;Fliy Kf;fhf;fp ty;YWg;igtPf;Fk; 
   fUq;Fliyf; fPopwf;Fq; fhz;” 
- gjhh;j;j Fz rpe;jhkzp 
 
This study also revealed the majority cases were from in Neithal thinai. 
 
PARUVA KAALAM 
In  Paruva Kaalam (Season) Out of 40 cases, 26 cases(65%) were  included in 
Koothirkaalam  and 12 (30%) cases were included  in Munpanikaalam, 2% (5) in Pinpani 
kalam. 
 According to Siddha literature in  Kaar kalam Vali azhal keelvayu like Vatha 
diseases may occur at greater incidence. In Muthuvenil Kaalam the disease 
may worsen than before 
 According to a recent research, predictors of radiographic progression 
unveiled a distinct  relationship between RA progression and seasonal onset 
postulate that this could be as a result of either a Vitamin D deficiency or 
environmental factors such as winter viruses, influencing protein 
citrullination especially winter and spring
(6)
. 
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KOSANGAL 
     Among 40 cases, Vignanamaya kosam was affected in all cases due to pain and 
restricted of movements of the minor and major joints. Annamaya kosam was affected in 31 
cases (77.5%) due to  loss of appetite. Pranamaya kosam  was affected in 5 cases(12.5%) 
due to dyspnoea on exertion. Manomaya kosam  was affected in 26 cases (65%) due to 
mental depression. Ananthamaya kosam affected in 3 cases (7.5%) duo to disturbed sexual 
life owing     to pain, restriction of movements and mental depression. 
 RA impacts on the sexual lives of a large minority of patients. This limitation was in 
general symptom-related, fatigue, pain and reduced joint function being the primary 
culprits 
(7) 
. 
 Depression is more commen in patients with Rheumatoid arthritis than in healthy 
individuals.(Psychomatic Medicine 64:52-60(2002)) sighing was significantly and 
strongly related to patient’s level of depression and non significant and less strongly 
related to their reported pain and number of flare days 
(8)
. 
 
GUNAM 
        In Gunam, 38 (95%) of cases had Raso gunam and 2 (5%) of cases had Thamo 
gunam. 
 
BODY CONSTITUTION  
In Body constitution Out of 40 cases, 35 cases (87.5%) were came under Thontha  
thegi and 5 cases (12.5%) were came under kaba thegi. 
 
CONDITION OF MUKKUTTRAM: 
 
Derangement in vatha kutram: 
Viyaanan and Samanan were affected in all 40 cases (100%)  which  resulted in 
pain, swelling , morning stiffness and restricted movements of the joints. Praanan was 
affected in 5 cases (12.5%)  which resulted in dyspnoea on exertion. Abaanan was affected 
in 37 cases (92.5%)  which resulted in constipation. naagan was affected in 1 case(2.5%) 
which resulted in diminished vision. Devathathan was affected in 28 cases (70%) which 
resulted in lethargy & disturbed sleep. Uthanan, Koorman , Kirukaran, and Dhananjeyan 
remained normal in all cases. 
 
136 
 
Derangement in pitha kutram: 
In Pitham Among 40 cases, Saathagam was affected in all 19 cases (47.5%) which 
indicates difficulty in walking, difficulty to perform regular duties. Ranjagam was  affected 
in 27 cases (67.5%)  which resulted  in pallor of conjunctiva. Analagam was affected in 31 
cases (77.5%) which resulted loss of appetite. 
 
Derangement in kaba kutram: 
Among 40 cases, Avalambagam and  santhigam were affected in all the 40 
Cases (100%) due to pain in joints Klethagam was affected in 31 cases(77.5%) which 
caused by loss of appetite. Tharpagam was affected in 1 case(2.5%) due to burning 
sensation of eyes. 
 
INCIDENCE WITH REFERENCE TO THE ENVAGAI THERVU 
     In Envagai Thervu , Naadi : Under the study of naadi, all the 40 cases showed 
Thontha naadi. Sparisam was affected in  40 cases (100%)  as they had swelling, tenderness 
in joints with local heat. Vizhi was affected in 27 cases (67.5%) as it showed pale 
conjunctiva. Naa was affected in 27 cases(67.5%)  as it showed coating of tongue and 
pallor. Malam was affected in 37 cases (92.5%) leading to constipation. Mozhi ,niram and 
Moothiram were found to be normal in all 40 cases. 
 
INCIDENCE WITH REFERENCE TO THE NAADI TYPE 
 While seeing  the Naadi, Among 40 cases showed Thontha naadi Vatha pitha naadi 
was found in 32 cases (80%), Pitha vatha naadi was found in 3 cases (7.5%), Pitha kaba 
naadi was found in 1 cases (2.5%), Vaatha kaba naadi was found in  2 cases (5%) and Kaba 
vatha naadi was found in 2 cases (5%).  
In this study , Vatha pitha naadi  was predominant in 32 cases(80%)  . 
 
INCIDENCE WITH REFERENCE TO THE NEIKKURI 
Among 40 cases ,5 cases (12.5%)  had Vatham pattern of Neikuri i.e. Aravena 
neendathu (Spreading like a snake) 35 cases (87.5%) had Kapham pattern of Neikuri, i.e 
Muththothu Ninrathu( Stands like a pearl.) 
In this study, Most of the cases (87.5%) had Kapham pattern of Neikuri. 
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INCIDENCE WITH REFERENCE TO THE UDAL THAATHUKKAL    
Among 40 cases, Saaram was affected in all 40 (100%) cases that produced the 
symptoms like lethargy. Senneer was affected in  27 cases (67.5%) that produced the 
symptoms like loss of strength and loss of appetite. 
  Oon was affected in all 40 (100%) cases that produced the symptoms like swelling, 
morning stiffness of affected joints and pain in affected joints. Kozhuppu was affected in 
all 40 (100%) cases that produced the symptoms like swelling in the affected joints 
particularly interphalangeal, difficulty in movements of affected joints.  
Enbu was affected in all 40 cases (100%) was affected in all 40 (100%) cases that 
produced the symptoms like swelling, redness of affected joints, deformities and restriction 
in movements. Moolai was affected in all 40 (100%) cases that produced the symptoms like 
swelling in the affected joints particularly interphalangeal joints. 
Sukkilam and suronitham were  not affected in all the cases concerned to the 
disease. 
 
IN KANMENDRIUM, 
 Kai and Kaal were affected in 40 cases (100%) due to pain, swelling, morning 
stiffness and deformities. Eruvai was affected in 37 (92.5%) cases. 
 
DURATION OF ILLNESS 
In Duration of illness, In this study, about 9 (22.5%) cases had upto 1 yr  duration,  
11(27.5%) cases had  1 to 2 yrs of duration,13 (32.5%) cases had 2-5 yrs of duration, 5 
(12.5%) cases had  5 to 7 yrs of duration and 1 (2.5%) cases had 7-10 yrs and another one 
case had  10-15 yrs of duration. 
 
MODE OF ONSET   
              According to the mode of onset  In my study  30  (75%)  cases had Gradual onset 
of illness, 10 (25%)  cases had Sudden onset of illness. 
 
INVOLVEMENT OF JOINTS   
Cervical vertebrae were involved before treatment in 15 (37.5%) cases after 
treatment it was in 5 cases (12.5%).Elbow joint were involved in before treatment in 35 
case (87.5%). After treatment it was in 10 cases (25%). 
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Wrist joint and ankle joint   were involved   in 39 cases (97.5%), 35 cases (87.5%) 
respectively. After treatment it was 12 cases (30%), and 24 cases (60%). MCP joints were 
involved in 37 cases (92.5%), after treatment it was in 19 cases (47.5%) 
Knee joint was involved   in 36 cases (90%). After treatment it was 20 cases (50%), 
PIP joint were involved in 40 cases (100%) before treatment, after it was in 25 cases 
(62.5%). 
 Lumbosacral joint was affected in 14 cases (35%) before treatment after treatment it 
was in 8 cases (20%). (25%) 10 cases were affected in hip joint before treatment, after it 
was in 5 cases (12.5%). 
 
CLINICAL SYMPTOMS 
Observation with reference to Clinical symptoms 
Pain 
Before treatment all 40 cases (100%) had pain, After treatment it was reduced into 
24 cases (60%). 
 Swelling in joints 
    All 40 cases (100%) had swelling before treatment, No one had swelling after 
treatment . 
Morning stiffness 
    All 40 cases (100%) had morning stiffiness before treatment, It was reduced to (2 
cases)  5%.  
Tenderness, 
    All 40 cases (100%) had tenderness before treatment, after treatment it was reduced 
to 0 case (0%)  
Fever 
Before treatment Fever was found in 2 cases (5%)  which was relieved  after 
treatment.  
Restricted movements. 
    All 40 cases (100%) had restricted movements before treatment, after treatment it 
was reduced to 10 cases (25%). 
Polyarthralgia 
       Before treatment  40 cases (100%) had polyarthralgia, after treatment it was reduced to 
25 cases (62.5%). 
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Deformities 
       Deformities  remained the same before and after treatment in 19 cases (47.5%) 
Among the Deformities in this study, 11( 27.5%)  cases had Spindle shaped deformity, 7 
(17.5%)  cases had Button hole derormity, 1  (2.5%) cases  had  Swan neck  deformity. 
 Anorexia 
       Before treatment  31 cases (77.5%) had Anorexia , After treatment no cases were 
reported with anorexia. 
 
PRIMARY OUTCOME 
PAIN ASSESSMENT SCALE 
In this study, 25 cases (62.5%) had severe pain, 15(37.5%) cases had Moderate pain. 
After treatment no one had severe pain, one (2.5%) case had Moderate pain, 23(57.5%) 
cases had Mild pain, 16 (40%) cases had no pain. 
The mean± standard deviation of pain score before and after treatment were 7 ± 1.22 
and  1.3±1.24  respectively which is statistically significant (p<0.001) The analysis 
revealed that  significant reduction of pain with the trial drug  i.e. there is 81.4% reduction 
in pain compared to start of the treatment. 
 
FUNCTIONAL ABILITY GRADATION  
Grade I - Fit for all activities 
Grade II - Mild restriction 
Grade III - Moderate restriction 
Grade IV  - Confined to chair or bed ridden 
    Among 40 cases, before treatment 4 (10%) cases were in grade IV, 19 (47.5%) cases 
were in Grade III. After treatment no one came under Grade IV and III. Before treatment 
17(42.5%) cases were in Grade II after treatment 10(25%) cases under Grade II. After 
treatment 30 cases (75%) came under Grade I 
IMPROVEMENT IN   FUNCTIONAL ABILITY ASSESSMENT OF PATIENTS: 
As per Cross tabulation, Before treatment 4 cases (10%) came under grade IV after 
treatment 1 case (2.5%) under grade I and 3 cases (7.5%) under Grade II. Before treatment  
19 cases  (47.5%) came under  Grade III after treatment 12 cases (30%) came under grade I 
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and 7  cases (17.5%) came under grade II, Before treatment 17(42.5%) cases in Grade II  
after treatment  all 17 (42.5%) cases came under Grade I. 
It revealed that over all good improvement  
SECONDARY OUTCOME OBSERVATION 
 
LABORATORY INVESTIGATIONS 
Observation with reference to RA factor. 
Among 27 cases (67.5%)   who are positive at commencement of the treatment 9 
(33.3%) were screened negative and 18 (45%) cases remained positive for RA factor after 
the treatment. 
 Although the diagnosis of RA is a clinical one, rheumatoid factor is an 
important prognostic marker, those who test positive are more likely to have 
a worse prognosis with respect to joint destruction, physical/ occupational 
disability and quality of life in general.  
Observation with reference to C Reactive Protein 
Among 25 cases (62.5%)   who are positive at commencement of the treatment 
6(24%) were screened negative and  19 (47.5%) cases remained positive for C reactive 
protein after the treatment. 
 
Observation with reference to ASO titre 
Among 10 cases   who are positive at commencement of the treatment 2(20%) cases 
were screened negative and 8 (20%) cases remained positive for ASO titre after the 
treatment. 
 
HAEMOGLOBIN 
Among 40 cases , there was no significant changes after the treatment statistically. 
 
ERYTHROCYTE SEDIMENTATION RATE (ESR) 
The analysis revealed  that there is 49.7% reduction in ESR ½ HR   
and  52.44% reduction in ESR 1 HR compared to start of the treatment. 
 The mean ± standard deviation before treatment is 32.02± 19.75 and after treatment is   
16.1 ±10.91 for  ½ hr.  The analysis revealed that there is 49.7% reduction in ESR ½ HR 
compared to start of the treatment. 
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               The mean ± standard deviation before treatment is 57.97± 32.54 and after treatment is 
27.57 ±19.52 for 1 hr. The analysis revels that there is 52.44% reduction in ESR 1 HR 
compared to start of the treatment. 
   The statistical analysis reveals that there has been a significant reduction in ESR 
value after treatment indicating the control over the inflammatory process of the disease. 
The erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) -Acute phase 
reactant is measured in RA either, both of which are elevated during active disease as a sign 
of inflammation. 
 
BIOCHEMICAL ANALYSIS  
     Qualitative analysis of MERUGULLI THYLAM done in NIS biochemical lab 
revealed that Merugulli thylam contains Calcium, Silicate, Iron , Phosphate, Alkaloids , 
Starch etc. 
 
Standardization Report 
           
S.NO      PARAMETERS  RESULTS 
1 Refractive index 1.4752 
2 Acid value 9.41 
3 Saponification Value 181.45 
4 Peroxide Value 5.36 
5 Iodine value 83.11 
6 Weight 0.964 
 
TLC & HPTLC  
                 HPTLC   finger print of Merugulli thylam could serve as a marker and which is      
responsible for expression of its biological and clinical actions. 
 HPTLC was carried out in UV at 254 nm , UV at 366 nm to establish the finger 
printing profile and to show the possibly active phytochemical constituents  . 
 In   254 nm UV the peak corresponds to the Rf values 56.51% has maximum peak 
area of 4140.6 AU(area 43.84%) is a marker.      
 In   366  nm UV the peak corresponds to the Rf values  83.03% has maximum peak 
area of 2547.0 AU(area 80%) is a marker. 
 No Aflatoxins were detected in Merugulli thylam.     
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SUMMARY 
 
 The aim of the study was to evaluate the efficacy of the drug MERUGULLI 
THYLAM (Internal) in Vali azhal keelvayu. 
Before initiating the clinical trial, approval was got from the Institutional Ethical 
Committee for conducting the clinical study by submitting the well defined protocol 
and proforma.             IEC NO: NIS/IEC/2016/11-07/14.10.2016 
 Then the clinical trial was registered in CTRI(Clinical Trial Registry -India). After that 
the enrolment of patients was started. 
                                  CTRI NO: CTRI/2018/03/012365 
 The raw drugs were authenticated by the Assistant Professor, Medicinal Botany and the 
trial drug was prepared by the investigator in the Gunapadam lab of National Institute 
of Siddha as per the Standard Operating Procedure mentioned in the protocol. 
 Bio chemical studies were done at the bio chemistry lab of National Institute of Siddha, 
The standardization and TLC &HPTLC were done at the  Captain Srinivasa Murthy 
Regional Ayurveda Drug Development Institute, Arumbakkam, Chennai.(as per letter 
of CSMRADDI) And  detection of aflatoxin were done in Regional Research Institute 
of Unani Medicine, Royapuram respectively.  
 Among the 105 cases screened at the OPD of department of Maruthuvam NIS, 40 cases 
were recruited for the trial as per the inclusion and exclusion criteria. 
 Clinical diagnosis of valiazhal keelvayu was made by Siddha and Modern 
methodology. 
 Before inducement into the trial informed consent was obtained from the patients. Out 
of the 40 cases 39 cases were treated in OPD and 1 case in IPD. 
 The trial medicine selected for  Internal treatment was  MERUGULLI THYLAM   
9 ml/dose morning only in empty stomach with the adjuvant hot water referred under 
Siddha literature Theraiyar Thylavarga Surukkam. 
 During the treatment period of 45 days the trial drug MERUGULLI THYLAM 
(internal) is given for 3 days followed by a re dieting (drug holiday) of 2 days. Likewise 
the medicine is given till the end of the course. 
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 Diet restriction was strictly followed during the period of drug administration as well as 
re dieting period (Diet free of salt, coconut, horse gram etc) as per noted in the form IV 
(Dietary advice form). 
 Required lab investigations were carried out before and after the treatment and the data 
was recorded in the proforma. 
 Clinical assessment was done daily in IP patient and OP patients it was assessed once in 
5 days. 
 During the study period, there was no event of any adverse reactions owing to the drug 
or disease. 
 In these studies out of 40 cases 81.4% of cases showed reduction in pain. There was 
improvement in other clinical symptoms before and after treatment revealing the effect 
of drug in reducing the pain and other clinical symptoms. Thus improvement of the 
patients in their daily life activities. 
 As per the Siddha Literature and modern science reviews and research articles, the 
ingredients of the trial drugs were found to have the property of controlling the Vatha 
diseases, some drugs exhibited anti inflammatory, anti analgesic activities owing to the 
disease manifestations. 
 Clinical Lab parameters there was reduction in RA factor, CRP and ASO titre [RA 
factor- 27 cases (67.5%) positive at commencement of the treatment 9 (33.3%) were 
screened negative after the treatment, CRP-25 cases (62.5%) positive at commencement 
of the treatment 6(24%) were screened negative after the treatment, ASO titre -10 cases  
positive at commencement of the treatment 2(20%) cases were screened negative after 
the treatment] and ESR - 49.7% reduction in ESR ½ HR   and  52.44% reduction in 
ESR 1 HR which showed the therapeutic effect of the drug in controlling the disease to 
a greater extent. 
  Statistical analysis showed significant reduction in pain scale and a significant 
reduction in ESR value after treatment indicating the control over the inflammatory 
process of the disease.         
 Bio chemical analysis showed the precence if inevitable constituents like 
Iron,Calcium,Sulphur which played a role in repairing and preventing the joint damage 
in the disease.    
 TLC & HPTLC – HPTLC finger print of Merugulli thylam could serve as a marker and 
which is responsible for expression of its biological and clinical actions. 
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 HPTLC was carried out in UV at 254 nm , UV at 366 nm to establish the finger printing 
profile and to show the possibly active phyto chemical constituents  . 
 In   254 nm UV the peak corresponds to the Rf values 56.51% has maximum peak area 
of 4140.6 AU(area 43.84%) is a marker.      
 In   366  nm UV the peak corresponds to the Rf values 83.03%  % has maximum peak 
area of 2547.0 AU(area 80%) is a marker      
 No Aflatoxins were detected in Merugulli thylam. 
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                                                       CONCLUSION 
 Statistical analysis [Paired “t” test] revealed that the therapeutic efficacy of the trial 
drug  Merugulli thylam by showing, reduction in pain 81.4% of cases.                                     
( Universal pain assessment scale: Ref: Clinical Manual for Nursing Practise 
National Institute of Health Warren Grant Magnuson Clinical Centre ) 
 As per cross tabulation (vide table no.32) 30 cases (75%) came under Grade I (Fit 
for all activities) & 10 cases (25%) came under Grade II (Mild restriction) after the 
treatment. It revealed that 100% cases showed Good improvement in functional 
ability. 
 There is a significant reduction in the elevated lab parameters [RA factor- 27 cases 
(67.5%) positive at commencement of the treatment 9 (33.3%) were screened 
negative after the treatment, CRP-25 cases (62.5%) positive at commencement of 
the treatment 6(24%) were screened negative after the treatment, ASO titre -10 
cases positive at commencement of the treatment 2(20%) cases were screened 
negative after the treatment]. 
 The mean ± standard deviation before treatment is 32.02± 19.75 and after treatment is   
16.1 ±10.91 for ESR ½ hr. The analysis revealed that there is 49.7% reduction in 
ESR ½ hr compared to start of the treatment. 
 The mean ± standard deviation before treatment is 57.97± 32.54 and after treatment is 
27.57 ±19.52 for ESR 1 hr. The analysis revels that there is 52.44% reduction in 
ESR 1 hr compared to start of the treatment. 
 There were no adverse reactions complained during the trial period. 
 The results of the clinical trial indicates that the trail drug  MERUGULLI 
THYLAM is clinically effective,safe and also economical. 
 Because of the encourage clinical outcome, the study may be further carried out 
with the same durg in large number of cases. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
An Open  Clinical study on ”Merugulli thylam (Internal Medicine)”  in the 
treatment of “Vali Azhal keel Vayu” (Rheumatoid Arthritis)  
 
Principal Investigator: Dr.M.Suganthi              Reg.No.                                                
 
FORM I - SCREENING & SELECTION PROFORMA 
 
1. SERIAL NO: …………………………….. 2. OP /IP NO: ……………………                              
3. NAME: ……………………………………      4. AGE/GENDER: …………........  
5. OCCUPATION: ………………………….       6. INCOME: …………………….. 
 
INCLUSION CRITERIA 
 
 
 
 
 
 
DEPARTMENT OF  MARUTHUVAM 
Age between 20 and60 Yes/No Sex M / F 
Arthritis of three or more joints Yes/No 
Rheumatoid Factor- Positive 
 
Yes / No 
Symmetrical joint involvement Yes/No Anorexia Yes/ No 
Swelling especially in inter phalangeal 
joints 
Yes/No Low grade fever Yes/No 
Morning stiffness of joints > than an 
hour 
Yes/No Pain Yes/No 
Willingness to undergoRadiological & 
Laboratoty investigations 
Yes/No Willing to give consent 
Yes/No 
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EXCLUSION CRITERIA: 
 
 
ADMITTED TO TRAIL 
 
 
Yes:                                  No: 
 
 If Yes: OPD                           IPD: 
 
Date:        
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD   
 
                            
 
 
 
 
 
 
 
 
 
 
 Diabetes mellitus Yes/No 
 
Thyroidism(Hypo/Hyper) 
 
           Yes/No 
 
Hypertention 
Yes/No Pregnancy and lactation Yes/No 
 
Cardiac disease 
Yes/No 
 Any other serious illness 
like cancer 
Yes/No 
            
                   Tubercular Arthritis 
Yes/No      Psoriatic Arthritis Yes/ No 
 
Gouty Arthritis 
Yes/No      Osteoarthritis Yes/ No 
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                                     NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF  MARUTHUVAM 
An open  Clinical study on ”Merugulli Thylam (Internal Medicine)”  in the treatment of 
“Vali Azhal Keel Vayu” (Rheumatoid Arthritis)  
 
Principal Investigator: Dr.M.Suganthi 
FORM II-A – HISTORY TAKING PROFORMA 
 
STUDY  NO:   OP / IP NO: 
NAME: AGE / GENDER: 
ADDRESS: 
 
 
 
CONTACT NO : 
 RELIGION :  H / C / M / O. 
OCCUPATION: 
 
INCOME: 
MARITAL STATUS :       1. Married 2. Unmarried 
DATE OF INTIAL ASSESSMENT:  
COMPLAINTS & DURATION:  
 
 
 
                                                                                                                                                                             
PERSONAL HISTORY: 
 
 
 
Whether this problem runs in family? 
 
1. Yes            2. No    
 
If yes, mention the relationship of affected person(s) 
 
1._________________ 
 
2._________________ 
 
DIETARY STYLE: 1. Vegetarian    2. Non-vegetarian 
 
MENSTURAL AND OBSTETRIC HISTORY: 
 
 
 
 
PERSONAL HABITS YES NO 
IF YES SPECIFY 
DURATION 
AMOUNT/Quantity 
Smoking     
Tobacco Chewing     
Alcohol     
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FORM II B  
 
GENERAL EXAMINATION: 
1. Body weight [Kg]                 :                      
2. Height [cms]                                    :                        
3. Body Temperature [F]        :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min.        : 
6. Heart Rate / min.         : 
7. Respiratory Rate /min.               :   
                                                                                           Yes            No   
8. Pallor   :   
9. Jaundice   :   
10. Clubbing   : 
11. Cyanosis   : 
12. Pedal Oedema   :           
13. Lymphadenopathy            :                                        
14. Jugular venous pulsation   :   
SYSTEMIC EXAMINATION 
  Cardiovascular system                :  
  Respiratory system                 :  
  Gastro-intestinal system                :  
  Central Nervous system                :  
  Urogenital system                 :  
  Endocrine system                             :  
SIDDHA SYSTEM OF EXAMINATION 
1. THEGI (BODY CONSTITUTION): 
1. Vatha udal                                                                             
2. Pitha udal 
3. Kaba udal 
4. Thontha udal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji (Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
3. KAALAM: 
1. Kaar kaalam    (Aavani-Purattasi) 
2. Koothir kaalam     (Ippasi-Kaarthigai) 
3. Munpani kaalam      (Maargazhi-Thai) 
4. Pinpani kaalam       (Maasi-Panguni) 
5. Ilavenil kaalam        (Chithirai-Vaigasi) 
6. Muthuvenil kaalam (Aani-Aadi) 
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4. GUNAM: 
1. Sathuvam  
2. Rasatham 
3. Thamasam 
 
5. PORIPULANGAL (SENSORY ORGANS):          
                  
  
 
 
 
 
 
 
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
        
 
 
 
 
 
 
 
7.KOSANGAL (SHEATH):                
 
 
 
 
 
 
  
   
 
 
8. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 Before treatment After treatment 
Saaram Normal  /Affected Normal  /Affected 
Senneer  Normal  /Affected Normal  /Affected 
Oon Normal  /Affected Normal  /Affected 
Kozhuppu Normal  /Affected Normal  /Affected 
Enbu Normal  /Affected Normal  /Affected 
Moolai Normal  /Affected Normal  /Affected 
Sukkilam / Suronitham Normal  /Affected Normal  /Affected 
 
 
 
 Before treatment After treatment 
Mei (Skin) Normal  / Affected Normal  / Affected 
Vai (Tongue) Normal  / Affected Normal  / Affected 
Kann (Eye) Normal  / Affected Normal  / Affected 
Mooku (Nose) Normal  / Affected Normal  / Affected 
Sevi (Ear) Normal  / Affected Normal  / Affected 
 Before treatment After treatment 
Kai (Upper limb) Normal  /Affected Normal  /Affected 
Kaal (Lower limb) Normal  /Affected Normal  /Affected 
Vai (Oral cavity)   Normal  /Affected Normal  /Affected 
Eruvai (Anal 
region) 
Normal  /Affected Normal  /Affected 
Karuvai (Uro-
Genital region)  
Normal  /Affected Normal  /Affected 
 Before treatment After treatment 
Annamaya kosam Normal  /Affected Normal  /Affected 
Pranamaya kosam  Normal  /Affected Normal  /Affected 
Manomaya kosam  Normal  /Affected Normal  /Affected 
Vignanamaya kosam  Normal  /Affected Normal  /Affected 
Ananthamaya kosam Normal  /Affected Normal  /Affected 
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9. UYIR THAATHUKKAL: [THREE HUMORS] (VALI/ AZHAL/ IYYAM) 
 
A) VALI 
 
 0
th
 day 
5
th
 
day 
10
th
 
day 
15
nd
 
day 
20
th
 
day 
25
th
 
day 
30
th
 
day 
35day 
40 th 
day 
45 th 
day 
Praanan           
Abaanan           
Samaanan           
Udhaanan           
Viyaanan           
Naagan           
Koorman           
Kirukaran           
Devathathan           
Dhananjeyan           
 
 
B) AZHAL 
 
 
0
th
 
day 
5
th
 
day 
10
th
 
day 
15
nd
 
day 
20
th
 
day 
25
th
 
day 
30
rd
 
day 
35 th 
day 
40
th
 
day 
45 th 
day 
Analakam           
Ranjakam            
Saathakam            
Prasakam            
Aalosakam           
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C) IYYAM 
 
 
0
th
 
day 
5
th
 
day 
10
th
 
day 
15
nd
 
day 
20
th
 
day 
25
th
 
day 
30
rd
 
day 
35
th
 
day 
40 th 
day 
45 th 
day 
Avalambagam           
Kilethagam           
Pothagam           
Tharpagam           
Santhigam           
 
10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
 
NAADI 0
th
  day 5
th 
day
 10
th 
day 
15
nd
day 
20
th
day 
25
th
  
day 
30
rd
day 
35
th
day 
40 th 
day 
45 th 
day 
           
 
II. SPARISAM: [PALPATION] 
 
Day SPARISAM 
0
th
  day  
5
th 
day
  
10
th
  day  
15
nd
  day  
20
th
  day  
25
th
  day  
30
rd
 day  
35
th 
day  
40th day  
45th day  
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III. NAA: [TONGUE] 
 
NAA 0
th
day 5
th
day
 10
th
d
ay 
15
nd
day 
20
th
day 
25
th
day 30
rd
day 
35 th 
day 
40
th
day 45 th day 
           
 
IV. NIRAM: [COMPLEXION]   
    1. Vadham         
     2. Pitham 
      3. Kabam  
 
V. MOZHI: [VOICE] 
      1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
 
VI.VIZHI: [EYES] 
VIZHI 
0
th
  
day 
5
th 
day
 
10
th
day 
15
nd
day 
20
th
day 
25
th
  
day 
30
rd
day 
35 th 
day 
40
th
da
y 
45 th 
day 
           
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
 Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
 
VIII. MOOTHIRAM [URINE EXAMINATION]   
NEERKKURI: 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   
Enjal   
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NEIKKURI:  
 
Neikkuri Before treatment After treatment 
 Aravana neendathu/ 
Snake like pattern 
 
  
Azhipol paraviyathu 
Annular/Ring pattern 
 
 
 
parav paraparavoiyadu 
  
Muththothu ninrathu  
Pearlbeadepattern 
  
Other patterns   
 
CLINICAL ASSESSMENT              
 
S.NO CLINICAL  
SYMPTOMS 
 0
th
  
day   
  5
th
 
day                               
 
10
th
 
day 
        
  
 15
nd 
day       
20
th
 
day 
25
th
 
day 
30
rd
  
day 
35
th
  
day 
40 th 
day 
45 th 
day 
1. Arthritis of 
more than 3 
joints 
   
 
       
2. Arthritis of 
hand joints 
    
 
      
3. Morning 
stiffness > 1 
hr 
          
4. Symmetrical 
arthritis 
          
5. Restricted 
movements 
          
6. Spindled 
appearance of 
fingers 
          
7. Anorexia           
8. Low grade 
fever 
          
9. Subcutaneous 
nodules in 
specific 
places 
          
10.  Depression     
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CLINICAL EXAMINATION: 
I.INSPECTION: 
S
N
O 
 0
th
 day 5
th
 day 
 
10
th
 
day 
 
15
nd
  
day 
 
20
th
 
day 
 
25
th
 day 
 
30
rd
 day 
 
35
th
 day 
40 th 
day 
45 th 
day 
1 
Muscle 
wasting of 
the upper 
limbs: 
Proximal- 
Distal 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present
/Absent 
Present/
Absent 
 
2 
Joint 
swelling:                   
Major 
joints 
Present/
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present
/Absent 
Present/
Absent 
3 
Joint 
swelling: 
Minor 
joints 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present
/Absent 
Present/
Absent 
4 
Skin over 
the joints: 
 
Normal/ 
Reddish 
Normal/ 
Reddish 
Normal/
Reddish 
Normal/
Reddish 
 
Normal
/Reddis
h 
 
Normal/
Reddish 
 
Normal/
Reddish 
 
Normal/
Reddish 
Normal
/Reddis
h 
Normal/
Reddish 
5 
Muscle 
wasting of 
the lower 
limbs: 
Present/ 
Absent  
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/ 
Absent 
Present
/Absent 
Present/
Absent 
6 Nodules: 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present
/Absent 
Present/
Absent 
7 
Spindled 
appearanc
e of 
fingers 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present
/Absent 
Present/
Absent 
8 
Deformiti
eSwan 
neck 
deformity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present/
Absent 
Present
/Absent 
9 
Button 
hole 
deformity 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present
/Absent 
1
0 
Z shaped 
deformity 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present
/Absent 
1
1 
Ulnar 
deviation 
of hand 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present/
Absent 
Present
/Absent 
1
2 
Ulnar 
deviation 
of foot 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present/
Absent 
Present
/Absent 
1
3 
Hallus 
valgus 
Present/
Absent 
Present/
Absent 
Present/
Absent 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
 
Present/
Absent 
Present/
Absent 
Present
/Absent 
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II.PALPATION 
 
 
UNIVERSAL PAIN ASSESMENT SCALE: 
                  
 
                  0   :   No Pain 
                1-3  :   Mild pain 
                4-6  :   Moderate pain 
               7-10 :   Severe pain 
 
RESTRICTED MOVEMENT ASSESSMENT SCALE:                
GRADATION OF MOVEMENTS 
Grade 1 – Able to perform normal duties 
Grade II – Moderate Restriction – Self care is possible 
Grade III – Marked restriction – Limited self care/some assistance required. 
Grade IV – Confined to bed or wheel chair 
 0
th
 day 5
th
 day 10
th
 day 15th day 
 
20
th
 day 
 
25
th
 day 
 
30
rd
 day 
 
35
th
 day 
40 th 
day 
45 th 
day 
PAIN 
 Onset: 
 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
 
Sudden/ 
Gradual 
 
Sudden/ 
Gradual 
 
Sudden/ 
Gradual 
 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
 Early 
morning  
Stiffness 
 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 Local 
heat 
   Mild/ 
Moderat
e/  
Severe 
Mild/ 
Moderate/ 
Severe 
Mild/ 
Moderate/ 
Severe 
Mild/ 
Moderate/ 
Severe 
 Mild/ 
Moderate/ 
Severe 
Mild/ 
Moderate
/ Severe 
Mild/ 
Moderate/ 
Severe 
Mild/ 
Moderate/ 
Severe 
Mild/ 
Moderate
/ Severe 
Mild/ 
Moderat
e/ 
Severe 
 
Stiffness 
 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Tendern
ess 
 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Restricti
on 
 
 
Fully/ 
Partial/ 
No 
 
Fully/ 
Partial/ 
No 
 
Fully/ 
Partial/ 
No 
 
Fully/ 
Partial/ 
No 
 
Fully/ 
Partial/ 
No 
 
Fully/ 
Partial/ 
No 
 
Fully/ 
Partial/ 
No 
 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
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AUTONOMIC NERVOUS SYSTEM 
 
0
th
 day 5
th
 day 
10
th
 
day 
15
nd
 
day 
20
th
 
day 
25
th
 day 30
rd
 
day 
35
th
 
day 
40 th 
day 
45 th 
day 
Bladder 
          
Bowel 
          
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161 
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF  MARUTHUVAM 
An open  Clinical study on ”Merugulli thylam (Internal Medicine)” in the treatment of “Vali 
Azhal Keel Vayu” (Rheumatoid Arthritis). 
 
Principal Investigator: Dr.M.Suganthi 
1. SERIAL NO:      2. OP /IP NO:                              
3. NAME:            4. AGE/GENDER: 
 
FORM-III - LABORATORY INVESTIGATIONS 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TMT 
(WITH 
DATE) 
AFTER TMT 
(WITH DATE) 
 
HB( gm/dl) 
M:12-15 
W:11.5-14 
  
 
T.WBC (cells/cu.mm) 
4000-
11000 
  
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
 
T.RBC(million cells/cu.mm) 
 
M:4.0-5.5 
 W:3.5-4.5 
 
 
 
 
 
  ESR(mm/hour) ½ hr. M:6-12 
W:7-18 
  
 
 
 1 hr.   
Blood Investigations 
Normal 
Values 
Before 
TMT(WITH 
DATE) 
After TMT 
(WITH DATE) 
HCT/PCV 
 
Men:36-
51% 
Women:35- 
48% 
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MCV 
Men :78-
98%ft 
Women : 
78-98%ft 
  
MCH 
Men : 26-
34 pg 
Women : 
26-34pg 
  
MCHC 
Men : 31-
37 gms/dl 
Women : 
31-37 
gms/dl 
  
Platelet count 
Men : 1.5 – 
4.5 lkhs/µl 
Women : 
1.5-4.5 
lkhs/µl 
  
Bleeding Time 1-3 minutes   
Clotting Time 3-8 minutes   
Blood 
glucose 
(mg/dl) 
Fasting    70-110   
PP    80-140   
Random    80-120   
RFT (mg/dl) 
Blood urea    16-50   
Serum creatinine    0.6-1.2   
LFT (mg/dl) 
Total bilirubin    0.2-1.2   
Direct bilirubin    0.1-1.2   
Indirect 
bilirubin 
   0.2-0.7   
SGOT     0-40   
SGPT     0-35   
Alkaline 
phosphatase 
   80-290   
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OTHER 
TESTS. 
BLOOD  
INVESTIGATI
ONS 
8
.
       
- 
 
 
 
NORMAL 
VALUES 
 
BEFORE 
TMT 
 
 
AFTER TMT 
Serum calcium  8.5-10.5   
Serum 
phosphorus 
 3.0-4.5   
 
Serum uric 
acid 
  
Men:3.0-9.0 
Women:2.5-7.5 
  
Serum protein 
 
 6.0-8.0 
 
  
Serum albumin 
 
 3.5-5.0   
Serum globulin  2.3-3.5   
 
 
Special 
investigations 
Before TMT(with 
Date) 
After TMT (With 
Date) 
RA FACTOR   
ASO TITER   
CRP   
X – RAY 
FINDINGS 
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Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD 
 
 
 
Urine investigation Before TMT(with Date) After TMT (With Date) 
Neer kuri   
Niram   
Edai   
Manam   
Nurai   
Enjal   
Nei kuri   
Albumin   
Fasting sugar   
PP sugar   
Deposits 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF  MARUTHUVAM 
An open Clinical study on ”Merugulli thylam (Internal Medicine)” in the treatment of 
“Vali Azhal Keel Vayu” (Rheumatoid Arthritis). 
Principal Investigator: Dr.M.Suganthi                                                              
 
FORM –IV- DRUG COMPLIANCE FORM 
SERIAL NO:                                                                                                      
NAME:  
DRUG NAME:  
On 1
st    
 day-Date: Drugs issued: (Gms) Drugs returned:    (Gms) 
On 5
th
   day-Date:  Drugs issued: (Gms) Drugs returned:    (Gms) 
On 10
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 15
th
 day-Date:           Drugs issued: (Gms) Drugs returned:    (Gms) 
On 20t
h
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 25
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 30
th
 day-Date:            Drugs issued: (Gms) Drugs returned:    (Gms)  
On 35
th
 day-Date:            Drugs issued: (Gms) Drugs returned:    (Gms) 
On 40
th
 day-Date:            Drugs issued: (Gms) Drugs returned:    (Gms)  
On 45
th
 day-Date:            Drugs issued: (Gms) Drugs returned:    (Gms) 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
   Day    Date          Morning   Evening   Day    Date    Morning   Evening 
Day 1    Day25    
Day2    Day26    
Day3    Day27    
Day4    Day28    
Day5    Day29    
Day6    Day30    
Day7    Day31    
Day8    Day32    
Day9    Day33    
Day10    Day34    
Day11    Day35    
Day12    Day36    
Day13    Day37    
Day14    Day38    
Day15    Day39    
Day16    Day40    
Day17    Day41    
Day18    Day42    
Day19    Day43    
Day20    Day44    
Day21    Day45    
Day22                                                                                
Day23    
Day24    
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF  MARUTHUVAM 
An Open  Clinical study on ”MERUGULLI THYLAM (Internal Medicine)” 
in the treatment of “Vali Azhal Keel Vayu” (Rheumatoid Arthritis)  
                                 FORM V– PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.M.Suganthi, 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
       I, Dr.M.Suganthi, studying M.D (Siddha) I st year at National Institute of Siddha, 
Tambaram Sanatorium   doing  a clinical trial on „„Vali Azhal Keel Vayu” (Rheumatoid 
arthritis). It is a Auto immune disease, occurring throughout the world. In this regard, I am 
in a need to ask you few questions. I will maintain confidentiality of your comments and 
data obtained. There will be no risk of disclosing your identity and no physical, 
psychological or professional risk is involved by taking part in this study. Taking part in this 
study is voluntary. No compensation will be paid to you for taking   part in this study. 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
“MERUGULLI THYLAM” (Internal medicine) 9 gram(9 ml)-Morning only,(Drug 
administration-3 days.,drug holiday-2 days) for 45 days . If you wish to stay in the In 
Patient ward, the  internal medicine will be provided to you assuring that you will not be 
definitely hurt in any course of treatment. 
  The information I am collecting in this study will remain between you and the 
principal investigator (myself). I will ask you few questions through a questionnaire. I will 
not write your name on this form. Ur name won‟t be mentioned in the lab investigation 
form instead a code will be used. 
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The questionnaire will take approximately 20 minutes of your time. 
If you want to know more about this study before taking part, you can ask me all the 
questions you want or contact Dr.M.Suganthi, PG Scholar cum principal investigator of this 
study,   National Institute of Siddha, Chennai-47. You can also contact the Member-
secretary of Ethics committee, National Institute Siddha, Chennai 600047, Tel.No: 91-44-
22380789, for rights and participation in the study.  
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¾¸Åø  ÀÊÅõ. 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ,  
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É ¦ºý¨É 47 
ÅÇ¢  «Æø ¸£øÅ¡Ô ±ýÛõ §¿¡öì¸¡É ¦ÁÕÌûÇ¢ ¨¾Äõ (¯û ÁÕóÐ) º¢ò¾ 
ÁÕóÐ¸Ç¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø  ÀÊÅõ. 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷:   ÁÕòÐÅ÷ Á.Í¸ó¾¢ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷          :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, 
                               ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                               ¦ºý¨É 47 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý (ÁÕòÐÅ÷. 
Á.Í¸ó¾¢), ÅÇ¢  «Æø ¸£øÅ¡Ô ±ýÛõ §¿¡Â¢ø ÁÕòÐÅ ¬Ã¡öîº¢Â¢ø ®ÎÀðÎû§Çý.               
ÅÇ¢  «Æø ¸£øÅ¡Ô ±ýÛõ ±ýÛõ §¿¡Â¢ø º¢Ú, ¦ÀÕ ãðÎ¸Ç¢ø ÅÄ¢, 
Å£ì¸ò¨¾ ¯ñ¼¡ì¸¢ ¸¡¨ÄÂ¢ø Å¢¨ÈôÒ ¾ý¨Á¨Â ¯ñ¼¡ìÌõ  
 þÐ ÀÃÅ ÜÊÂ §¿¡ö «øÄ. 
 þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸û §¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ 
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý.  
þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ ±É 
¯Ú¾¢«Ç¢ì¸¢§Èý. 
þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ò ¦¾¡¨¸Ôõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð. 
þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸ 
¦ÁÕÌûÇ¢ ¨¾Äõ  9¸¢(9Á¢.Ä¢), 1 §Å¨Ç (¸¡¨Ä ÁðÎõ) ¯½×ìÌ  Óý 45 
¿¡ð¸û ¯ð¦¸¡ûÇ §ÅñÎõ. 3 ¿¡ð¸ÙìÌ ¦¾¡¼÷óÐ ÁÕóÐ ¯ñÎ À¢ý 2 
¿¡ð¸ÙìÌ ÁÕóÐ  ¯ñ½¡Áø Àò¾¢Âõ ÁðÎõ ¸¡ì¸ §ÅñÎõ.  ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 
5 ¿¡ð¸ÙìÌ ´ÕÓ¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. ¯û §¿¡Â¡Ç¢Â¡¸ ¾í¸ Å¢ÕôÀõ 
¦¾Ã¢Å¢ìÌõ Àðºò¾¢ø §¿¡öìÌ  º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
þó¾ ¬Ã¡öîº¢Â¢ø §¿¡Â¢ÉÃ¡¸ §º÷ó¾ À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø 
±ô§À¡Ð §ÅñÎÁ¡É¡Öõ Å¢Ä¸¢ ¦¸¡ûÇÄ¡õ. 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ ÁüÈ Å¢ÀÃí¸ÙìÌõ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕòÐÅ÷ Á.Í¸ó¾¢(Àð¼ §ÁüÀÊôÀ¡Ç÷ ¦À¡ÐÁÕòÐÅ Ð¨È) 
«Ï¸×õ. ¨¸ô§Àº¢ ±ñ 8056786753 
§ÁÖõ  þó¾ ¬Ã¡öîº¢ìÌ IEC º¡ýÚ ¦ÀÈôÀðÎûÇÐ 
þó¾ ÁÕóÐ º¢ÈôÀ¡¸ ÅÇ¢  «Æø ¸£øÅ¡Ô §¿¡öì¸¡¸ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ 
ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. 
²ü¸É§Å ¯À§Â¡¸ò¾¢ø ¯ûÇÐ §À¡ýÈ ÁÕóÐ  §¿¡Â¡Ç¢¸Ç¢¼õ ±ó¾ Å¢¾ Àì¸ 
Å¢¨Ç×¸¨ÇÔõ ²üÀÎò¾Å¢ø¨Ä. 
§ÁÖõ ¯½× Ó¨ÈÂ¢ø ÁÕòÐÅÃ¡ø ÜÈôÀÎõ Àò¾¢Âõ ¸¡ìÌÁ¡Ú 
«È¢×Úò¾ôÀÎ¸¢ÈÐ 
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An open  Clinical study on ”Merugulli thylam (Internal Medicine)” in the 
treatment of “Vali Azhal Keel Vayu” (Rheumatoid Arthritis). 
 
Principal Investigator: Dr.M.Suganthi                                                              
 
FORM-VI  – CONSENT FORM 
 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to my 
satisfaction.  
            I consent voluntarily to participate as a participant in this study and understand that I 
have the   right to withdraw from the study at any time without in any way it affecting my further 
medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm individual has given consent 
freely.”                                                   
 
Date: 
 
 
Signature of a witness  
(Selected by the participant bearing no connection with the survey team)    
      
          
            
 
 
 
 
 
Left thumb Impression of the Participant 
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FORM –VI   ´ôÒ¾ø ÀÊÅõ 
                      ¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
 
                                               §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, 
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É. 
 
  
ÅÇ¢  «Æø ¸£øÅ¡Ô ±ýÛõ §¿¡öì¸¡É ¦ÁÕÌûÇ¢ ¨¾Äõ (¯û ÁÕóÐ)  º¢ò¾ 
ÁÕóÐ¸Ç¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø  ÀÊÅõ. 
 ¾¸Åø  ÀÊÅõ.   
´ôÒ¾ø ÀÊÅõ-¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
    ¿¡ý þó¾ ¬ö¨Åì ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌô ÒÃ¢Ôõ Å¨¸Â¢ø 
±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 §¾¾¢ :                                                     ¨¸¦Â¡ôÀõ: 
 þ¼õ:                                                      ¦ÀÂ÷     : 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
±ýÉ¢¼õ  þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ ÁÕòÐÅ 
ÅÆ¢Ó¨È ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ì ¸ñ¸¡½¢ì¸×õ, «¾¨Éô 
À¡Ð¸¡ì¸×õ ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ ÀÃ¢§º¡¾¨É¸û ÀüÈ¢   ¾¢Õô¾¢ «Ç¢ìÌõ 
Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì ÜÈôÀð¼Ð. 
¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø, ±ô¦À¡ØÐ 
§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ ±ý¨É Å¢ÎÅ¢òÐì ¦¸¡ûÙõ ¯Ã¢¨Á¨Âò 
¦¾Ã¢ó¾¢Õì¸¢ý§Èý. ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ò §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì ¦¸¡ñÎ  
ÅÇ¢  «Æø ¸£øÅ¡Ô §¿¡öì¸¡É ¦ÁÕÌûÇ¢ ¨¾Äõ (¯û ÁÕóÐ) ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý. 
 §¾¾¢:                                           ¨¸¦Â¡ôÀõ:  
þ¼õ:                                             ¦ÀÂ÷     : 
 
 §¾¾¢:                                            º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
þ¼õ:                                          ¦ÀÂ÷:                            ¯È×Ó¨È:          
Å¢Ã¢×¨ÃÂ¡Ç÷ ¨¸¦Â¡ôÀõ:                                             Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ:  
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NATIONAL INSTITUTE OF SIDDHA, 
CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
An Open  Clinical study on ”Merugulli thylam (Internal Medicine)”  in the 
treatment of “Vali Azhal keel Vayu” (Rheumatoid Arthritis)  
FORM VII- WITHDRAWAL FORM/ADVERSE DRUG 
REACTION/PHARMACOVIGILANCE FORM 
IEC NO: NIS/IEC 
 NAME:  _______________________________      OPD/ IPD NUMBER: 
_____________ 
AGE: _________                                       SERIAL NO: 
_____________________ 
DATE OF TRIAL COMMENCEMENT:  
DATE OF WITHDRAWAL FROM TRIAL:  
REASONS FOR WITHDRAWAL: 
 Long absence at reporting :                 Yes/ No 
 Irregular treatment:                           Yes/ No 
 Shift of locality :                                    Yes/No 
 Increase in severity of symptoms:    Yes/No 
 Development of severe adverse drug reactions:   Yes/No 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  
SIDDHA DRUGS 
 
 
 
 
Please note:  i.  All consumers / patients and reporters information will remain 
confidential. 
ii. It is requested to report all suspected reactions to the concerned, even if it 
does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
Name  Father name Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 Geographical area: 
 
 
 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle – 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha 
 
     
Any other 
system of 
medicines 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the drug 
used 
   
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used 
as self medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
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6. The result  of the adverse reaction / side effect / untoward effects (please complete 
the boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
 
10. Other illness (please describe): 
 
 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
Signature of the reporter:       Date: 
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Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha 
Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 22381314 
        Website : www.nischennai.org  
        Email : nischennaisiddha@yahoo.co.in   
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * * 
This filled-in ADR report may be sent within one month of observation /occurrence of 
ADR   
 
 
 
Date:                                                                              
Station:                                                         
          
 
Date :      
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       Signature of the HOD 
 
Who Can Report?   
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for 
legal claim  
Name & address of the RRC-
ASU / PPC-ASU 
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      NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF  MARUTHUVAM 
An open Clinical study on ”Merugulli thylam(Internal Medicine)” in the 
treatment of “Vali Azhal Keel vayu” (Rheumatoid Arthritis). 
 
Principal Investigator: Dr.M.Suganthi                                                              
 
§º÷ì¸ ÜÊÂ ¯½×¸û: 
¸¡ö¸û: 
ÓÕí¨¸À¢ïÍ, 
«Å¨ÃÀ¢ïÍ, 
À¢Ãñ¨¼, 
¸¡Ãð, 
À£ðåð. 
 
¸£¨Ã¸û: 
¸Ã¢º¡¨Ä, 
¦À¡ýÉ¡í¸ñ½¢, 
Á½ò¾ì¸¡Ç¢,              
ÓÕí¨¸¸£¨Ã, 
Àº¨Ä¸£¨ Ã, 
º¢Ú¸£¨ Ã,                 
¸È¢§ÅôÀ¢¨Ä,  
      ¦¸¡ò¾ÁøÄ¢. 
Ò¾¢É¡. 
ÀÆí¸û: 
Á¡Ð¨Ç, 
¬ôÀ¢û, 
Å¡¨Æ, 
§ÀÃ£î¨º, 
«ò¾¢,               
¾¢Ã¡ð¨º, 
¦¸¡öÂ¡                
¿¡Åø,  
ºô§À¡ð¼¡, 
¯Ä÷ ¾¢Ã¡ð¨º. 
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¾¡É¢Âí¸û  
Ó¨Ç ¸ðÊÂ ÀÂ¢÷ Å¨¸¸û,  
§º¡Â¡À£ýŠ,  
¯ÙóÐ, 
¦Åó¾Âõ. 
«¨ºÅõ: 
¦ÅûÇ¡ðÎ¸È¢ ®Ãø, 
±ÖõÒÁˆ¨ƒ, 
ÁüÈ¨Å: 
À¨É ¦ÅøÄõ 
À¡ø   
¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û:      
 ¯ôÒ 
§¸¡Æ¢ì¸È¢, Á£ý, ¿ñÎ, ¸ÕÅ¡Î, 
§Å÷ì¸¼¨Ä, 
±û, 
§¾í¸¡ö, 
ÀÄ¡, 
ÒÇ¢ôÒ ¦À¡Õû¸û, 
ÒÇ¢ôÒ ¾Â¢÷ §Á¡÷, 
°Ú¸¡ö, 
¦Àñ§À¡¸õ, Ò¨¸Â¢¨Ä , 
¦ÅüÈ¢¨Ä,À¡ìÌ. 
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